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The programmed cell death-1 (PD-1) receptor is a key regulator of T cell activation 
and cytokine production. Multiple studies performed in PD-1-deficient mice 
demonstrate its importance in preventing autoimmunity. Evidence suggests that PD-1-
mediated regulation is reduced during chronic inflammation in human diseases, such 
as rheumatoid arthritis (RA). In this thesis, the role of inflammation in influencing 
PD-1-mediated regulation of human CD4+ T cells is further characterised. First, PD-1 
and PD-L1 expression, as well as the functional consequences of PD-1 ligation in 
rheumatoid (RA) and psoriatic arthritis (PsA) were analysed. Using flow cytometry 
and analysis of existing gene expression arrays, it was determined that the percentage 
of PD-1+ cells within the CD4+ and CD8+ T cells compartment was increased in RA 
and PsA synovial fluid (SF) compared to paired peripheral blood (PB).  Upon in vitro 
T cell receptor (TCR) stimulation of HC CD4+ T cells in the presence of plate-bound 
PD-L1fc chimera, significantly decreased proliferation and interferon (IFN)-γ 
secretion was observed. In contrast, RA and PsA PB- and SF-derived CD4+ T cells 
appeared resistant to such PD-1-mediated inhibition. Second, it was investigated 
whether proinflammatory cytokines modulate PD-1-mediated regulation of healthy 
CD4+ T cells (HC). Addition of proinflammatory cytokines tumour necrosis factor 
(TNF)-α, interleukin (IL)-6 and IL-1β, which were increased in RA and PsA SF 
compared to HC and osteoarthritis (OA) controls, consistently abrogated PD-1-
mediated suppression in HC CD4+ T cell cultures. Inhibitors of these cytokines 
reversed this effect. Finally, it was evaluated whether soluble PD-1 (sPD-1) negatively 
regulates the PD1/PD-L1 interaction. Soluble PD-1 (sPD-1) levels were increased in 
cell culture supernatants from TNFα and IL-6-stimulated cultures compared to 
untreated controls, and also in RA and PsA, but not in OA, serum and SF nor in HC 
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serum. qPCR analysis of HC CD4+ T cells from TNFα- and IL-6-stimulated cultures 
also revealed increases of the PD-1Δex3 splice variant. Functionally, addition of sPD-
1fc counteracted PD-1-mediated suppression of HC CD4+ T cells, increased T cell 
proliferation in HC CD4+ T cell/monocyte co-cultures but had no effect on HC CD4+ 
Treg cell-mediated suppression. Together, the data presented in this thesis provide 
new evidence that the inflammatory environment of the RA and PsA joint 
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This introduction will begin with a brief description of effector T cell subsets and 
the process of T cell activation and regulation. Next, I will introduce a number of 
different T cell inhibitory receptors including CTLA-4, PD-1, TIGIT, TIM-3 and 
LAG-3. Since this thesis focuses on the role of PD-1-mediated regulation in human 
rheumatoid and psoriatic arthritis, a comprehensive review of the literature regarding 
the PD-1/PD-L1 pathway will be presented. This will include detailed descriptions of: 
i) the gene and protein structure of PD-1 and its ligands, ii) PD-1 transcriptional 
regulation, iii) PD-1 and PD-1 ligands expression, iv) the effects of PD-1 on T cell 
signalling and T cell metabolism, v) the effect of reverse signalling through the PD-1 
ligand PD-L1. Since PD-1 function has been extensively investigated in human cancer 
but only partially in human autoimmunity, the role of PD-1 in cancer immunotherapy 
will be briefly discussed. This will be followed by a more detailed analysis of current 
literature outlining the development of autoimmune-like adverse effects following 
PD-1 blockade as well as the role of PD-1 in autoimmunity and in mouse and human 
arthritis. Finally, a brief description of the clinical aspects of rheumatoid and psoriatic 
arthritis will be provided, followed by the rationale and aims of this thesis. 
 




















1.1 T cells 
A key feature of the immune system is the ability to distinguish self from non-
self. This process begins with recognition and binding of a T cell receptor (TCR) to an 
antigen displayed by the major histocompatibility complex (MHC) expressed on the 
surface of an antigen-presenting cell (APC). Multiple factors then come in place to 
influence whether this process leads to T cell activation or anergy. In the thymus, T 
cells proliferate and develop a repertoire of TCRs by recombining TCR gene 
segments. T cells displaying reactivity to self-peptides undergo deletion in the thymus 
(1). This process called central tolerance helps to prevent the development of 
autoimmunity (2). T cells lacking the ability to bind to MHC molecules undergo 
apoptosis. T cells that can respond to MHC molecules mature in the thymus before 
entering the periphery. Importantly, some TCRs may have a specificity that is cross-
reactive with self-antigens. From the thymus, naïve T cells circulate through the 
blood, spleen and lymphatic organs. In the periphery T cells are exposed to APCs 
displaying foreign antigens, in case of infection, and both self or mutated self-
molecules in the case of malignancy (2). CD8 and CD4 are two transmembrane 
glycoproteins that serve as co-receptors and which bind to the invariant parts of MHC 
class I and II, respectively, stabilising the MHC-peptide-TCR complex during T cell 
activation. CD8+ T cells have cytotoxic functions, enabling killing of target cells such 
as infected cells or cells that have undergone malignant transformation (3). CD4+ T 
cells, also known as T “helper” cells, are fundamental for adaptive immune responses. 
They can i) activate B cells to secrete antibodies, ii) help macrophages to clear 
pathogens and iii) support cytotoxic T cells to clear infected and transformed cells.  At 
present, the best-characterised T helper (Th) cell subsets are Th1, Th2 and Th17 cells 
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but Regulatory T cells (Treg) and follicular T helper cells (Tfh) are becoming highly 
important in many biological scenarios (4).  
 
1.2 Th1, Th2 and Th17 cells  
Th1 cells are activated in response to infection mediated by intracellular 
pathogens and produce specific cytokines including interferon-gamma (IFNγ), 
interleukin-2 (IL-2), lymphotoxin, and tumour necrosis factor alpha (TNFα). These 
cytokines are important for T cell proliferation and to enhance the phagocytic and 
antigen presenting capacity of macrophages. Th1 cells are also able to promote 
complement-fixing and opsonising antibodies, specifically immune-globulin G1 
(IgG1) in humans and IgG2a in mice (4). Th2 cells are induced in the presence of 
extracellular pathogens (i.e. nematodes and helminths). During Th2 responses, these 
cytokines induce B cell activation and class switching to IgE and subtypes of IgG. 
Th2 cell-derived cytokines can also stimulate mast cells and eosinophil promoting 
their activation and leading to antibody and allergic responses (4). Th17 cells play an 
important role in adaptive immunity during infection by extracellular bacteria and 
fungi. Like other T helper cells, Th17 cells can interact with B cells in response to 
pathogens and they are involved in B cell recruitment via the CXCL13 chemokine 
signalling (4-6). Genetic defects associated with development of Th1, Th2 and Th17 
cell subsets lead to different pathologies and clinical manifestations (7, 8).  
For example, abnormal activation of Th1 and Th17 cells is typically found in a 
variety of autoimmune diseases. Th1 and Th17 dysregulation is associated with 
disease pathogenesis via production of proinflammatory cytokines such as interleukin-
17A (IL-17A), interferon-gamma (IFNγ) and tumour necrosis factor-alpha (TNFα) (9-
12). Work from our lab has demonstrated that IL-17+, IFNγ+ and TNFα+ CD4+ T 
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cells are abundantly represented at sites of inflammation (synovial fluid and tissue) in 
patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (13-15).  
 
1.3  Differentiation of naïve CD4+ T cells into Th1, Th2 and Th17 subsets  
TCR-stimulated naïve CD4+ T cells differentiate into different subpopulations 
following specific cytokines stimuli and following activation of transcription factors 
of the Signal Transduction and Activator of Transcription (STAT) family.  Naïve 
CD4+ T cells are driven towards a Th1 phenotype by the cytokines IFNγ and IL-12 
which signal through STAT1 and STAT4, respectively (16). This is followed by 
expression of the T-bet transcription factor, which induces production of IFNγ, the 
hallmark cytokine of the Th1 subset (17). Th1 also produce IL-2 and TNFα (18). 
Th2 differentiation is driven by IL-4 signalling via STAT6 together with TCR 
stimulation. This combined stimulation leads to expression of GATA binding protein 
3 (GATA-3) and production of cytokines IL-4, IL-5, IL-9 and IL-13 (18-20). IFNγ 
and IL-4 are known to amplify Th1 and Th2 differentiation, respectively, through an 
autocrine mechanism but they are also capable of antagonising one another. For 
example, the Th1 hallmark cytokine IFNγ can activate STAT1 leading to expression 
of T-bet (19). T-bet is a repressor of Th2 cell differentiation and when transduced in 
polarised Th2 cells can modulate their phenotype towards the Th1 profile (15).  
CD4+ T cell differentiation into Th17 cells requires stimulation via the 
cytokines transforming growth factor-beta (TGF-β) and IL-6. IL-6 signals through 
STAT3 which promotes the expression of the gene encoding retinoic acid receptor-
related orphan receptor-γt (RORγt; the master transcriptional regulator; encoded 
by Rorc). This leads to expression of the Th17 lineage specific cytokine IL-17 (21, 
22). Other cytokines including IL-1β, TNFα and IL-23 can promote or amplify Th17 
 23 
differentiation (22). Th17 cells can produce proinflammatory cytokines TNFα, IL-
17F, IL-21 and IL-22 (10). In addition to their signature cytokines and specific 
transcription factors, Th1, Th2 and Th17 subsets express lineage specific chemokine 
receptors. For example, within CXCR3+CD4+ the most represented subset is Th1 
while CCR4+CD4+ T cells contain Th2 cells. Conversely, the CCR6+ CCR4+ subset 
contains predominantly Th17 and a small percentage of Th1 cells (23).  
 
1.4  T cell activation and T cell inhibitory pathways 
During the first step of T cell activation the TCR binds to the MHC/peptide 
complex. A second step in T cell activation is the binding of CD80 (B7-1) and CD86 
(B7-2) molecules expressed on the APC to CD28 molecules expressed on the T cell. 
This second step provides a co-stimulatory signal important for cell activation. 
Following TCR:MHC and CD28:CD80/86 interactions, several intracellular pathways 
become activated leading to cell proliferation, increased expression of cell survival 
genes and cell differentiation through the production of growth cytokines such as IL-2 
and IFNγ (24). Several receptors, functioning as immune checkpoints are in place to 
downregulate immune responses, prevent uncontrolled immune activation, reduce 
inflammation and maintain peripheral self-tolerance (2, 25).  
The two best-characterised inhibitory receptors are the cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4, CD152) and the programmed cell death 1 
(PD-1, CD279) (26) receptor but multiple additional molecules have been discovered 
in recent years and represent promising targets for therapeutic manipulation. These 
molecules include the T-cell immunoglobulin and ITIM domain (TIGIT), the 
lymphocyte activation gene 3 (LAG-3) and the T-cell Ig and mucin domain-3 (TIM-
3). In the next sections the inhibitory receptors CTLA-4, PD-1, TIGIT, TIM-3 and 
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LAG-3 will be described. Stronger attention will be dedicated to PD-1 receptor and its 
involvement in cancer and autoimmunity. 
 
1.5 Immune checkpoints: CTLA-4 
CTLA-4 is an essential negative regulator of T cell immune responses. CTLA-
4 is expressed by T cells and regulates the magnitude of the early stages of T-cell 
activation in the lymphoid organs (27-29). Specifically, CTLA-4 stops autoreactive T 
cells within the lymph nodes at the initial stage of naïve T-cell activation by both 
outcompeting CD28 in binding CD80 and CD86, as well as actively delivering 
inhibitory signals to the T cell (25, 30).  CTLA-4 is a homolog of CD28 but has a 
higher binding affinity for CD80 and CD86.  Upon CTLA-4 engagement with CD80 
and CD86, several mechanisms play a role in reducing T cell activation. CTLA-4 is 
able to inhibit directly the TCR immune synapse, it can modulate the CD28-mediated 
signalling pathway and it has been shown to increase T cell mobility making it harder 
for T cells to interact with APCs (31, 32). Qureshi et al. elegantly showed that CTLA-
4 is also able to capture its CD80 and CD86 ligands from opposing cells by a process 
called trans-endocytosis. Removed costimulatory ligands are then degraded inside 
CTLA-4-expressing cells resulting in reduced costimulation via CD28 (33). 
CTLA-4 delivers an inhibitory signal within the T cell blocking IL-2 
production and inhibiting the cell cycle (25, 34-36). Evidence also suggests that 
whether a cell will undergo activation or anergy is determined by the relative amount 
of CD28:B7 binding versus CTLA-4:B7 binding (30). CTLA-4 expression on the 
surface of T cells can be regulated by the intensity of the TCR and CD28:CD80/CD86 
signalling. In resting naïve T cells CTLA-4 is located primarily in intracellular 
vesicles and cell surface expression of CTLA-4 rapidly increases by rising of 
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intracellular calcium levels. Furthermore, during T cell activation, intracellular and 
cell surface CTLA-4 re-direct towards sites of TCR activation (37).  
Regulatory T cells (Treg) are important players during immune responses and 
their role in maintaining peripheral tolerance has been extensively demonstrated (38, 
39). Treg cells constitutively express CTLA-4 and use this molecule during 
suppressive functions (39, 40). Several authors have shown that CTLA-4 deficiency in 
Tregs leads to impaired suppressive capacity and that Tregs are able to control 
effector T cells activation by binding and downregulating CD80 and CD86 ligands on 
APCs, leading to reduced CD28 costimulation (33, 39, 40). Interestingly, T cell 
regulatory ability via CTLA-4-mediated regulation is not a unique feature of Treg 
cells and CTLA-4 transfection in resting human CD4+CD25- T cells has been shown 
to confer suppressive capacity in absence of the forkhead box P3 (FoxP3) protein (41). 
The critical role for CTLA-4 in immune tolerance is demonstrated by the fact 
that CTLA-4 knockout mice rapidly develop a fatal T cell–mediated multiorgan 
inflammation similar to a systemic autoimmune disease (42, 43). CTLA-4 is essential 
in prevention of autoimmunity and blockade of this molecule has been shown to 
exacerbate autoimmunity in different mouse models including Systemic Lupus 
Erithematosous (SLE), multiple sclerosis (MS), and type 1 diabetes (44). In human, 
polymorphisms in the CTLA-4 gene are associated with autoimmune diseases 
including type 1 diabetes, Graves’ disease and RA while heterozygous CTLA-4 
mutations result in reduced CTLA-4 mRNA and CTLA-4 protein expression and to 
severe immune dysregulation, defective Treg function, hyperproliferative T cells and 
lymphocytic infiltrates in nonlymphoid organs (45-47).  
The critical role of CTLA-4 in controlling T cell activation has led to the 
development of a recombinant fusion protein (abatacept) comprising the extracellular 
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domain of human CTLA4 and a fragment of the Fc domain of human IgG1. This 
molecule is able to compete with CD28 for CD80 and CD86 binding to selectively 
modulate T-cell activation and is currently used for the treatment of RA (48, 49) and 
juvenile idiopathic arthritis (JIA) (50). 
CTLA-4 is also an important target for anti-tumour therapies. In murine tumour 
models, anti-CTLA-4 antibodies have been shown to be highly efficient in promoting 
antitumor immune responses (51-53). The therapeutic effect of anti-CTLA-4 
antibodies is likely due to two mechanisms. The first mechanism is blocking the 
interaction between CTLA-4 on T cells and B7 ligands (CD80/CD86) on APCs. The 
second mechanism may operate by blocking CTLA-4 on Treg cells and depleting 
intra-tumoural CTLA-4+ Treg cells via antibody-dependent cellular cytotoxicity (52, 
53).  These studies led to clinical development of anti-CTLA-4 blocking antibodies 
for cancer therapy and anti-CTLA-4 treatment (ipilimumab) is now approved as a 
treatment for metastatic melanoma (54, 55). 
 
1.6 Immune checkpoints: PD-1 
1.6.1  Gene and protein structure of PD-1 
The Programmed Cell Death 1 (PD-1) protein was first described in 1992 as an 
upregulated gene in a T cell hybridoma undergoing cell death (56). In 1999, 
Nishimura et al. demonstrated that PD-1 has important negative regulatory functions 
and showed that lack of the receptor in the Pdcd1−/− mice phenotype led to the 
development of autoimmunity including lupus-like autoimmune disease and 
autoimmune dilated cardiomyopathy (57, 58). The identification of the PD-1 ligands 
PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273) (59-62) has been paramount in 
understanding the functions of the PD-1 signalling pathway. In mouse, the Pdcd1 gene 
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is located on chromosome 1 while in human the PD-1 gene (PDCD1) is located on 
chromosome 2. In both species, the PD-1 gene is composed of 5 exons. The exon 1 
and 2 encode a short signal sequence, and the IgV-like domain, respectively. Exon 3 
encodes the stalk and transmembrane domains while exon 4 encodes a short sequence 
of 12 amino acids (aa) marking the beginning of the cytoplasmic domain. The C-
terminal intracellular residues and the 3’UTR are encoded by exon 5. Five splice 
variants of the PD-1 gene have been identified in activated human T cells. These 
transcripts lack exon 2 only, exon 3 only, exons 2 and 3, or exons 2 through 4 and 
they can be induced following anti-CD3/CD28 stimulation (63). Interestingly, the 
transcript lacking exon 3 (PD-1Δex3) encodes a protein lacking the transmembrane 
domain and strongly resembling the soluble form of CTLA-4, a molecules that plays 
an important role in autoimmunity (47).  
 
PD-1 is a member of the CD28/CTLA-4 superfamily having 15% aa identity 
with CD28, 20% identity with CTLA-4, and 13% identity with inducible T cell 
costimulator (ICOS).  The receptors in the CD28/CTLA-4 superfamily are all type I 
transmembrane glycoproteins composed of three major parts: i) an Ig Variable-type 
(V-type) extracellular domain, ii) a transmembrane domain, and iii) a cytoplasmic tail 
responsible for the binding of signalling molecules (Figure 1.3). PD-1 is a 288 aa 
protein composed of an extracellular signal sequence, an immunoglobulin IgV-like 
domain, a 20 aa stalk, a transmembrane domain and a cytoplasmic domain (see 
Figures 1.2 and Figure 1.3B). PD-1 cytoplasmic tail contains the N-terminal sequence 
VDYGEL which forms an Immunoreceptor Tyrosine-based Inhibition Motif (ITIM). 
PD-1 cytoplasmic tail also contains the C-terminal sequence TEYATI, which forms an 
Immunoreceptor Tyrosine-based Switch Motif (ITSM) (Figure 1.2) (64). CD28, 
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CTLA-4, and ICOS are covalently linked homodimers due to the interchain disulfide 
mediated by the equivalent of Cys122 in CTLA-4 (65). In contrast, PD-1 cannot form 
such a covalent dimer as it lacks the analogous Cys residue. In addition, PD-1 
possesses only a single intrachain disulfide in its Ig V-type domain, while CD28, 
CTLA-4, and ICOS contain two intrachain disulfides. Another specific feature of PD-
1 is that the complementarity-determining region 3 (CDR3) loop of the receptor does 
not contain the conserved XXPPP (F/Y) motif present in CD28, CTLA-4, and ICOS. 
Fluorescence resonance energy transfer (FRET) analyses of full-length PD-1 and 
analytical ultracentrifugation on a soluble extracellular PD-1 IgV-like domain showed 
that PD-1 is monomeric (66). PD-1 has other distinct molecular features compared to 
the members of the CD28 family (67). Specifically, CD28, CTLA-4, and ICOS have 
SH2-binding motifs (YxxM) located in their cytoplasmic tails. CTLA-4 and CD28 
also have one and two SH3-binding motifs (PxxP), respectively, in their cytoplasmic 
tails. On the contrary, the PD-1 receptor has no SH2- or SH3-binding motifs in its 















Figure 1.2 Schematic diagram showing the cytoplasmic tail of CTLA-4 and PD-1.   
YVKM (Sh2 binding domain), PTEP (Sh3 Binding domain), VDYGEL (ITIM) and TEYATI 




The cytoplasmic tail of the PD-1 receptor has important signalling functions. 
Chemnitz et al. demonstrated that PD-1-mediated inhibitory effect on the PI3K 
signalling pathway is lost when the ITSM tyrosine is changed to phenylalanine 
(Y248F) but remains functional when this change affects the ITIM tyrosine (Y223F) 
(69). Using mass spectrometry it was found that the ITSM motif of PD-1 acts as a 
docking site of Src homology 2 domain–containing tyrosine phosphatase 2 (SHP-2) 
and possibly Src homology 2 domain–containing tyrosine phosphatase 1 (SHP-1) 
although the role of SHP-1 remains unclear (69, 70). This was further demonstrated 
using live-cell imaging during T cell activation by Yokosuka et al., which 
demonstrated that only SHP-2 interacts with PD-1 in the selected experimental model 
(71). During T cell activation, the PD-1 receptor clusters with T cell receptors (TCRs) 
upon binding with its ligand PD-L1 and is transiently associated with the phosphatase 
SHP-2. These negative costimulatory micro-clusters dephosphorylate the proximal 



















Figure 1.3 B7–CD28–CTLA-4 costimulatory molecules and the structure of 
programmed cell death 1 (PD-1).  
(A) Members of the B7-CD28-CTLA-4 family of costimulatory molecules. Black arrows 
indicate stimulatory signals and red arrows indicate inhibitory signals. (B) Structure of human 
PD-1 showing the signal sequence, the immunoglobulin variable region (IgV)-domain, the 
transmembrane domain and the ITIM and ITSM domains. 
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1.6.2  Gene and protein structure of PD-1 ligands PD-L1 and PD-L2 
PD-L1 is the best-characterised ligand for PD-1. PD-L1 is a 290 aa type I 
transmembrane protein which in mice, is encoded by the Cd274 gene located on 
chromosome 19 and in human is encoded by the CD274 gene located on chromosome 
9. CD274 is composed of seven exons. Exon 1 is non-coding and contains the 5’UTR. 
Exons 2, 3 and 4 contain the signal sequence, IgV-like domain, and IgC-like domains, 
respectively. The transmembrane domain and the intracellular domains are encoded 
by exons 5 and 6, respectively. Exon 7 encodes intracellular domain residues and the 
3’UTR. The intracellular domain of PD-L1 is composed by 30 aa and it is highly 
conserved among different species. In humans, only one splice variant has been 
reported for PD-L1. This splice variant lacks the IgV-like domain encoded in exon 2 
and theoretically should not be able to bind PD-1 although its function has not been 
investigated (72). No splice variants have been identified for PD-L1 in mouse.  
PD-L2 is the second ligand of PD-1 (61). PD-L2 is a type I transmembrane 
protein encoded by the Pdcd1lg2 gene which is adjacent to the Cd274 gene in both 
mouse and human. The two genes are separated by only 23 kilobase (kb) of 
intervening genomic DNA in mouse and 42 kb in human. In mouse, the Pdcd1lg2 
gene located on chromosome 19. In human, the PDCD1LG2 gene is located on 
chromosome 9.  
The PD-L2 gene is composed of six exons in mouse and seven in human. Exon 
1 and 6 are non-coding, while exon 2 encodes a signal sequence. Exon 3 and 4 encode 
for the IgV-like domain, the IgC-like domain respectively, while exon 5 encodes for a 
short stalk, the transmembrane region and the beginning of the cytoplasmic domain. A 
stop codon in the mouse exon 5 results in a cytoplasmic domain of 4 aa. In human, 
exon 6 and 7 encode for an additional coding region resulting in a longer cytoplasmic 
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domain of 30 aa as compared to the mouse domain. The long form of the cytoplasmic 
domain of PD-L2 has no signalling motifs but is conserved across diverse species, 
including human, macaque, chimp, dog, cow and pig suggesting a possible functional 
role for the cytoplasmic tail of PD-L2. Three different splice variants for PD-L2 have 
been identified following activation of human PBMC (61, 73). The first variant lacks 
the exon 3 and since PD-L2 binding activity resides in the IgV-like domain (74) this 
truncated form is unlikely to bind PD-1 (61). A second form lacks the IgC-like 
domain and it is thought to be still able to bind PD-1 although this has not been further 
investigated. Finally, a third variant lacks both the IgC-like and the transmembrane 
domains but maintains the intracellular residues leading to a soluble form of the PD-
L2 ligand. 
 
1.6.3 Transcriptional regulation of PD-1 expression  
Cis-regulatory elements (CREs) such as enhancers and promoters are regions 
of non-coding DNA that regulate the transcription of nearby genes. Genetic mutations 
affecting the function of these sequences are responsible for phenotypic diversity (75).  
Several cis-elements have been identified as regulators of PD-1 gene expression. By 
using two models consisting of murine EL4 cells, which constitutively express PD-1, 
and primary murine CD8+ T cells that express PD-1 upon T cell stimulation, 
Oestreich et al. identified two tissue-specific hypersensitive sites at the 5′ conserved 
region of the PD-1 locus. The two conserved regions (CR-B and CR-C) are associated 
with Pdcd1 activation, they contain multiple transcription factor binding sites and are 
located 100 bp and 1.1 kb upstream of the transcription start site (TSS) (76). A 
binding site for the activator protein 1 (AP-1) is encoded within CR-B (77) while CR-
C contains an IFN-stimulated response element (ISRE) (78), a nuclear factor of 
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activated T-cells cytoplasmic 1 (NFATc1) binding site (76), a Forkhead box protein 
O1 (FoxO1) binding site (79), and a nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) binding site (80). Interestingly, it was shown that PD-1 
expression is not induced by constructs containing the PD-1 promoter but lacking 
the CR-C region. This suggests that the CR-C region is critical for PD-1 expression 
(76, 80). In mouse-derived T cells, several transcription factors have been shown to 
modulate PD-1 expression.   
 
One example is NFATc1. This transcription factor is necessary for initial 
activation-induced expression of PD-1 in CD4+ and CD8+ T cells. TCR activation 
leads to activation of the calcineurin pathway and NFAT1c (81). Following activation, 
NFAT1c translocate to the nucleus and binds strongly to the CR-C region of the PD-1 
gene regulating PD-1 expression in T cells. The role of NFATc1 as inducer of PD-1 is 
further demonstrated by the fact that the NFATc1-specific inhibitor peptide VIVIT 
and cyclosporine A, an inhibitor of calcineurin, are able to abrogate PD-1 expression 
(76). AP-1 is another transcription factor that positively regulates PD-1 expression. 
TCR-mediated stimulation leads to the activation of the MAPK cascade and AP-1 
(82). Using a lung carcinoma tumour model, Xiao et al. demonstrated that 
overexpression of the AP-1 subunit c-Fos induces PD-1 expression in CD4+ and 
CD8+ T cells resulting in the inhibition of antitumor T cell-mediated responses. 
Conversely, a mutation at the AP-1 binding site reduced PD-1 expression in tumour-
infiltrating T cells leading to increased tumour clearance (77). The Notch signalling 
pathway is also capable of inducing PD-1 expression. Using specific inhibitors of this 
pathway, Mathieu et al. showed that in vitro blockade of the Notch pathway had a 
moderate, dose-dependent reduction of PD-1 expression and Pdcd1 transcription in 
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activated CD8+ T cells, without affecting the overall activation of the T cells (83). 
FoxO1 is a transcription factor known to promote transcription of genes necessary for 
homeostatic maintenance of naïve and memory T cells (84). Starron et al. 
demonstrated that FoxO1 binds to the CR-C region of the Pdcd1 locus and that it is 
necessary to generate PD-1hi T cells in a chronic murine lymphocytic choriomeningitis 
virus infection model. On the contrary, it was shown that FoxO1 knockout mice had 
lower PD-1 expression compared to controls (79).  
 
The two best-characterised inhibitors of PD-1 are T-bet, the transcription 
factor encoded by T-box transcription factor TBX21, and the PR domain zinc finger 
protein 1 (PRDM1) also known as Blimp-1. T-bet was the first identified inhibitor of 
PD-1 (85). T-bet bounds directly to a regulatory region upstream of 
the Pdcd1 transcriptional start site. Kao et al. examined the role of T-bet in regulating 
virus-specific CD8+ T cell responses during chronic viral infection in mouse and 
showed that T-bet expression is downregulated in exhausted CD8+ T cells in response 
to persisting antigen. Furthermore, T-bet knockout mouse was shown to have 
exacerbated CD8+ T cell exhaustion and increased viral load while overexpression of 
T-bet strongly reduced the expression of PD-1 (86). Similarly to T-bet, Blimp-1 is 
also capable of negatively regulating PD-1 expression in mouse. Lu et al. showed that 
Blimp-1-deficient CD8+ T cells fail to repress PD-1 during the early stages of CD8+ 
T cell differentiation after acute infection with lymphocytic choriomeningitis virus. 
Blimp-1 represses PD-1 via two different mechanisms. Firstly, it negatively regulates 
PD-1 directly and secondly, it is able to displace the PD-1 activator NFATc1 from its 
binding site (87).  
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Further indication that Blimp-1 is a negative regulator of PD-1 comes from a 
study showing that T follicular helper cells (TFH) express high levels of PD-1 but they 
lack Blimp-1. In this study, exogenous expression of Blimp-1 abrogated the PD-1hi 
TFH cell subsets indicating an inverse correlation between Blimp-1 levels and PD-1 
expression (88). In contrast with the reported data, Blimp-1 might also act as an 
inducer of PD-1 under specific circumstances. In a mouse model of lymphocytic 
choriomeningitis virus (LCMV) chronic viral infection Blimp-1 was expressed in 
exhausted PD-1+CD8+ T cells while in exhausted CD8+ T cells from a Blimp-1 
knockout mice, PD-1 expression was slightly reduced compared to the control 
suggesting a different role for Blimp-1 in regulating Pdcd1 in these experimental 
conditions (89).  
Studies focusing on murine macrophages have also identified NF-κB and 
interferon-stimulated gene factor 3 (ISGF3) as two inducers of PD-1 in this specific 
cell population. Bally et al. found that the NF-κB p65 subunit binds to a site in CR-C 
region and that NF-κB was able to induce PD-1 expression following TLR 
stimulation. Importantly, blocking NF-κB binding to the DNA using an inhibitor was 
shown to abrogate PD-1 expression (80). PD-1 regulation in macrophages following 
cytokine stimulation was also examined. Cho et al. showed that following interferon 
alpha (IFNα) stimulation of macrophages, the IFN-stimulated gene factor (ISGF3) 
complex, which is composed by STAT1, STAT2, and IRF9 (90), was able to bind to 
the ISRE in the CR-C region and to induce PD-1 expression (78). 
 
1.6.4  Expression of PD-1 and its ligands 
In the late 90s Nishimura et al. found that CD4−CD8− thymocytes express 
PD-1 at low levels during TCRβ rearrangement (91) and further showed that 
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Pdcd1−/− mice spontaneously developed autoimmune diseases demonstrating the 
important role of PD-1 in immune regulation (57, 92).  Further studies also showed 
that PD-1 is only mildly expressed on resting T and B cells and that TCR and BCR 
ligation is necessary to induce PD-1 expression at the surface level (91, 93). Agata et 
al. described that mRNA transcription in mice does not strictly correlate with protein 
production and that PD-1 expression is sustained by the presence of persistent antigen 
stimulation (93).  
PD-1 can be detected on T cells during chronic HIV infection where it 
negatively modulates expansion, cytokine production and cytolysis (94). Unlike 
CTLA-4, which is only expressed by T cells, PD-1 is broadly expressed on different 
cell phenotypes. PD-1 can be detected in a variety of cell phenotypes including CD4+ 
and CD8+ T cells, natural killer T (NKT) cells, natural killer (NK) cells, B cells, 
monocytes and dendritic cell (DC) subsets (25, 26, 95). PD-1 expression can also be 
induced by cytokine stimulation in absence of TCR-mediated stimulation. Cytokines 
that have roles in peripheral T cell expansion and in cell survival such as the γ-chain 
cytokines IL-2, IL-15, IL-7 and IL-21 have all been shown to induce PD-1 expression 
in human T cells in vitro (96).  
CD4+ regulatory T cells are also able to express PD-1. In Treg cells PD-1 is 
thought to have a key role in the maintenance of Treg suppressive functions. Several 
lines of evidence from mice studies support this role. Wang et al. has shown that PD-
L1 contributes to the conversion of naïve CD4+ T cells into CD4+ Treg cells (97). 
Similarly Francisco et al. demonstrated that PD-L1 synergizes with transforming 
growth factor beta (TGF-β) to promote induced Treg cell (iTreg) conversion and 
further showed that PD-L1–induced CD4+FoxP3+ Treg cells are able to suppress 
CD4+ Teff cells (98). Mechanistically, it appears that PD-L1 regulates Treg cell 
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development by crosslinking PD-1 on Treg cells and by antagonizing the Akt–mTOR 
signalling pathway. These findings are supported by experiments showing that PD-L1 
deficiency in recombination-activating gene (Rag) mice impaired Treg cell conversion 
(98). Further evidence supporting the role of PD-1 for the correct function of Treg 
cells, comes from a study showing that anti-PD-1 drug nivolumab was able to 
overcome Treg-mediated suppression of CD8+ T cells by i) increasing resistance to 
Treg suppression and ii) by directly limiting Treg-suppressive capacity (99). 
Furthermore, in a different study nivolumab was shown to reverse Treg-mediated 
suppression of effector T cells restoring CD4+ T-responder cell proliferation and IFNγ 
production (100).   
 
Similarly to PD-1, PD-L1 and PD-L2 are widely expressed across different 
cell phenotypes (25, 95, 101, 102). This differs from the distribution of the CTLA-4 
ligands CD80 and CD86, which are mostly expressed by professional APCs and 
activated B and T cells (25, 26). PD-L1 can be detected on activated T and B cells, 
DCs, macrophages, mesenchymal stem cells and bone marrow–derived mast cells 
(103). PD-L1 is also expressed on a wide range of non-hematopoietic cells, in non-
lymphoid tissues, and can be induced on parenchymal cells by inflammatory cytokines 
or tumorigenic signalling pathways. The PD-L1 ligand can also be found on different 
tumour cell types and in the tumour microenvironment on APCs where it is associated 
with an increased amount of tumour-infiltrating lymphocytes (TILs) and poorer 
prognosis (104-107). The second ligand for PD-1, PD-L2, has a higher affinity for PD-
1 as compared to PD-L1 (108) but its expression patterns are still not extensively 
characterised. PD-L2 is primarily expressed on DCs and monocytes, but can be 
induced on other cells phenotypes, including T cells, and on tumour cells following 
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different stimuli from the local microenvironment (109). The expression of PD-L1 and 
PD-L2 is highly regulated by cytokines. Type 1 and type 2 interferons and TNFα 
induce PD-L1 expression in T cells, B cells, endothelial cells, and epithelial cells (95). 
The common γ chain cytokines IL-2, IL-7, and IL-15 are able to increase PD-L1 on 
human T cells and both PD-L1 and PD-L2 on monocytes (96). PD-L1 is also induced 
on monocytes by IL-10 and on CD19+ B cells by IL-21. IL-4 and 
granulocyte/macrophage colony-stimulating factor (GMCSF) have been shown to 
induce expression of PD-L2 on DCs (110-112).  
 
1.7 Signalling through PD-1 
PD-1 antagonises TCR-mediated signalling by modulating different pathways. 
Upon PD-1 engagement with its ligands, SHP-2 is recruited at the cytoplasmic tail of 
the receptor. This leads to a reduction in the phosphorylation of several TCR 
downstream signalling molecules including CD3ζ, zeta-associated protein of 70 kD 
(Zap70), and protein kinase C θ (PKC-θ) (70). Another key signalling target of PD-1 
is the phosphatidylinositol-3-kinase (PI3K) pathway (36, 113). PD-1 blocks the 
activation cascade mediated by PI3K by reducing the phosphorylation of serine-
threonine kinase Akt (36). Specifically, the PD-1-mediated inhibition of the PI3K–Akt 
signalling pathway involves the targeting of phosphatase and tensin homolog (PTEN) 
protein phosphorylation and phosphatase activity, which are mediated by CK2. PTEN 
is a serine–threonine phosphatase that regulates PI3K activity suppressing 
downstream signals of the PI3K complex. During T-cell activation, PTEN is 
phosphorylated by CK2 in the S380–T382–T383 serine-threonine cluster within the 
C-terminal regulatory domain (114, 115). This phosphorylation leads to a stabilized 
and more abundant PTEN but it also suppresses PTEN phosphatase activity (116). 
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PD-1 modulates this pathway by blocking CK2 thereby resulting in diminished PTEN 
abundance but increased PTEN phosphatase activity and consequent reduced 
signalling via PI3K and Akt (116).  
Another mechanism by which PD-1 modulates T cell function is by targeting 
the Ras–MEK–ERK pathway (70, 113). In T cells, the protein PLC-γ1 is responsible 
for the formation of two molecules, diacylglycerol (DAG) and inositol triphosphate 
(IP3). IP3 acts by releasing calcium from cell organelles, a mechanism important for T 
cell activation. Calcium and DAG activate a RasGRP1 protein, which is responsible 
for conversion of GDP-Ras into GTP-Ras leading to downstream activation of the 
MEK-ERK-MAP kinase pathway and to cell proliferation and cell differentiation 
(117). The PD-1 receptor acts by inhibiting the activation of PLC-γ1 impairing the 
activation of Ras and negatively modulating the MEK–ERK-MAP kinase pathway 
(113).  
PD-1 can also induce the transcription factor BATF41, which is responsible 
for immune cell differentiation but is unable to modulate p38 MAP kinase activation 
(113) indicating that PD-1-mediated signalling does not cause a global inhibition but 
rather acts on specific pathways. Interestingly, T cell functions appear to be 
differentially sensitive to PD-1 expression. Wei et al. developed a model to study PD-
1 signalling in primary human T cells and investigated how PD-1 expression affected 
T cell function. High levels of PD-1 expression were required to inhibit macrophage 
inflammatory protein 1 beta (MIP-1β) production while lower levels were required to 
block cytotoxicity and IFN-γ production, and very low levels of PD-1 expression were 
enough to inhibit TNFα and IL-2 production as well as T cell expansion (118).   
Other studies have suggested that PD-1 might also have a role in modulating 
interactions between T cells and dendritic cells.  
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During T cell activation in vivo, the duration of contact between T cells and 
dendritic cells is highly variable and it ranges from minutes to several hours. Three 
distinct phases have been described for T cell priming. During phase I, lasting 
approximately 8 hours, T cells migrate and establish frequent contacts with dendritic 
cells. During phase II, which can range between 8 to 20 hours, T cells mainly form 
stable contacts with dendritic cells and initiate cytokine secretion. During phase III, 
which lasts for the subsequent 24 hours, T cells dissociate from dendritic cells and 
start to proliferate. T cells that remain in the migratory state instead of engaging with 
dendritic cells are thought to become anergic (119).  
Fife et al. used a mouse model of diabetes in which islet-specific TCR 
transgenic T cells stimulated with an islet antigen peptide-mimic lose the natural stop 
signal becoming anergic and showed that blockade of PD-1 interaction with its ligand 
PD-L1 is able restores stable T cell–dendritic cell contacts preventing induction of 
anergy (120). Similarly, Honda et al. used a mouse model of hypersensitivity in the 
skin to demonstrate that blockade of PD-1/PD-L1 enhances T cells interactions with 
antigen-bearing APCs (121). These two studies suggest that PD-1 might prevent the 
formation of stable interactions between T cells and dendritic cell reducing the 
development of effector functions and reducing APC-mediated activation. In contrast 
with these findings, it was shown that in a model of lymphocytic choriomeningitis 
virus infection, PD-1 blockade during the early stage of infection led to rapid 
detachment and migration of T cells away from antigen-bearing APCs (122). The 
observed differences are likely a consequence of the different experimental models 





Figure 1.4 Effects of PD-1 on different signalling pathways in T cells.  
During T-cell receptor (TCR) crosslinking the cytoplasmic tail of PD-1 become 
phosphorylated. SHP-2 is recruited to the ITSM. Phosphorylation of TCR proximal signalling 
molecules, including LCK and ZAP-70, is impaired. Activation of the PI3K–Akt–mTOR and 
Ras-MEK-ERK pathway is also inhibited. These events modulate cell-cycle progression, gene 
transcription, metabolism, and epigenetic programs in T cells. 
 
 
1.8  PD-1 effect on T cell metabolism 
The metabolism of resting T cells is characterised by oxidation of glucose-
derived pyruvate, along with lipids and amino acids. This process produces adenosine 
triphosphate (ATP), which is required for immune surveillance. Following activation, 
T cells undergo metabolic reprogramming and aerobic glycolysis and glutamine 
oxidation intensifies. These mechanisms lead to production of biosynthetic precursors 
required for rapid cell growth and proliferation. Once the immune response is 
completed, the surviving cells acquire a memory phenotype and revert back to lipid 
oxidation (123). Patsoukis et al. have demonstrated that PD-1 engagement in activated 
T cells suppresses oxygen consumption and T cells become unable to engage in 






























increased (124). PD-1 modulates cell metabolism by promoting FAO of endogenous 
lipids. This is achieved by increased expression of carnitine palmitoyl transferase and 
induction of lipolysis as shown by increased adipose triglyceride lipase, increased 
glycerol and elevated release of fatty acids. Upon PD-1 engagement, glutathione, a 
molecule with strong antioxidant properties is decreased indicating the presence of an 
oxidative environment in T cells receiving PD-1 signals (124). The possibility that 
PD-1 may lead to a more oxidative environment is further suggested by a study 
showing that after allogeneic bone marrow transplantation, both murine and human 
alloreactive T cells upregulate PD-1 and increase the production of reactive oxygen 
species (ROS) derived from fatty acid oxidation facilitating apoptosis of alloreactive T 
cells. Furthermore, cell sensitivity to metabolic inhibition by F1F0–ATP synthase 
complex inhibitors also increase suggesting that PD-1-mediated signalling is able to 
skew the cell towards an oxidative environment (125). These data suggest that the 
effect on T cell metabolism upon PD-1 engagement might have a role in PD-1–
mediated T-cell dysfunction during chronic infections and cancer. 
 
1.9 Reverse signalling via PD-L1 & PD-L1:CD80 interaction 
PD-L1 and PD-L2 ligands modulate TCR and BCR signalling by engaging 
with the PD-1 receptor but new evidence indicate that they might also deliver reverse 
signals on APCs.  Kuipers et al. cultured bone marrow-derived mouse DCs with a 
soluble PD-1-Ig fusion protein containing the extracellular domain of mouse PD-1 
fused to the constant region of human IgG and demonstrated that this soluble form of 
PD-1 (sPD-1) inhibited DC activation/maturation and increased IL-10 production in a 
mechanism 2,3-dioxygenase (IDO)-independent. Neutralisation of sPD-1 with anti-
PD-1 was shown to prevent these effects, suggesting a PD-1-specific effect occurring 
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via PD-L1 or PD-L2 although the specific ligand responsible for such an effect was 
not investigated (126). Different lines of evidence also indicate that B7-1 (CD80) can 
bind and signal via the PD-L1 ligand and vice versa. Using the technique of surface 
plasmon resonance Butte et al. (127) demonstrated that there is a specific interaction 
between PD-L1 and B7-1 (127). The PD-L1:B7-1 interaction was found to have an 
affinity (∼1.7 µM) which is intermediate between B7-1:CD28 (4 µM), B7-1:CTLA-4 
(0.2 µM) and PD-L1:PD:1 (0.5 µM) affinities. The authors found that B7-1:PD-L1 
interactions induced an inhibitory signal into mouse T cells. Specifically, ligation of 
PD-L1 on CD4+ T cells by B7-1 but also ligation of B7-1 on CD4+ T cells by PD-L1, 
was shown to deliver an inhibitory signal. Interestingly, anti-CD3/B7-1-coated beads 
were able to reduce in vitro proliferation of CD28/CTLA4-/- T cells while no effect on 
proliferation and cytokine production was found on T cells lacking all the receptors 
for B7-1 (CD28, CTLA-4, and PD-L1).  
This indicates that B7-1 acts specifically through PD-L1 on the T cell in the 
absence of CD28 and CTLA-4. Similarly, anti-CD3/PD-L1-coated beads were able to 
decrease proliferation and cytokine production in T cells lacking the receptor for PD-
L1 (PD-1) while proliferation was no longer affected in T cells lacking all known PD-
L1 receptors (PD-1 and B7-1) demonstrating the inhibitory effect of PD-L1 ligation of 
B7-1 on T cells. These results are important as they demonstrate a specific 
bidirectional interaction between B7-1 and PD-L1 that inhibits T cell responses (127).  
Very little is known about PD-L1 function on PD-L1 expressing T cells. 
Latchman et al. generated a PD-L1-deficient mouse and showed that CD4+ and CD8+ 
T cell responses were markedly enhanced as compared to wild-type mice both in vitro 
and in vivo. Compared to wild-type dendritic cells, PD-L1-/- dendritic cells were able 
to stimulate to a greater extent CD4+ T cell responses and PD-L1-/- CD4+ T cells were 
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shown to produce more cytokines than wild-type CD4+ T cells in vitro, indicating an 
inhibitory role for PD-L1 on both APCs and T cells (102). 
 
1.10 Immune checkpoints: TIGIT, TIM-3 and LAG-3  
CTLA-4 and PD-1 are strong regulators of T cell responses and effective 
targets in cancer immunotherapy. Furthermore, CTLA-4-Ig (abatacept) has proven 
successful in the treatment of chronic autoimmune diseases such as RA and JIA. 
Unfortunately, many cancer and arthritis patients fail to respond to therapies based on 
immune checkpoints regulatory activity. The next sections will briefly describe three 
inhibitory receptors, TIGIT, TIM-3 and LAG-3, which have been shown to modulate 
autoimmunity but also cancer progression. These receptors are promising targets for 
future clinical trials and a better understanding of their functions will be important to 
introduce to the clinic new therapies that target these receptors. 
 
1.10.1  TIGIT 
The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory 
receptor of the immunoglobulin (Ig) superfamily.  TIGIT is a type 1 transmembrane 
protein containing an IgV extracellular domain and an immunoglobulin tail tyrosine 
(ITT)-like phosphorylation motif followed by an immunoreceptor tyrosine-based 
inhibitory motif (ITIM) in the cytoplasmic tail. TIGIT ligands are Ig-like 
transmembrane cell adhesion molecules called nectins and include CD155, CD112 
and CD113 (128). TIGIT is not found on naïve T cells, but is expressed on activated 
and memory T cells, Treg cells (128) and on NK cells and NKT cells (129) in both 
mice and humans. In human, TIGIT crosslinking with CD155 induces a tyrosine 
phosphorylation on the receptor’s ITT domain followed by the recruitment of the 
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phosphatase SHIP-1 leading to inhibition of phosphatidylinositol 3-kinase (PI3K), 
MAPK, and NF-kB signalling (130). TIGIT is also able to downregulate NK cell 
killing ability and to induce production of anti-inflammatory IL-10 by APCs (131). 
A single nucleotide polymorphism (SNP) in the positive regulator CD226 
(Gly307Ser) of the TIGIT-CD226 pathway is associated with predisposition to 
multiple autoimmune diseases in humans including type 1 diabetes, multiple sclerosis, 
and rheumatoid arthritis (132). In the in collagen-induced arthritis (CIA) models 
blockade of TIGIT is associated with exacerbation of the disease and with enhanced 
proinflammatory T cell responses (133) suggesting that TIGIT plays an important role 
in maintaining peripheral tolerance by negatively modulating T cell activation. In a 
pre-clinical murine model, Johnston et al. demonstrated that TIGIT is co-expressed 
with PD-1 in tumour-infiltrating CD8+ T cells and that blockade of both PD-L1 and 
TIGIT leads to a restored anti-tumour immunity which is higher as compared to PD-
L1 blockade alone (134). In human melanoma patients, Chauvin et al. showed that 
TIGIT and PD-1 are overexpressed on both tumour antigen-specific CD8+ T cells and 
tumour-infiltrating CD8+ T cells and that blockade of these receptors leads to 
increased cell proliferation, cytokine production, and degranulation of cytotoxic CD8+ 
T cells (135). Collectively, these data indicate that TIGIT acts by dampening effector 
T cell responses and promotes T cell regulation. 
 
1.10.2 TIM-3 
 The T cell/transmembrane, immunoglobulin, and mucin 3 (TIM-3) co-
inhibitory receptor is a transmembrane proteins containing a single IgV domain 
followed by a mucin domain and a cytoplasmic tail with a tyrosine-based signalling 
motif (136). TIM-3 is expressed by a subset of activated CD4+ T cells and it is further 
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upregulated upon anti-CD3/CD28 stimulation. TIM-3 is expressed at high levels on in 
vitro polarized Th1 cells and at lower levels on Th17 cells (137). TIM-3 expression is 
also upregulated by antigenic stimulation and in response to proinflammatory 
cytokines. TIM-3 interaction with its ligand Galectin-9 (Gal-9) causes an inhibitory 
signal resulting in apoptosis of Th1 cells (138, 139) and cytotoxic CD8+ T cells in 
vitro (140). Blockade of Gal-9 via siRNA and Gal-9 KO in mice (138) induces 
symptoms of experimental autoimmune encephalomyelitis (EAE), the mouse model of 
multiple sclerosis (141). Furthermore, both TIM-3 blocking antibody and TIM-3–Ig 
fusion protein have been shown to worsen the symptoms of EAE (138, 142, 143) and 
type I diabetes in non-obese (NOD) mice (144). In line with experiments performed 
on TIGIT, it has been shown that in mice, combined treatment with anti–Tim-3 and 
anti–PD-L1 enhances antitumor immune responses as compared to single treatment 
indicating that both pathways are important in tumour clearance (145). These data 
strongly support the idea that TIM-3 on activated T cells plays a critical role in 
attenuating immune responses. 
 
1.10.3  LAG-3 
LAG-3 is another T-cell regulatory molecule belonging to the Ig superfamily. 
LAG-3 associates with the TCR:CD3 complex following TCR engagement and 
negatively regulates signal transduction (146). This molecule can be found on 
activated CD4+ and CD8+ T cells and on activated CD4+ Tregs (147). LAG-3 is also 
detected on Tr1 cells (148) on a subset of NK cells (149), B cells (150) and 
plasmacytoid DCs (151). In non-activated T cells, Bae et al. and Woo et al. have 
shown that LAG-3 is localized and degraded within the lysosomal compartments (152, 
153). LAG-3 is connected to development of autoimmunity in mice. LAG-3 blockade 
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or LAG-3 deficiency has been shown to accelerate diabetes in the NOD mice (154, 
155), while combined LAG-3 and PD-1 deficiency in mouse is a trigger for the 
development of severe autoimmune conditions and early death in several different 
genetic backgrounds (154, 156) indicating that LAG-3 is a strong negative T cell 
regulator. LAG-3 and PD-1 can be found on both CD4+ and CD8+ tumour infiltrating 
lymphocytes in several pre-clinical murine models of cancer and blockade of both the 
Lag-3 and PD-1 pathways has been shown to ameliorate anti-tumour responses 
mediated by CD8+ T cells (156). Similarly to mouse, co-expression of Lag-3 and PD-
1 can be found in dysfunctional CD8+ T cells in human ovarian cancer and, as 
observed in pre-clinical cancer models, Lag-3 and PD-1 co-blockade led to higher 
cytokine production and proliferation of CD8+ T cells (157). Indications of the 
potential of LAG-3 to regulate immune responses come from the observation that 




1.11 The role of PD-1 in cancer  
The role of PD-1 in regulating T cell activation in human autoimmune diseases 
remains unclear. On the contrary, PD-1 function has been extensively investigated in 
cancer studies. Hence, it is important to illustrate the current literature on this matter.  
The immune system has the ability to recognise and eliminate malignant cells. 
However, the tumour microenvironment is highly immunosuppressive and tumour 
cells have developed mechanisms to evade immune regulation. T cell inhibitory 
pathways such as the PD-1- and CTLA-4-mediated pathways are in place to regulate 
the strength and duration of immune responses. Through these pathways the immune 
system is able to limit immune-mediated tissue damage, control inflammation and 
maintain tolerance to prevent autoimmunity.  
A key component of the immunosuppressive milieu found in many tumours is 
the expression of PD-L1 on malignant cells. Early studies performed in animal models 
demonstrated that expression of PD-L1 on tumours inhibits T cell activation and 
reduces lysis of malignant cells leading to increased death of tumour-specific T cells 
(160, 161). Importantly, disrupting the PD-1/PD-L1 pathway by using anti-PD-L1 
monoclonal antibodies or by injecting tumour cells into Pdcd1−/− mice was shown to 
augment antitumor responses and tumour-specific cytotoxicity (161-163). Tumour-
associated APCs can also modulate immune responses via the PD-1 pathway. Curiel 
et al. demonstrated that tumour environmental factors can induce PD-L1 expression 
on a population of tumour-associated myeloid DCs, and further showed that T cells 
cultured with PD-L1-blocked DCs had a stronger ability to inhibit autologous human 
ovarian carcinoma growth in non-obese diabetic-severe combined immunodeficient 
(NOD-SCID) mice (164). This indicates that upregulation of PD-L1 in the tumour 
 48 
microenvironment and on tumour infiltrating APCs have a role in reducing T-cell 
cytotoxic activity.  
In human, PD-L1 expression has been demonstrated on a wide variety of 
tumours including, but not limited to, lung, ovarian, melanoma, bladder, pancreas, 
gastric, non–small cell lung cancer, breast cancer, squamous cell head and neck cancer 
and Hodgkin lymphoma. It is now widely accepted that cancer cells use this ligand to 
negatively modulate the cytotoxic activity of tumour-specific PD-1+ T cells (165-
176). Multiple mechanisms drive PD-L1 and PD-L2 expression on tumour cells. 
These mechanisms include constitutive activation of signalling pathways, 
chromosomal copy gain, viral infection and cytokine stimulation. Persistent activation 
of different signalling pathways including the epidermal growth factor 
receptor (EGFR) pathway, the mitogen-activated protein kinase (MAPK) pathway and 
the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)–Akt pathway (177-180) 
can increase PD-L1 expression in animal model systems. Elevated expression of 
signal transducer and activator of transcription 3 (STAT3) and hypoxia-inducible 
factor (HIF)-1 transcription factors (181, 182) are also associated with PD-L1 
upregulation in various cancer types through both transcriptional and post-
transcriptional mechanisms.  
Chromosomal copy gain is another identified mechanism driving PD-L1 
upregulation. In classical Hodgkin’s lymphoma, a type of cancer characterised by the 
presence of a specific malignant cell type called Reed-Stemberg Cell (183), copy 
number alterations involving chromosome 9p24.1 result in overexpression of the PD-1 
ligands PD-L1 and PD-L2 on tumour cell surface and it is associated with poor 
prognosis (174-176). Copy alterations in JAK2, which is also located on chromosome 
9p24.1, lead to increased JAK-STAT signalling and further PD-L1 overexpression 
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(175). PD-L1 expression on tumour cells is also modulated by viral infection, as 
shown by the presence of positive PD-L1 cells in the Epstein–Barr virus (EBV)–
positive gastric and nasopharyngeal cancers (184, 185), and by epigenetic mechanisms 
through microRNAs (miRs). MiRs are non-coding single-stranded RNAs of 22–24 
nucleotides in length, which have the ability to regulate gene expression by binding 
target gene mRNAs preventing translation into protein (186). Several lines of 
evidence show that miR-513, miR-570, miR-34a and miR-200 all have an inverse 
correlation with PD-L1 expression complementing with three untranslated regions of 
PD-L1 mRNA and repressing PD-L1 protein expression (187-190).  
Malignant cells can also upregulate PD-L1 in response to a proinflammatory 
milieu. When tumour-infiltrating T cells recognise tumour antigens presented via 
MHC molecule by APCs they mount tumour-specific responses, which include 
production of cytokines. Within the tumour microenvironment IFN-γ and IL-4 have 
been shown to induce expression of PD-L1 and PD-L2 on cancer cells (107). 
Inflammatory mediators can also induce expression of PD-L1 and PD-L2 on other cell 
types in the tumour microenvironment including macrophages, dendritic cells, and 
stromal cells (107). Activated PD-1+ tumour-infiltrating T cells engage with PD-L1+ 
and PD-L2+ cells and this results in a very selective suppression of tumour-specific T 
cells activity.  
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1.12 The other side of immune checkpoint blockade: inflammation 
In recent years, drugs blocking the negative immune checkpoint regulators 
CTLA-4 and PD-1 have shown remarkable clinical activity. These therapies have 
added immeasurably to the longevity of cancer patients. However, they come with an 
associated cost: the development of numerous inflammatory conditions that can 
resemble autoimmune responses. The following sections will describe the role of PD-
1 in the development of autoimmunity and will review the current literature related to 
the PD-1 pathway in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Next, a 
description of RA and PsA will be provided along with data outlining differences and 











Figure 1.5 Clinical application for PD-1 agonists and antagonists.  
Signalling via PD-1 (ON) leads to cytotoxic T cell inhibition and tumour progression. PD-1 
antagonists that enhance T cell-mediated immune response by blocking PD-1 are successful in 
cancer treatment. Conversely, a lack of signalling (OFF) via PD-1 might be responsible for 
hyperactivation of T cells and autoimmunity. PD-1 agonists that enhance PD-1-mediated 
signalling may be useful in treating autoimmune diseases including rheumatoid arthritis (RA) 
















1.12.1  PD-1 and CTLA-4 blockade in human cancer 
In multiple preclinical models, blockade of the PD-1/PD-L1 pathway enhanced 
antitumor T cell cytotoxicity and proliferation, thereby promoting more efficient 
tumour clearance (191). PD-1 is now used as a therapeutic target in a vast array of 
cancers and targeting the PD-1 pathway has been shown to drive expansion of oligo-
clonal populations of tumour-infiltrating CD8+ T cells (191, 192). Checkpoint 
inhibitor drugs directed towards the PD-1 pathway such as nivolumab (anti-PD-1), 
pembrolizumab (anti-PD-1), atezolizumab (anti-PD-L1) and towards CTLA-4 
(ipilimumab), have shown remarkable clinical activity in various tumours (165, 193-
196). Given the success of these drugs in treating cancer, two new compounds named 
avelumab and durvalumab (both anti-PD-L1 mAb) have recently received 
commercialisation approval and are now available for cancer patients. These therapies 
are ground breaking in enhancing disease free survival and life expectancy (165). 
However, because the PD-1 and CTLA-4 checkpoint pathways have also key roles in 
the maintenance of self-tolerance, blocking their biological activity can lead to the 
development of serious adverse events (AEs) including autoimmune-like 
inflammatory conditions (197, 198). The strong immune responses following 
checkpoint inhibitor therapy can cause damage to tissues and organs that are normally 
protected by the correct functional activity of the PD-1 and CTLA-4 pathways. 
Immune-related AEs can include mucosal and cutaneous toxicity, gastrointestinal 
toxicity, pulmonary, endocrine and renal toxicity and in some cases life-threatening 
disorders such as Sweet’s syndrome, Stevens-Johnson syndrome and toxic epidermal 
necrolysis (199-202). Dermatological AEs, have been described in >30% of patients 
who received nivolumab or pembrolizumab for melanoma (202) while 15% of 
patients treated with nivolumab and ipilimumab combination therapy developed 
 52 
hypothyroidism (203). More severe AEs like colitis, pneumonitis and hepatitis 
although less common were reported in patients with melanoma treated with 
ipilimumab (54, 203). In non-small cell lung cancer, 5% of patients treated with anti-
PD-1 (nivolumab) developed pneumonitis (195). Pneumonitis was also seen in 
patients treated for Renal Cell Carcinoma (204) and in melanoma patients without 
BRAF mutation (194). Finally, autoimmune hepatitis was reported in 5%–10% of 
patients treated with either nivolumab or ipilimumab (194, 205). Treatments targeting 
PD-1 have shown a more favourable safety profile compared to those targeting 
CTLA-4, with lower toxicity and milder inflammatory side effects (199, 206). This is 
in line with the milder inflammatory pathology observed in PD-1-deficient compared 
to CTLA-4-deficient mice and likely reflects the more restricted role of PD-1 in 
constraining on-going immune responses in contrast to the role of CTLA-4 in immune 
homeostasis (95, 207).   
 
1.12.2  PD-1 and autoimmunity in mice 
The fact that checkpoint inhibitor therapies are associated with recurrent AEs 
and autoimmune-like conditions should not be unexpected. Some of the observed side 
effects following PD-1 inhibitor therapy in cancer patients, such as renal or endocrine 
toxic effects and cardiomyopathy, closely resemble the autoimmune manifestations 
described in PD-1–deficient mice and in in vitro targeting of the pathway via PD-1 
blockade (57, 58, 202, 208). Further studies on autoimmune disease models have 
shown that PD-1 interactions with its ligand PD-L1 are important during the initial 
phase of activation and expansion of self-reactive T cells and during the process of 
antigen re-encounter. In the non-obese diabetic (NOD) mouse model of autoimmune T 
cell–mediated diabetes, PD-L1 is increased in the pancreas islet cells and loss or 
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blockade of PD-1 or PD-L1 can exacerbate diabetes, insulinitis and induce 
proinflammatory cytokine production by T cells (110, 209, 210). Further studies have 
also shown that PD-L1 expression on non–bone marrow–derived cells, including islet 
cells, inhibits T cell effector function in tissues (211) suggesting an important role for 
the PD-1 pathway in controlling immune-mediated tissue damage in the periphery 
(212). The PD-1 pathway is also important in controlling self-reactive T cells in the 
experimental autoimmune encephalomyelitis (EAE) model of human multiple 
sclerosis (MS) and PD-1, PD-L1 and PD-L2 are increased on cellular infiltrates within 
the meninges during active EAE disease in C57BL/6 mice (110). Salama et al. 
showed that treatment with anti-PD-1 or anti-PD-L2 blocking antibodies during the 
induction of EAE was able to exacerbate disease severity leading to increases in 
reactive T cells (213).  
Interestingly, further evidence suggest that the B7-1:PD-L1 axis might also 
have a role in controlling the development of autoimmunity in vivo, albeit with a 
weaker impact that the classic PD-1:PD-L1 mediated mechanism. Yadav et al. have 
shown that in the NOD mouse model, Cd80−/− NOD mice develop autoimmunity more 
rapidly as compared to classical NOD but that in Pdcd1−/− and Cd274−/− NOD mice 
stronger inflammation is found as compared to the Cd80−/− NOD (214). This suggests 
a weaker effect mediated by the B7-1:PD-L1 axis as compared to the PD-1:PD-L1 
interaction.  Further studies are needed to clarify the role of PDL1:B7-1 interactions in 
promoting peripheral tolerance.  
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1.12.3  PD-1 in mouse and human arthritis  
A strong indication that PD-1-mediated signalling is important in rheumatic 
disease comes from studies on the collagen II induced arthritis (CIA) murine model. 
The CIA is a murine experimental model of human RA, where intradermal 
administration of type II collagen leads to joint swelling, articular cartilage destruction 
and ankylosis of the joints.  Using this model, Wang et al. showed that triggering the 
PD-1 receptor in CIA mice through administration of a PD-L1 immunoglobulin 
ameliorated the disease as assessed by clinical arthritis score and histology of the joint 
assessments. Furthermore, it was shown that PD-L1-Ig treatment reduced the levels of 
proinflammatory cytokines IL-17 and IL-23 in the serum of treated mice and inhibited 
CII-specific splenocyte proliferation (215). Similarly, Raptopoulou et al. 
demonstrated that Pdcd1−/− mice had increased incidence/severity of CIA, enhanced T 
cell proliferation and increased production of IFN-γ and IL-17 cytokines. In line with 
work from Wang et al. (215) it was shown that PD-L1 administration ameliorated the 
severity of CIA and reduced T cell responses (216). More recently, Yang et al. 
confirmed that PD-1 deficiency leads to the development of severe CIA in mice and 
described aberrant antigen-specific Th17 responses and deregulated activation of 
PKC-θ and Akt. Interestingly, it was shown that treating Pdcd1−/− mice with an 
inhibitor of PI3K, which is upstream of PKC-θ and Akt, significantly suppressed the 
disease severity (217). 
In humans, indications that disruption of the PD-1 pathway might lead to 
development of autoimmunity are found in studies showing that polymorphisms in the 
PDCD1 gene are associated with different human autoimmune diseases, including 
SLE, type 1 diabetes, RA, psoriasis, ankylosing spondylitis (AS) and MS (218, 219). 
In line with these findings, a growing spectrum of rheumatic events is emerging 
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following PD-1 inhibitor therapies in cancer patients. Arthritis and tenosynovitis have 
been described in metastatic melanoma patients treated with anti-PD1 antibody (220). 
Man et al. reported a case of psoriasis and psoriatic arthritis induced by anti-PD-1 
nivolumab in a patient with advanced lung cancer (221). More recently, Cappelli et al. 
analysed 13 patients treated with anti-CTLA-4 or a combination of anti-CTLA-4 and 
anti-PD-1 and found that 9 of 13 patients developed inflammatory arthritis with cases 
of synovitis and inflammatory synovial fluid. In the studied cohort further AEs 
included pneumonitis, colitis, interstitial nephritis and thyroiditis and patients required 
treatment with corticosteroids or in some cases methotrexate (MTX) and antitumor 
necrosis factor (anti-TNF) therapy (222).   
Due to the lack of dedicated studies, it is unclear whether i) pre-existing 
autoimmune disorders are exacerbated by checkpoint inhibitor therapy and ii) whether 
the presence of AEs augments or weakens anti-tumour responses.  A recent study 
performed on advanced melanoma patients with pre-existing autoimmune disorders 
including RA, psoriasis, inflammatory bowel disease, multiple sclerosis, autoimmune 
thyroiditis and SLE found that CTLA-4 blockade with ipilimumab was associated 
with exacerbations of autoimmune disease in 27% of analysed patients (223). 
Currently, it remains unclear whether anti-PD-1 blockade is able to exacerbate pre-
existing autoimmunity. These preliminary results show that immuno-oncology 
therapies and development of autoimmune-like AEs are strongly interconnected and 
indicate that comprehensive studies are required to properly understand the biological 
mechanisms involved in checkpoint inhibitors treatment. Further characterisation of 
PD-1 in human arthritis is provided in chapter 3, chapter 4 and chapter 5. 
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1.13 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that 
typically affects the hands and feet, although any joint lined by a synovial membrane 
may be affected. RA is characterised by cell migration to the synovial compartment, 
synovial and systemic inflammation, autoantibody production (i.e. rheumatoid factor 
and anti-citrullinated protein antibody (ACPA), cartilage and bone destruction and 
systemic features, which include cardiovascular, pulmonary and skeletal disorders 
(224). RA affects 23.7 million people worldwide and although multiple treatments are 
available, up to one third of patients do not adequately respond, and about half stop 
responding to any particular disease-modifying antirheumatic drug (DMARD) within 
five years (225-230). As a result, additional investigations to develop alternative 
treatments are needed. 
 
1.13.1  Genetics and environmental factors in RA 
It has been demonstrated that in patients who are positive for rheumatoid 
factor (RF) or ACPA there is a strong association with the human leukocyte antigen 
(HLA)-DRB1 locus and that alleles containing a common amino acid motif (QKRRA) 
in the HLA-DRB1 locus confer susceptibility to RA (231). This suggests that RA is a 
disease where predisposing T cell repertoire selection, antigen presentation or 
alterations in peptide affinity might have a role in promoting autoreactive immune 
responses. Other identified risk factors associated with predisposition to ACPA-
positive RA include dysregulation in nuclear factor κB (NF-κB)–dependent signalling, 
T cell stimulation, T cell activation and functional differentiation (i.e. TRAF1-C5, 
STAT4, PTPN22, CTLA-4 and PD-1) (232-236). Genetic risks for ACPA-negative 
RA are also important and include different HLA alleles  (HLA-DRB1*03), interferon 
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regulatory factors (Interferon response factor 5) and lectin-binding proteins (237). 
Studies on gene and environment interactions have shown that blood transfusions, 
obesity and especially smoking and other pulmonary stress like silica exposure, can 
increase the risk of developing RA especially among individuals with susceptibility 
HLA-DR4 alleles (238). Infectious agents such as Epstein-Barr virus, 
cytomegalovirus, Escherichia Coli and Porphyromonas gingivalis have also been 
linked to the development of RA (239-241). 
 
1.13.2  Innate immunity in RA 
Different innate effector cells can be found in RA. Macrophages, mast cells, 
natural killer cells and neutrophils can be detected both in the synovial membrane and 
in the synovial fluid (242, 243). Macrophages are the central effectors in promoting 
inflammation in RA. Macrophages are activated by toll-like receptors (TLRs), 
nucleotide-binding oligomerisation domain (NOD)-like receptors (244), inflammatory 
cytokines, T cell interaction and by the protease-rich milieu found in the inflamed 
synovium (245). Monocytes play several different roles in RA including, but not 
limited to, antigen presentation to T cells, polarisation of CD4+ T helper cells, 
recruitment of T helper cells in the arthritic joint and modulation of CD4+ Treg cells 
function through production of soluble mediators (246). Monocytes can release 
proinflammatory cytokines including TNFα, IL-1β, IL-6, IL-15, IL-12 and IL-23 and 
they are able to produce reactive oxygen species (ROS) and matrix degrading-
enzymes (246-248). RA-derived monocytes from the site of inflammation are able to 
specifically promote Th17 responses in a TNFα and IL-1β, but not IL-6 or IL-23-
dependent manner, compared with resting CD14+ monocytes from the blood (13). 
CD14+CD16- and CD14+CD16+ monocytes activated in vitro with LPS or with 
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cytokines known to be present in the RA joint, can induce expression of 
proinflammatory cytokines IL-17 and IFNγ by CD4+CD25+CD127low Treg cells, a 
mechanism that occurs in a IL-6-, TNFα-, and IL-1β-dependent manner (249). Recent 
work from our lab also showed that SF-derived monocytes from RA patients are 
resistant to spontaneous and anti-Fas-mediated apoptosis, they display increased levels 
of mature mir-155 expression and a corresponding decrease of two mir-155-target 
mRNAs, namely apoptosis mediators CASP10 and APAF1, suggesting that an 
increase in mir-155 may partially contribute to this apoptosis-resistant phenotype 
(250). 
Mast cells and neutrophils are also highly represented in the inflamed 
synovium and synovial fluid. Mast cells can produce vasoactive amines, cytokines 
including IL-17A, chemokines and proteases while neutrophils contribute to 
inflammation by synthesizing prostaglandin, proteases and reactive oxygen 
intermediates (251-253). NK cells are another cell phenotype detected in the synovial 
fluid of RA patients. RA-derived NK cells are generally CD56bright, highly 
CD94/NKG2A positive and have decreased expression of KIRs and CD16. SF-
derived NK have been shown to produce more TNFα as well as IFNγ compared to 
peripheral blood derived NK cells and have upregulated expression of several 
chemokine receptors and adhesion molecules suggesting a role in cell recruitment into 
the inflamed synovium (254-256). 
 
1.13.3 Adaptive immunity in RA 
The genetics of RA and the presence of autoantibodies indicate that adaptive 
immunity is at the centre of RA pathogenesis.  The inflamed RA synovium contains 
both lymphoid (T, B and NK cells) and myeloid cells such as monocytes, 
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macrophages and dendritic cells. Both cell lineages are capable of producing 
proinflammatory cytokines contributing to a state of chronic inflammation (257). 
Myeloid cells express HLA class II molecules and a variety of costimulatory 
molecules important for T cell activation and antigen presentation (258-260). B 
lymphocytes have multiple important functions in RA. They are responsible for the 
production of the rheumatoid factors and anti-citrullinated protein antibodies, they 
present antigens to T cells and they further activate them through expression of 
costimulatory molecules. B cells are able to produce chemokines and cytokines 
promoting leukocyte infiltration into the joints and can contribute to angiogenesis and 
synovial hyperplasia (261, 262).  
The pathogenic role of CD20+ B cells is confirmed by the efficacy of cell-
depleting drug rituximab which is approved for treatment in RA (263). RA has been 
long considered to be a type 1 helper T cells (Th1)-mediated disease. However, in 
recent years, another cell subset named type 17 helper T cells (Th17) has become 
increasingly important in the context of RA progression. Macrophage- and dendritic 
cell-derived cytokines such as transforming growth factor β (TGF-β), IL-1β, IL-6, IL-
21, and IL-23 can all promote Th17 differentiation. The Th17 subset produces 
interleukin (IL)-17A, IL-17F, IL-21, IL-22, IL-6 and TNFα and it positively correlates 
with systemic disease activity (264-266).  
 
1.13.4  Key cytokines & intracellular signalling pathways in RA 
The cytokine produced by the numerous SF-derived populations are central in 
the pathogenesis of RA and their pattern of expression appears to change over time. 
Raza et al. analysed the cytokine profile of newly diagnosed early RA patients and 
patients with established RA and described that in early arthritis IL-2, IL-4, IL-13, IL-
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17, IL-15 were significantly elevated as compared to patients who did not develop 
RA. Furthermore, this specific cytokine profile was no longer present in established 
RA suggesting that certain cytokines might be involved in influencing the 
microenvironment required for chronic RA (267). Cytokines TNFα, IL-6 and IL-1β 
play a fundamental role in the progression of RA (257, 268). TNFα drives cytokine 
and chemokine expression and it has been shown to upregulate endothelial-cell 
adhesion molecules promoting cell migration. TNFα is also important for fibroblast 
function and is a potent inducer of angiogenesis. Finally, TNFα-mediated signalling is 
capable of suppressing regulatory T cells promoting effector T cell proliferation (269-
272). IL-6 can drive lymphocyte activation, autoantibody production and promote 
acute phase responses and lipid-metabolism dysregulation. (270, 273). Interleukin-1 
family cytokines like IL-1α and IL-1β are also found in RA (274). IL-1β is a potent 
proinflammatory cytokine. It promotes activation of leukocytes, endothelial cells, 
chondrocytes and osteoclasts (257). Furthermore, IL-1β is able to trigger 
vasodilatation and to attract monocytes and neutrophils at the site of inflammation 
(270, 275). The central role of these cytokines has been confirmed by successful 
therapeutic blockade of TNFα and IL-6 in patients with RA (276). 
Although the network of intracellular signalling pathways that regulate 
cytokine-receptor mediated functions in RA is highly complex, different attempts 
have been made to target new molecules. The JAK pathway mediates the function of 
several cytokines, interferons and growth factors and it is upregulated in RA (277).  
Unlike other therapies for RA, which are directed at extracellular targets such as pro-
inflammatory cytokines, novel approaches targeting the intracellular pathways 
modulated by inflammatory cytokine networks have shown promising results. Recent 
progress in treating RA has been achieved with Janus kinase (JAK) inhibitors 
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(Jakinibs) (278, 279) and this pathway is now targeted in RA by a dedicated drug 
(tofacitinib) (280, 281). Interestingly, the use of this JAK1/JAK3 inhibitor has shown 
promising results in other inflammatory diseases including psoriasis (282, 283) and 
psoriatic arthritis (284, 285) indicating that targeting intracellular signalling pathways 
might be beneficial in group of patients which do not respond to or progress after 
currently available treatments. 
Another molecule that has drawn interest as a new possible target for treatment 
was the spleen tyrosine kinase (Syk). Syk is a cytoplasmic tyrosine kinase that is an 
important mediator of immunoreceptor signalling in a variety of cells, including mast 
cells, macrophages, neutrophils, and B cells (286). Syk expression can been detected 
in RA synovium and increased levels of phosphorylated Syk have been described in 
RA synovial tissue as compared to osteoarthritis controls. Syk activation is important 
for TNF–induced cytokine and metalloproteinase production in RA synoviocytes 
(286).  R788 (fostamatinib), a prodrug of active metabolite R406, was shown to 
inhibit Syk kinase and to be active in a variety of in vitro and in vivo models, 
suggesting potential activity in the treatment of RA. Fostamatinib was investigated as 
a new therapy in rheumatoid arthritis (287-289) but unfortunately limited efficacy as 
compared to placebo in a Phase III study lead to dismissal of it (290). Other 
intracellular targets, including PI3K, MAPK, Bruton’s tyrosine kinase and 




1.14 Psoriatic Arthritis 
Psoriatic arthritis (PsA) is an inflammatory disease of the joints that develops 
in up to 30% of patients with a skin condition called psoriasis. It is an asymmetric 
arthropathy, which causes pain, stiffness of the joints and an overall reduction of the 
quality of life. Psoriasis usually precedes the development of arthritis by an average of 
10 years, although in some cases the two diseases might appear simultaneously (292, 
293). The diagnosis of PsA is based mainly on clinical and imaging analysis since no 
specific biomarkers are currently known. In 50% of PsA patients, the disease affects 
the distal joints. This is not observed in RA. During disease onset, PsA is 
asymmetrical but with time can develop as polyarticular and symmetrical (294). 
 
1.14.1 Genetic and environmental factors in PsA 
PsA is a highly heritable disease (295).  PsA is associated with class I MHC 
alleles. Frequencies of HLA-B*08 B*27, B*38, and B*39 have all been observed 
(40).  Genome wide association analyses have shown that there is an association 
between PsA and polymorphisms in the gene encoding for the IL-23 receptor (IL23R). 
Furthermore, variants in nuclear factor κB (NF-κB) gene expression (TNIP1) and 
signalling (TNFAIP3) are also associated with psoriatic arthritis.  Association studies 
have identified additional risk alleles in patients with psoriasis and psoriatic arthritis. 
These alleles include interleukin-12A (IL12A), interleukin-12B (IL12B), IL23R, and 
genes that regulate NF-κB (296, 297).  Obesity, severe psoriasis, other localised 
subtypes of psoriasis, trauma or deep lesions at the trauma site are all environmental 
risk factors that can lead to development of psoriatic arthritis (298, 299). 
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1.14.2 T cells in PsA and key cytokines 
T cells are important players in psoriatic arthritis. The presence of association 
with HLA class I alleles as well as oligoclonal CD8+ T cell expansion support the 
hypothesis of a central role for CD8+ T cells in the pathogenesis of PsA. IL-17+CD8+ 
T cells and IL-17A/IL-22 producing cells known as type 3 innate lymphocytes are 
increased in psoriatic synovial fluid as compared with rheumatoid synovial fluid (15, 
300, 301). Recent studies have shown that IL-23, IL-17 and TNFα are likely to be 
very important in the pathogenesis of PsA (15, 301, 302). IFN-α is also important in 
modulating inflammation. This cytokine was shown to activate dermal DCs, which 
triggered the differentiation of Th1 and Th17 cells in the lymph nodes. Th1 and Th17 
cells were shown to migrate back to the dermis and to induce potent inflammatory 
responses (303). 
 
1.15 Similarities and differences between RA and PsA 
RA and PsA are two chronic inflammatory conditions characterised by both 
similarities and differences. Both diseases show signs of tender and soft tissue 
swelling of the joints but following a more accurate analysis the patterns of joint 
inflammation and damage in PsA are distinct from RA, and more closely match the 
clinical changes found in seronegative spondyloarthropathies.  Contrary to RA, PsA 
joint pathology can include the axial skeleton, and specifically the sacroiliac joints and 
the lumbosacral spine, once again, matching what it is observed in ankylosing 
spondylitis (304). PsA and RA have different genetic associations with the major 
histocompatibility complex region that encodes HLA. RA is associated with HLA 
class II, whereas PsA is associated with HLA class I indicating a difference in genetic 
susceptibility and pathogenesis between the two diseases and suggesting that CD8+ T 
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cells, rather than CD4+ T cells, might have a central role in PsA (305-307). 
Furthermore, several genes associated with ankylosing spondylitis and inflammatory 
bowel disease such as the IL-23 receptor, CARD9 and ERAP1 have been also 
identified in patients with PsA (308). Direct comparison of synovial tissue biopsies 
from RA and PsA patients indicate that, as compared to RA, PsA display a less 
marked cellular infiltrate and a less extended hyperplasia of the lining layers of cells. 
Conversely, higher vascularisation can be found in PsA as compared to RA (309). In 
line with these findings increased expression of angiogenic growth factors including 
the vascular endothelial growth factor (VEGF), the angiopoietin 2 (Ang2), and the 
basic fibroblast growth factor (BFGF) are found in the PsA synovium as compared to 
RA (310, 311). As seen for RA, T cells have an important role in promoting 
inflammation in PsA as demonstrated by beneficial effects of therapies such as 
cyclosporine and anti-CTLA-4 (abatacept) in the treatment of PsA (312, 313). 
Specific subsets of T cells are likely responsible for promoting inflammation and 
disease activity as shown by work from Menon et al. which identified an enrichment 
of IL-17+CD8+ T cells in the synovial fluid of PsA patients but not in RA (15). 
Finally, although PsA is not associated with RA-specific circulating autoantibodies 
(i.e. RF and ACPA), it is reported that B-cell aggregates can be found both in PsA and 
RA synovial biopsies although it is not clear what is the role of B cells in PsA (314, 
315). Once again, both similarities and differences can be found in the therapeutic 
responses of RA and PsA. Disease modifying anti-rheumatic drug (DMARD) 
methotrexate (MTX) and biologics such as tumour necrosis factor inhibitors (TNFi) 
appear to be effective in the management of both RA and PsA (316, 317). The fusion 
protein against CTLA-4 (abatacept) which acts by binding to CD80 and CD86 on 
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APCs, blocking the engagement of CD28 on T cells and preventing T cell activation, 
has also shown similar activity in both PsA and RA (48, 313, 318). 
Conversely, different results have emerged from important clinical trials 
targeting the IL-17 and IL-12/IL-23 pathways. The importance of IL-17 and IL-12/IL-
23 in the pathophysiology of PsA has led to the development of specific monoclonal 
antibodies targeting these cytokines. The fully humanised anti-IL-12/IL-23 antibody, 
ustekinumab, has been studied in two large phase III randomised clinical trials and is 
now approved for the treatment of psoriasis and psoriatic arthritis (319, 320). 
Similarly a monoclonal antibody toward IL-17A (sekukimumab) is now approved for 
the treatment of PsA (321) but not for RA after it failed to demonstrate major benefits 
in a phase III study in comparison with anti-CTLA-4 abatacept (322). 
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1.16 Thesis rationale and thesis aims. 
Literature presented in this chapter indicates that PD-1 is an important 
regulator of T cell functions and that blockade or lack of this inhibitory receptor is 
directly associated with autoimmune conditions both in mouse and human. Several 
lines of evidence indicate that the frequencies of PD-1+CD4+ T cells are increased in 
RA synovial fluid (SF) compared to RA and healthy peripheral blood (PB) (216, 323, 
324) while only limited data exists regarding the ability of SF-derived cells to be 
regulated via PD-1. An indication of a defective PD-1 pathway in the context of 
inflammatory arthritis comes from a study performed in RA showing that synovial 
fluid (SF) CD4+ T cells display reduced PD-1-mediated inhibition compared to RA 
PB cells (216). This suggests that under conditions of chronic inflammation the PD-1 
pathway might be negatively modulated. In PsA, it is unclear whether PD-1+CD4+ T 
cells are increased at the site of inflammation and whether PD-1 is able to regulate 
their proliferation and cytokine production.  Hence, further investigation is required.  
 
Therefore, the first main aim of this thesis (chapter 3) was to extend data from 
previous investigations by examining PD-1 and PD-L1 expression in different cell 
subsets from both patients with RA or PsA. A minor aim was to assess the presence of 
any differences between these two arthrides.  
The second major aim (chapter 4) was to explore whether PD-1 ligation in 
healthy PB and in RA- and PsA-derived PB and SF CD4+ T cells is able to modulate 
T cell proliferation and cytokine production. Further experiments were also designed 
to investigate whether PD-1-mediated regulation in healthy CD4+ T cells is affected 
by proinflammatory cytokines typically associated with RA and PsA.   
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The third and final aim (chapter 5) was to identify a mechanism by which 
proinflammatory cytokines modulate PD-1 ligation in vitro and to examine whether 
the above findings had a clinical relevance in RA and PsA settings. This included i) 
analysis of the presence of a soluble form of PD-1 (sPD-1) in both the serum and SF 
of RA and PsA patients, ii) preliminary analysis aimed at identifying differences 
between patient groups undergoing therapy with DMARDs vs. Biologics and iii) in 
vitro experiments to evaluate whether a soluble PD-1fc chimera, used to mimic 
naturally expressed sPD-1, modulates PD-1 mediated suppression of proliferation. 
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2 Materials and Methods  
2.1 Human samples  
Heparinised peripheral blood (PB) and matched synovial fluid (SF) samples 
(where available) were obtained from patients with osteoarthritis (OA), rheumatoid 
arthritis (RA) and psoriatic arthritis (PsA) recruited from the rheumatology outpatient 
clinic at Guy’s and St. Thomas’ Hospital NHS Trust (London, UK). Healthy control 
(HC) subjects were recruited from among local student and staff volunteers. Written 
informed consent was received from all participants. Ethics approval was given by the 
Bromley Research Ethics Committee (approval no. 06/Q0705/20). For OA samples, 
ethics approval was given by the Guy’s Research Ethics Committee (01/05/01). All 
samples were collected in compliance with the Declaration of Helsinki. A small 
amount of peripheral blood (PB) was drawn into a BD Vacutainer® tube (Becton 
Dickinson, Franklin lakes, NJ, USA) containing no anticoagulant. Blood was 
incubated in an upright position at 4°C for 30-45 min to allow clotting and a small 
aliquot of serum (1-2 ml) was removed. The serum aliquot was centrifuged twice at 
1200 rpm for 10 minutes and cell-free serum was stored at -80°C for analysis of 
cytokine and soluble PD-1 (sPD-1) content. Information on clinical and demographic 
















































































































Table 2.1 Demographic and clinical parameters of the patients included in the study.  
Some samples were used for flow cytometry or functional assays only, whilst other samples 
were only used for cytokine detection in serum and SF. Clinical and demographic data are 
provided, where available. Abbreviations used: RA, rheumatoid arthritis; PsA, psoriatic 
arthritis; PB, peripheral blood; SF, synovial fluid; DAS28, disease activity score of 28 joints; 
DMARDs, disease-modifying anti-rheumatic drugs. DAS28 > 5.1 indicates highly active 
disease, 3.2 – 5.1 moderate activity, 2.6 - 3.2 low activity, <2.6 remission. 
 
2.2 Cell Isolation 
2.2.1 Peripheral blood mononuclear cell (PBMC) isolation  
Peripheral blood mononuclear cells (PBMC) from healthy volunteers, 
osteoarthritis (OA), rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients 
were isolated using Lymphoprep™ (Axis-Schield, Oslo, Norway) by density-gradient 
centrifugation. Blood was diluted 1:1 in sterile phosphate buffer saline (PBS) (Sigma-
Aldrich, St. Louis, MO, USA) solution and layered on 15 ml of Lymphoprep™ 
reagent in 50ml falcon centrifuge tubes (Corning Inc. New York, USA). Tubes were 
centrifuged at 1600 rpm (515 xg) for 20 mins at room temperature using an Eppendorf 
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5810R centrifuge (Eppendorf, Hamburg, Germany). After centrifugation, the cloudy 
white layer of PBMC was collected using a sterile Pasteur pipette. The PBMC layer 
was transferred in a new sterile falcon centrifuge tube, washed twice at 1200 rpm (515 
xg) for 10 minutes in PBS. Supernatants were removed and cell pellets resuspended in 
cold MACS buffer (sterile PBS containing 0.5% bovine serum albumin (BSA; Sigma-
Aldrich) and 2 mM EDTA (Life Technologies, Paisley, UK)). Live cells were counted 
using trypan blue (Sigma-Aldrich) exclusion and adjusted to a concentration of 10 x 
106/ml before proceeding to magnetic-activated cell sorting (MACS) isolation. Extra 
aliquots of PBMC were centrifuged and the pellets were resuspended in freezing 
solution, made up of fetal calf serum (FCS) and 10% Dimethyl sulfoxide (DMSO), at 
final concentrations of 20x106/ml. Cells were transferred to a -80 °C freezer for a 
minimum of 24 hours. The cryovials were then stored into liquid nitrogen tanks.  
  
 
Figure 2.1 PBMC isolation via density gradient centrifugation. 
Before centrifugation (A) and after centrifugation (B). 
 
2.2.2  Synovial fluid mononuclear cell (SFMC) isolation 
Synovial fluid was removed by needle aspiration and collected in 50 ml sterile 
tubes. A small aliquot of fluid (1-2 ml) was centrifuged at 1200 rpm for 10 minutes 











(sPD-1) content analysis. The cell pellet from the small aliquot was resuspended in 
sterile PBS and added to the main synovial fluid sample before processing. Synovial 
fluid was diluted 1:2 in sterile PBS solution. In some cases of excessively viscous 
samples, a higher dilution (up to 1:5) was used. SFMC were isolated by density-
gradient centrifugation as previously described in section 2.1.1 and counted using 




Figure 2.2 SFMC isolation via density gradient centrifugation.  
Before centrifugation (A) and after centrifugation (B). 
 
2.3  Isolation of different cell subsets 
2.3.1 CD4+ T cell isolation 
CD4+ T cells were negatively isolated by magnetic bead separation using the 
CD4+ T cell isolation kit (130-096-533) from Miltenyi Biotec (Bergisch Gladbach, 
Germany). PBMC or SFMC were isolated from PB and SF, respectively, as described 
in sections 2.2.1 and 2.2.2. Cells were then counted and incubated with a cocktail of 
biotin-conjugated monoclonal antibodies (mAb) against CD8, CD14, CD15, CD16, 
CD19, CD36, CD56, CD123, TCR γ/δ, and CD235a (Glycophorin A) for 5 minutes at 








cells were further incubated at 4°C for additional 10 minutes. During the second 
incubation, a LS column (Miltenyi Biotech, Bergisch Gladbach, Germany) was placed 
in a QuadroMACS™ magnet (Miltenyi Biotech) and pre-wet with 3ml of MACS 
buffer composed by 0.5% BSA (Sigma-Aldrich), 2mM EDTA (Life Technologies, 
Carlsbad, USA) and PBS (Sigma-Aldrich). After the second incubation, the cell 
suspension was added directly to the LS column and the flow-through containing the 
unlabeled CD4+ T cells was collected. To wash the column, 3 ml of MACS buffer 
solution were applied and combined with the first flow-through.  The purified CD4+ T 
cells eluted from the column were counted using trypan blue and stained for purity. 
CD4+ T cells purity was determined by flow cytometry (purity range 95-99%).  In 
some cases HC CD4+ T cells were centrifuged and the pellets were resuspended in 
freezing solution, made up of Fetal Bovine Serum (FBS) and 10% Dimethyl sulfoxide 
(DMSO), at final concentrations of 20x106/ml. Cells were transferred to a -80 C 
freezer for a minimum of 24hours. The cryovials were then stored into liquid nitrogen 
tanks.  
 
2.3.2  CD4+CD25+ T regulatory (Treg) cell isolation 
In some experiments, after CD4+ T cell isolation, a further step using the 
Dynabeads® Regulatory CD4+CD25+ T Cell Kit (11363D; Life Technologies, 
Carlsbad, USA) was performed in order to isolate CD4+ Treg cells. For Treg cells 
isolation 1.5×107 CD4+ T cells (volumes were scaled up accordingly to 
manufacturer’s instructions) were incubated with pre-washed and resuspended 
Dynabeads® CD25 reagent for 25 min at 4°C with rolling and tilting. After this 
incubation, cells were put in a DynaMag™ magnet (Life Technologies) for a 
minimum of 2 minutes and the supernatant containing the CD4+CD25- cells was 
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carefully removed. The bead-cell complexes formed by the CD25 beads and the 
CD4+CD25+ Treg cells were then washed twice in MACS buffer and resuspended in 
500 µl of RPMI (RPMI-1640; Gibco) with 1% FBS. Following this step, 80 µl of 
DETACHaBEAD® reagent was added and cells were incubated for 45 minutes at 
room temperature with tilting and rotation. Cells were then put again in the magnet for 
a minimum of 2 minutes and the supernatant containing the CD4+CD25+ Treg cells 
was carefully removed. Two final washes were then performed and supernatants were 
combined. The purified CD4+CD25+ T cells were then counted using trypan blue and 
stained for purity. Treg purity was determined by flow cytometry (purity >90%).   
 
2.3.3 CD14+ cell isolation 
In some experiments isolation of CD14+ cells was performed. CD14+ monocyte 
isolation was performed from HC PBMC purified as described in sections 2.1.1. 
Monocytes were positively isolated using a CD14 Microbeads kit (130-050-201; 
Miltenyi Biotec).  HC PBMC were counted, resuspended in MACS buffer at the 
suggested volume and incubated with CD14+ Microbeads for 15 minutes at 4°C. Cells 
were then centrifuged at 300xg for 10 minutes and resuspended in MACS buffer. 
During this 15 minutes incubation, a LS column was placed in a QuadroMACS™ 
magnet (Miltenyi Biotech) and rinsed with 3ml of MACS buffer. Cell suspension was 
then applied to the column followed by 3 washes of 3 ml each. The column was 
removed from the magnet and placed in a collection tube. 5 ml of MACS buffer were 
applied to the column and the magnetically labelled CD14+ cells were flushed out 
using the provided plunger. Cells were then counted and stained for purity by flow 
cytometry (purity range 96-98%). 
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2.4 Cell Culture 
All cells were cultured in Roswell Park Memorial Institute (RPMI) (RPMI-
1640; Gibco) medium supplemented with 1% penicillin/streptomycin, 1% L-
glutamine (Gibco) and 10% heat-inactivated fetal calf serum (Gibco) and maintained 
in an incubator at 37°C and 5% CO2 atmosphere. Cells were plated at different 
concentrations ranging from 4x104/ml to 1x106/ml depending on the assay. Cells were 
typically cultured for 3 to 5 days depending on the chosen assay. In CD4+ T cell-only 
cultures cells were stimulated with plate-bound anti-CD3 mAb (OKT3, Janssen-Cilag 
Ltd, Wycombe, UK) (1.5 µg/ml) while in CD4+ T cell/CD14+ monocyte co-cultures, 
soluble anti-CD3 (OKT3, Janssen-Cilag Ltd, Wycombe, UK) (100 ng/ml) was 
added. Treg:Teff co-cultures cells were stimulated with either soluble anti-CD3 mAb 
(100 ng/ml) or with anti-CD3/anti-CD28 beads (Life Technologies) at a ratio of 1 
bead for every 5 Teff cells. Where indicated, neutralising antibodies, recombinant 
cytokines or other reagents were added at the start of the culture period.  
2.4.1 Cell culture reagents 
The following reagents were used for cell culture according to the experiment.  
Reagent Supplier Amount used 
Lymphoprep™ Axis-Schield 15 ml / 50 ml 
RPMI-1640 Gibco As required 
Penicillin/Streptomycin Gibco 1% 
L-glutamine Gibco 1% 
Phosphate buffer saline Sigma-Aldrich                                                   As required
BSA Sigma-Aldrich As required  
Fetal Calf Serum Gibco 10% 
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DMSO Sigma-Aldrich As required 
Anti-CD3 mAb Janssen-Cilag As indicated 
Anti-CD3/CD28 beads Gibco As indicated 
[3H]-thymidine GE Healthcare 0.25 µCi/well 
CellTrace™ Violet Life Technologies 2µM 
 
Table 2.2 List of culture reagents used for cell culture. 
 
2.4.2 Cytokines 
The following cytokines were added to specific cell cultures: 
Cytokine Supplier Concentration used 
TNFα R&D Systems 10ng/ml 
IL-6 R&D Systems 10ng/ml 
IL-1β R&D Systems 10ng/ml 
 
Table 2.3 List of cytokines used during cell culture.  
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2.4.3 Antibodies  
The following mAb antibodies were added to specific cell cultures:  
 































































Table 2.4 List of antibodies used in cell culture. 
 
2.4.4  Chimera proteins 
The following carrier free chimera proteins were used to coat 96 well plates or added 
in soluble form at the start of the cell culture. To control for the addition of the 
proteins the relevant control was used as listed.  
Protein Supplier Concentration used 
PD-L1fc R&D Systems Range: 0, 0.1, 1, 2 and 5 µg/ml 
PD-1fc R&D Systems Range: 0, 0.25, 0.5, 1 and 2 µg/ml 
IgG1fc R&D Systems Range: 0, 0.1, 0.25, 0.5, 1, 2 and 5 µg/ml 
 














Figure 2.3 Schematic representation of the PD-L1fc and PD-1fc chimera and IgG1fc 
control.  
The PD-L1fc chimera is composed by a human IgG1, a link peptide (DIEGRMD) and the 
extracellular portion of the PD-L1 ligand. The PD-1fc chimera is composed by a human IgG1, 
a link peptide (IEGRMD) and the extracellular portion of the PD-1 receptor. The IgG1fc 


















2.5  PD-1-mediated T cell suppression assay  
To assess T cell suppression of proliferation in CD4+ T cell-only cultures, 96-
well flat-bottom plates (Costar, Corning Inc., Corning, NY, USA) were coated with 
anti-CD3 mAb (1.5 µg/ml) and either PD-L1fc or IgG1fc (R&D Systems, 
Minneapolis, MN, USA) (range from 0 to 5 µg/ml according to the experiment) for 4 
hrs at 37°C and 5% CO2 in 100 µl final volume of sterile PBS. Plates were washed 
twice with sterile PBS before cells were added for culture. In T cell-only assays, 
CD4+ T cells were negatively isolated from cryopreserved HC PBMC, RA and PsA 
PBMC and RA and PsA SFMC as described in section 2.3.1 and cultured at a 
concentration of 1x105 cells per well in a final volume of 200 µl of culture medium. 
At day 4, cells were pulsed with  [3H]-thymidine (0.25 µCi/well) (GE Healthcare, 
Chicago, IL, USA) and T cell proliferation was assessed after 18 hrs (on day 5) using 
a Topcount scintillation counter (Perkin Elmer, Waltham, MA, USA). Cells were 
harvested in a glass fiber filter (Perkin Elmer) and proliferation was determined as 
counts per minutes (cpm), a measure of the detection rate of ionization events per 
minute. In some cultures, human recombinant (hr) TNFα, hrIL-6 or hrIL-1β (all at 
10 ng/ml, R&D Systems, Minneapolis, MN, USA) were added from the start of the 
culture in the absence or presence of anti-TNFα drug adalimumab (AbbVie, Lake 
Bluff, IL, USA), anti-IL-6R drug tocilizumab (Roche, Basel, Switzerland) and anti-
IL-1β (R&D Systems) (all at 1 µg/ml). 
 Clinical grade therapeutics were purchased via Guy’s Hospital Pharmacy and 
frozen in aliquots at -20°C. In some experiments, to assess T cell proliferation in 
presence of a soluble form of the PD-1 receptor, HC CD4+ T cells were cultured in 
PD-L1fc (0, 0.1 and 1 µg/ml)-coated plates in the presence of soluble PD-1fc chimera 
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or the appropriate control (0.5 and 1ug/ml, R&D Systems, Minneapolis, MN, USA). 
Proliferation was expressed as counts per minute (cpm) and as suppression of T cell 
proliferation (%) according to the following formula:  
[(medium only condition − PD-L1fc condition) / medium only condition] × 100 
The schematic representation of the described experiments is shown in Figures 2.4A 
and 2.4B. 
 
2.6 T cell:Monocyte co-culture assay  
This co-culture set up was used to test the effect of soluble PD-1fc chimera 
(sPD-1) in a T cell/APC co-culture system. Freshly isolated HC CD4+ T cells and 
autologous CD14+ monocytes were co-cultured in 96-well flat bottom plates (Costar) 
at 1:1 and 1:0.5 ratio (total cells per well 1x105) in 200 µl final volume of culture 
medium containing 100 ng/ml soluble anti-CD3 mAb and sPD-1fc or IgG1fc (0, 0.25, 
0.5 and 1 µg/ml). In all assays, at day 4, cells were pulsed with [3H]-thymidine (0.25 
µCi/well) and T cell proliferation was assessed after 18 hrs (on day 5) using a 
Topcount scintillation counter. Proliferation was expressed as counts per minutes 
(cpm) and as suppression of T cell proliferation (%) according to the formula reported 
in section 2.5. The schematic representation of the described experiments is shown in 
Figure 2.5A. 
 
2.7  Treg:Teff cell suppression assay 
Suppression assays were carried out using freshly isolated whole PBMCs as T 
effector (Teff) cells and freshly isolated CD4+CD25+ cells as regulatory T cells 
(Treg). Up to 10x106 Teff cells were stained with 2 µM of CellTrace™ Violet (CTV) 
dye (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s 
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protocol. Subsequently, cells (4x104/well) were cultured in 96 well U-bottom plates in 
200 µl final volume of culture medium containing 100 ng/ml soluble anti-CD3 mAb 
or anti-CD3/anti-CD28 beads  (1 bead every 5 cells; 8000 beads/well) in the absence 
or presence of autologous CD4+CD25+ Treg cells (2x104/well and 1x104/well 
equivalent to 1:0.5 and 1:0.25 Teff/Treg ratio). Teff cells were also cultured alone at 
6x104/well (1.5:0 Teff/Treg ratio) to control for cell overcrowding in the wells. In 
some experiments, the sPD-1fc chimera or the sIgG1fc control were added from the 
start of the culture (1 µg/ml and 2 µg/ml, R&D Systems). Cells were cultured for 48 
hours and the proliferation percentage of CD4+ and CD8+ T cells within PBMC Teff 
population was determined by flow cytometry as CTV dye dilution. The schematic 
































Figure 2.4 Schematic representation of the CD4+ T cell suppression assay in presence of 
the PD-L1fc chimera.  
CD4+ T cells were isolated from HC PBMC, RA and PsA PBMC and SFMC and cultured for 
5 days in plates pre-coated with anti-CD3 mAb (OKT3; 1.5µg/ml) and PD-L1fc/IgG1fc (0, 
0.1, 1, 2 and 5 µg/ml). Proliferation was assessed on day 5 by [3H]-thymidine incorporation. 
Cells were cultures with ± cytokines and ± neutralizing mAb (A) or ± sPD-1fc/IgG1fc (B) 


















































Figure 2.5 Schematic representation of the T cell:Monocyte co-culture and Treg:Teff cell 
suppression assay in presence of the sPD-1fc chimera.  
(A) CD4+ T cells and autologous CD14+ monocytes were isolated from HC PBMC and 
cultured for 5 days at 1:1 and 1:0.5 ratios in the presence of soluble anti-CD3 mAb (100 
ng/ml) and soluble PD-1fc/IgG1fc control (0, 0.25, 0.5 and 1 µg/ml). (B) Whole PBMC Teff 
cells from healthy controls were labelled with cell trace violet (CTV) and cultured in the 
presence of anti-CD3 monoclonal antibody (100 ng/ml) or anti-CD3/CD28 beads (1 bead 
every 5 cells), ± autologous PB CD4+CD25+ Treg cells and ± PD-1fc (1 and 2 µg/ml) or 





























2.8 Cytokine analysis 
2.8.1 Introduction 
ELISA assay: The Enzyme-linked immunosorbent assay (ELISA) is a method 
used to detect soluble proteins like cytokines, chemokines and growth factors in a 
biological sample of interest.  To perform an ELISA assay, a capture antibody specific 
for an analyte of interest is used to coat a 96 well ELISA plate.  The plate is then 
blocked for a minimum of 1 hour with protein (i.e. 1% Bovine Serum Albumin in 
PBS) to prevent unspecific interaction. The sample of interest is then added and 
incubated for about 2 hours. The analyte of interest present in the sample will bind the 
capture antibody. Then, a secondary biotinylated detection antibody is added to the 
plate for a time, which can range from 1 to 2 hour according to the assay. The 
secondary antibody will bind the analyte of interest at a different epitope then the one 
recognized by the capture antibody. Finally, streptavidin-HRP followed by a 
chromogenic substrate is added to allow colour visualization. The optical density of 
each well is then determined using a microplate spectrophotometer reader set to 450 
nm.  
Luminex assay: The Luminex assay is based on three core elements: 
Antibody-coated microspheres which are dyed to emit fluorescence and which have 
distinctive colour codes or spectral addresses to allow discrimination and 
simultaneous detection of multiple analytes. A specific flow cytometer to measure the 
specific molecules bound on the beads surface and a digital signal processor to 
analyse the fluorescence data. In this specific assay, beads are coupled with specific 
capture antibodies directed towards different biomarkers of interest. The beads react 
with the samples containing the specific biomarker forming a bead-biomarker bound. 
Residual un-bound beads are then removed with washing steps and a secondary 
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biotinylated detection antibody is added to create a complex as previously described 
for the ELISA assay. Finally, Streptavidine-Phycoerytrin (SA-PE) conjugate is added 
to provide the fluorescent signal.   
 
2.8.2 Ex vivo analysis of cytokine and soluble PD-1 levels 
Cell free serum and synovial fluid were collected as described in sections 2.1 
and 2.1.2 and kept at -80°C until the specific analysis was performed. Serum samples 
from HC donors and serum and paired cell-free synovial fluid samples from patients 
with OA, RA or PsA were thawed at room temperature before each analysis. For 
cytokine detection using Luminex technology, samples were diluted 1:2 in the dilution 
buffer provided by the analysis kit. The cytokine levels in the samples were tested 
using the Bio-Plex Pro™ (Bio-Rad, Hercules, CA, USA) kit and analysed on the 
Luminex FlexMap 3D platform (Luminex Corporation, Austin, TX, USA). The assay 
and the data analysis were performed according to the manufacturer’s protocol. For 
soluble PD-1 (sPD-1) detection using the ELISA technique, serum and SF samples 
were diluted 1:10 and 1:40 in PBS supplemented with 10% fetal calf serum (FCS) as 
recommended by the manufacturer’s protocol. Samples were run at two different 
concentrations to ensure they fell in the linear part of the standard curve. A serial 
dilution starting at 10,000 pg/ml of the provided standard was performed in each assay 
to create the standard curve. Finally, the optical density of each well was determined 
using a microplate spectrophotometer reader (Wallac 1420 Viktor, Perkin Elmer) set 
to 450 nm. 
 
 85 
2.8.3  Post-culture analysis of cytokine and soluble PD-1 levels 
T cell culture supernatants were collected at day 5, spun to remove cellular 
debris, and stored at −80°C until analysis. IFN-γ levels from HC, RA and PsA CD4+ 
T cell cultures and IL-10 levels from HC CD4+ T cell cultures stimulated with TNFα 
and IL-6, were determined by ELISA using the ELISA MAX™ standard sets 
(Biolegend, San Diego, CA, USA). A serial dilution of the provided standard was 
performed in every assay and cell culture supernatants were diluted 1:10 and 1:20 
before each assay. In some cases, HC CD4+ T and RA or PsA PBMC and paired 
SFMC culture supernatants were tested using the Bio-Plex Pro™ kit and analysed on 
the Luminex FlexMap 3D platform as previously described in section 2.8.2. HC CD4+ 
T cell culture supernatants were also tested (neat) for sPD-1 using the Human PD-1 
DuoSet ELISA (R&D Systems) and analysed as described in section 2.8.2. 
 
2.8.4 ELISA and LUMINEX kits 
The following ELISA and Luminex kits were used to assess cytokine levels in Serum 
and SF of HC, RA and PsA donors and in HC CD4+ T cell cultures.  
 






































Table 2.6 List of target molecules and respective assay performed for detection. 
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2.9  Flow Cytometry 
2.9.1  Introduction  
In all multicolour flow cytometry experiments, single-stained compensation 
controls were used to optimise fluorescence compensation. BD CompBeads (BD 
Biosciences) were stained with fluorescently conjugated antibodies, according to 
manufacturer’s instructions. For the viability dye, a single-stained control was 
prepared using a mixture of live cells and cells that had been heat-killed at 65°C for ≥ 
1 minute. Single-stained controls for cellular proliferation dye (CTV) were prepared 
by pooling unlabelled cells with dye-labelled, unstimulated cells.  
 
2.9.2  Extracellular staining (ex vivo) 
For ex vivo analysis of frequency and phenotype of each cell subset, PBMC or 
SFMC were extracellularly stained using antibodies conjugated to fluorochromes. 
Cells (approximately 5x105 per stain) were washed in fluorescence-activated cell 
sorting (FACS) buffer composed by PBS plus 1% BSA (Sigma-Aldrich) and 0.1% 
sodium azide (Severn Biotech, Kidderminster, UK) and then stained with specific 
antibodies against CD3, CD8, CD4, CD14, CD25, CD127, CD274 (PD-1) and CD279 
(PD-L1) (See Section 2.9.5). Isotype controls and fluorescence-minus-one (FMO) 
controls were also included in the staining. Cells were incubated at 4°C for 30 minutes 
to allow specific binding of the selected markers followed by two washes in FACS 
buffer at 1400 rpm for 8 minutes to remove unbound antibody. Cells were then fixed 
in a 2% paraformaldehyde (PFA) solution (Merck, Kenilworth, NJ, USA) for 15 min 
at 4°C, washed twice with FACS buffer and resuspended in 200 µl of FACS buffer for 
subsequent acquisition by flow cytometry.  
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2.9.3  Extracellular staining (post-culture) 
PBMC responders from Treg/Teff co-cultures (see section 2.7) were stained 
extracellularly with a cocktail of antibodies to assess CTV dye dilution for CD4+ and 
CD8+ cells within the Teff population. Cells from each experimental condition (this 
included unstimulated Teff, stimulated Teff and stimulated Teff + Treg cells) were 
transferred from a 96 well plate into specific labelled FACS tubes. Cells were washed 
with FACS buffer at 1400 rpm for 8 minutes and stained with a cocktail of antibodies 
against CD4, CD8 and CD14. In some case a live/dead dye (eBioscience, San Diego, 
CA, USA) was included in the stain to gate out both dead cells and monocytes. Cells 
were incubated at 4°C for 30 minutes to allow specific binding of the selected markers 
followed by two washes in FACS buffer at 1400 rpm for 8 minutes each to remove the 
unbound antibodies. Finally cells were fixed in 2% PFA (Merck) and washed twice in 
FACS buffer for subsequent acquisition by flow cytometry. A representative staining 
plot of an extracellular staining post-culture is shown in Figure 2.6 while 
representative plots of extracellular staining ex-vivo are shown in chapter 3. 
 
2.9.4 Acquisition and analysis 
Cells were acquired (at least 10.000 total events) using a BD FACSCalibur or 
a BD FACSCanto II (Beckton Dickinson, Franklin lakes, New Jersey, USA) and 





Figure 2.6 Schematic representations of one extracellular staining (post-culture) from a 
Treg:Teff suppression assay.  
Stimulated CTV+ PBMC cultured in presence or absence of autologous Treg cells at 
Teff:Treg ratio of 1:0 and 1:0.5. Cells were gated as follows: Total cells, Singlets, CD14-/live 
cells, CD4+ or CD8+. CTV dilution for CD4+ and CD8+ cells is shown as a dot plot. 
 
2.9.5 Flow cytometry antibodies 
The following fluorochrome-tagged antibodies were used for extracellular 
staining.  
 
mAb              Conjugate              Supplier              Isotype              Clone              per stain 
CD3 PE/Cy7 Biolegend mIgG1, κ UCHT1 1 µl 
CD4 PerCP/Cy5.5 Biolegend mIgG1, κ SK3 1 µl 
CD8 APC Biolegend mIgG1, κ SK1 1 µl 
CD8 Pacific Blue Biolegend mIgG1, κ RPA-T8 1 µl 
CD14 Vio770 Miltenyi mIgG2aκ TÜK4 5 µl 














CD127 PE BD Pharmingen mIgG1, κ HIL-7R-M2 5 µl 
CD127 FITC Biolegend mIgG1, κ A019D5 1 µl 
CD274 
(PD-L1) 
PE BD Pharmingen mIgG1, κ MIH1 20 µl 
CD279 
(PD-1) 
FITC Biolegend mIgG1, κ         EH12.2H7 5 µl 
Isotype PE BD Pharmingen mIgG1, κ MOPC-21 20 µl 
Isotype FITC BD Pharmingen mIgG1, κ  MOPC-21 5 µl 
 
Table 2.7 List of antibodies used for extracellular flow cytometry. 
 
2.10 Quantitative polymerase chain reaction (qPCR) 
2.10.1  RNA extraction and cDNA reverse-transcription 
Total RNA was isolated with a ReliaPrep™ RNA Cell Miniprep System 
(Promega, Madison, WI, USA) according to the manufacturer’s protocol. RNA was 
quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific).  RNA 
purity was assessed by analysing the ratio of absorbance at 260 nm and 280 nm and at 
260nm and 230nm. A 260/280 ratio of ~2.0 is generally accepted as “pure” for RNA 
while values lower than that denote presence of protein, phenol or other contaminants.  
The 260/230 ratio is a secondary indication of purity and expected 260/230 values are 
commonly in the range of 2.0-2.2.  RNA that met the purity criteria was then reverse-
transcribed into cDNA. cDNA synthesis was performed using the high capacity cDNA 
reverse transcription kit (Applied Biosystem, Carlsbad, CA, USA) according to the 




2.10.2 qPCR protocol and analysis 
QPCR reactions were performed using the SensiMix™ SYBR No-ROX Kit 
(Bioline, London, UK) and with specific primers for human PD-1Δex3 and β-Actin 
(Integrated DNA Technologies IDT, Heverlee, Belgium). Reactions were performed 
on a Rotor-gene® Q real-time PCR cycler (Qiagen, Hilden, Germany) according to 
the manufacturer’s protocol and data were analysed using the Rotor-Gene® Q 
Software version 2.1.1.49 (Qiagen). Thermocycler conditions included an initial 
holding at 95°C for 10 min, which was followed by a cycling program of 95°C for 15 
seconds, 60°C for 30 seconds and 72°C for 30 seconds for 50 cycles. The β-
Actin gene was used as an endogenous control to normalise for differences in the 
amount of total RNA in each sample. All values were expressed as folds relative to 
the expression of β-Actin. The mean value of the replicates for each sample was 
calculated and expressed as cycle threshold (CT). The amount of gene expression was 
then calculated as the difference (ΔCT) between the mean CT value of the sample for 
the target gene and the mean CT value of that sample for the endogenous control (β-
Actin). Relative gene expression was expressed as 2−ΔCT. To ensure a specific 
amplification of the PD-1Δex3 splice variant, the different primer sets were designed 
to anneal at the junction of the two exons spliced together  (2 and 4) for PD-1Δex3. 
Sequence alignment was verified using the ApE software: 
http://biologylabs.utah.edu/jorgensen/wayned/ape/. 
Target Forward Reverse 
PD-1Δex3 5’-AGGGTGACAGGGACAATAGG-3’ 5’-CCATAGTCCACAGAGAACAC-3’ 
β-Actin 5’-ATTGGCAATGAGCGGTTC-3’ 5’-CGTGGATGCCACAGGACT-3’ 
 













Figure 2.7 Schematic representations of primers, exon organisation and primers 
binding sites for PD-1Δex3.  
Schematic representation of primers binding sites for PD-1Δex3 (FWR: Positions 495–504 
and 661–670; REV: Positions 720–739). 
 
 
The specificity of the selected primers for PD-1Δex3 was further tested as 
follows: 2 grams of agarose (Invitrogen, Life Technologies) were dissolved in 1X 
TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) to obtain a 2% agarose 
gel. The fluorescent nucleic acid dye GelRed™ (Thermo Fisher Scientific) was added 
to visualise the DNA. Quantitative PCR products with an appropriate DNA ladder for 
reference were run on the 2% agarose gel for 1 hour at room temperature and the gel 
was visualised using a Gel Doc™ EZ imager (Bio-Rad, Hercules, CA, USA). A 
representative gel image showing the primers specificity for PD-1Δex3 amplification 
can be found in chapter 5. 
 
2.11 Genome-wide gene expression profiling  
Gene expression profiling data set #1: CD25+CD127low Treg cells and 
CD25−CD127+ Teff cells were sorted from the CD45RA+CD45RO− (naïve) or 
CD45RA−CD45RO+ (memory) CD4+ T cell compartments from the PB of healthy 
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controls and RA patients and a genome-wide expression profiling was carried out by 
Dr. Gina Walter (325) in the laboratory of Prof. Leonie Taams. A subset of the 
generated data were analysed by me and used for the purpose of this thesis to evaluate 
PD-1 and PD-L1 gene expression in CD4+CD45RO- (naïve) and CD4+CD45RO+ 
(memory) T cell compartments from the peripheral blood (PB) of healthy ad RA 
donors (Chapter 3; section 3.2.1; Figures 3.1 and 3.2).  The demographics of the 
patients used for this analysis can be found here: (325).   
Gene expression array profiling data set #2: PBMC and SFMC were collected 
from the blood and SF of 5 RA donors and Teff cells (CD25-CD127+) and Treg cells 
(CD25+CD127-) were sorted within the CD4+CD45RO+ population by Dr. Veerle 
Fleskens (unpublished data) in the laboratory of Prof. Leonie Taams. Genome-wide 
expression profiling was performed by Dr. Matt Arno in the KCL Genomics Centre 
using the Affymetrix HuGene 2_0st array. The freely available software from 
Affymetrix ‘Expression Console’ was used to perform the Quality control (QC) 
analysis. Qlucore Omics Explorer was used to perform the gene expression analysis. 
A subset of the generated data were analysed and graphed by me and used for the 
purpose of this thesis to evaluate PD-1 and PD-L1 gene expression in 
CD4+CD45RO+ (memory) T cell compartments from the peripheral blood (PB) and 
synovial fluid (SF) of RA patients. The demographics of the patients used for this 
analysis are shown in table 2.9.  
Gene expression array profiling data set #3: CD14+ monocytes were sorted 
from the PB of healthy volunteers and from the PB ad SF of patients with RA and a 
third genome-wide gene expression profiling was performed by Dr. Megha 
Rajasekhar (250) in the laboratory of Prof. Leonie Taams. A subset of the generated 
data were analysed by me and used for the purpose of this thesis to evaluate PD-1 and 
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PD-L1 gene expression in HC PB, RA PB and RA SF-derived CD14+ monocytes. 
The demographics of the patients used for this analysis can be found here: (250). 
 
 
Table 2.9 Demographic and clinical parameters of the patients included in the gene 
expression array #2. 
Chapter 3, section 3.2.2, Figure 3.4). Abbreviations used: DAS28, disease activity score of 28 
joints; Embrel, etanercept (anti-TNF); MTX, methotrexate; HCQ, Hydroxychloroquine; SSZ, 
Sulfasalazine; ADA, Adalimumab (Humira, anti-TNF); Abatacept (Orencia, CTLA-Ig). 
DAS28 > 5.1 indicates highly active disease, 3.2 – 5.1 moderate activity, 2.6 - 3.2 low 
activity, <2.6 remission. 
 
2.12 Statistical analysis 
Significance testing was performed with GraphPad Prism software (Version 7; 
GraphPad) using the appropriate statistical tests, as indicated in the figure legends. 
Comparative analysis between paired conditions (for example variations in percentage 
of a specific cell population between PB and SF of a same donor) was conducted 
using the Wilcoxon non-parametric t test. Comparisons between non-paired groups 
(for example patients treated with TNFi versus patients not treated with TNFi) were 
conducted using the Mann-Whitney non-parametric unpaired t test. In each analysis P 






































































3 Results from a phenotypic and gene expression analysis indicate 
that PD-1 expression is increased at the site of inflammation in 
both RA and PsA 
3.1  Introduction 
T cell activation is a highly regulated process that involves the interplay 
between many different molecules. Activation of T lymphocytes generally requires 
two signals, the first signal is provided by the engagement of the T-cell receptor 
(TCR) with an MHC–peptide complex on an antigen-presenting cell (APC). The 
second signal is delivered upon engagement of a co-stimulatory receptor on T cells 
with a ligand on the APC. A key costimulatory signal is provided by the interaction 
between CD28 on T cells with ligands CD80 and CD86 expressed by antigen 
presenting cells (APCs) (326-330). It has been proposed that in patients affected by 
RA and PsA, costimulatory receptors and ligands such as CD86, CD28 and ICOS are 
overexpressed on T cells, macrophages and in the synovial tissue (331-335). These 
observations suggest that these molecules can contribute to persistent activation of T 
cells and to disease progression.  
T cell activation is kept under control by CTLA-4 and PD-1, two important 
inhibitory receptors typically found on activated T cells (24, 36, 42, 43, 68, 336, 337).  
Over the past 10 years, the scientific community has shown an increased interest in 
understanding how chronic inflammation modulates the expression of PD-1 and its 
ligand PD-L1 in human inflammatory arthritis. In early studies performed on arthritis 
patients, it was found that PD-1+CD4+ T cells are increased in the synovial fluid (SF) 
of RA patients as compared to PB-derived cells from healthy controls (HC) and PB- 
and SF-derived cells from osteoarthritis (OA) controls (323, 324). RA SF-derived PD-
 95 
1+CD4+ T cells are for the most part memory cells (CD45RO+) and they can express 
the chemokine receptor CXCR3 (323).  Increased percentages of PD-L1+ monocytes 
have also been described in the synovial fluid of certain groups of patients, but data 
are limited and in some cases contradictory. Yet, despite increased levels of PD-1 at 
the site of inflammation, it is unclear why the immune system fails to regulate 
synovial T cell activation. In RA, PD-1 and PD-L1 expression is still widely 
unexplored in cell types other than bulk CD4+ T cells. Furthermore, while this study 
was performed, the expression of PD-1 and PD-L1 in other arthrides such as psoriatic 
arthritis (PsA) had not been comprehensively explored.  
 
Therefore, the aims of this chapter were: 
1. To investigate PD-1 and PD-L1 gene expression in PB naïve and memory T 
effector (Teff) and T regulatory (Treg) cells from RA patients and healthy 
volunteers.  
2. To investigate PD-1 and PD-L1 gene expression in paired PB and SF 
memory Teff and Treg cells from RA patients. 
3. To investigate PD-1 and PD-L1 gene expression in PB and SF monocytes 
from RA patients and in PB monocytes from healthy volunteers. 
4. To analyse, by flow cytometry, the expression levels of PD-1 and PD-L1 in 
PBMC and SFMC cell subsets from RA and PsA patients. 
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3.2  Results 
3.2.1 Gene expression analysis for PD-1 and PD-L1 in PB CD45RA+ and 
CD45RO+ Treg cells and Teff cells from RA patients and healthy controls 
The first aim of this chapter was to evaluate whether Teff and Treg cells from 
RA patients were different from HC cells at a molecular level regarding PD-1 and PD-
L1 expression. For this purpose, data were collected and analysed from a previously 
generated gene expression profiling dataset (325).   
A heat map, representing results from hierarchical cluster analysis, was 
generated to show the relative expression levels of PD-1 and PD-L1 in the different T 
cell subsets from the PB of healthy controls and RA patients (Figure 3.1).  The heat 
map analysis revealed a very similar, almost identical, expression of PDCD1 (PD-1) 
and CD274 (PD-L1) between HC and RA T cell subsets while the highest expression 
of both receptor and ligand was observed specifically in memory (CD45RO+) Teff 
cells (Figure 3.1). Paired data analysis revealed that PD-1 expression was significantly 
higher in HC and RA memory (CD45RO+) Teff cells as compared to naïve cells 
(CD45RA+). PD-1 expression was also higher in HC and RA memory Treg cells as 
compared to naïve cells but the observed differences were not statistically significant 
(Figure 3.2A). Next, PD-L1 gene expression was analysed in the different subsets. 
PD-L1 was significantly increased in both memory Teff and memory Treg cells as 
compared to naïve cells (Figure 3.2B).  No statistically significant differences for PD-
1 or PD-L1 expression were found when comparing Teff or Treg cells (both naïve and 
memory) between HC and RA donors or when comparing PD-1 and PD-L1 
expression between Teff and Treg cells (false discovery rate 5%, fold change in gene 
expression 1.5). 
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The ex vivo gene expression profiles for PD-1 and PD-L1 of Teff and Treg 
cells presented in this section indicate that no significant difference exists between the 
PB of RA patients and healthy controls. However, the higher expression levels of PD-
1 and PD-L1 observed within the memory cell compartment of both HC and RA, as 
compared to naïve cells, might indicate that antigen-experienced T cells are likely to 
use the PD-1 signalling pathway to modulate their activation to a greater extent than 




      
Figure 3.1 Gene expression profiling of naïve (CD45RA+) and memory (CD45RO+) 
Treg and Teff CD4+ T cell subsets from the PB of HC and patients with RA.  
CD25+CD127low Treg cells and CD25−CD127+ Teff cells were sorted from the 
CD45RA+CD45RO− (naïve) or CD45RA−CD45RO+ (memory) CD4+ T cell compartments 
from the PB of healthy controls and RA patients (n = 6) (325). The heatmap represents results 
from the hierarchical cluster analysis and shows the relative expression levels of PDCD1 (PD-
1) and CD274 (PD-L1) genes in the different T cell subsets from the PB of healthy controls 












Figure 3.2 PD-1 and PD-L1 mRNA expression of naïve (CD45RA+) and memory 
(CD45RO+) Treg and Teff CD4+ T cell subsets from the PB of HC and patients with 
RA.  
(A) Expression levels of PD-1 in HC and RA naïve and memory Teff cells and in naïve and 
memory Treg cells. (B) Expression levels of PD-L1 in HC and RA naïve and memory Teff 
cells and in naïve and memory Treg cells. HC and RA (n=6). RA n=7; PsA n=8) PB and SF 







3.2.2 Gene expression analysis for PD-1 and PD-L1 in PB and SF CD45RO+ 
Treg and Teff cells from RA patients 
The second aim of this chapter was to evaluate the gene expression of PDCD1 
(PD-1) and CD274 (PD-L1) in Teff and Treg cells from the PB and SF of RA patients. 
For this purpose, PD-1 and PD-L1 data were collected and analysed from a gene 
expression profiling dataset previously generated by Dr. Veerle Fleskens (unpublished 
data). In this specific array PBMC and SFMC were collected from the blood and SF of 
5 RA donors. Teff cells (CD25-CD127+) and Treg cells (CD25+CD127-) were sorted 
within the CD4+CD45RO+ population. Figure 3.3 shows the gating strategy for the 
sorting of the different cell subsets. Data analysis showed that in 4 of 5 donors tested, 
PD-1 expression was increased in SF-derived Teff and Treg cells as compared to PB-
derived cells (Figure 3.4A). Similarly, PD-L1 expression was also increased at the site 
of inflammation. PD-L1 expression was higher in 4 of 5 donors in SF-derived Teff 
cells and in 5 of 5 donors in SF-derived Treg cells as compared to PB-derived cells 
(Figure 3.4A). These data suggests that exposure to the highly proinflammatory 
environment found in the inflamed joint of RA can induce transcription of both the 
PDCD1 (PD-1) and CD274 (PD-L1) genes. No differences were found in the 
expression of PD-1 between Teff cells and Treg cells in the PB or SF (Figure 3.4B). 
On the contrary, PD-L1 expression was higher in Teff cells as compared to Treg cells 
in both the PB and the SF but only in the PB this increase reached statistical 
significance (Figure 3.4B). The ex vivo gene expression profiles for PD-1 and PD-L1 
of Teff and Treg cells presented in this section show that RA SF-derived cells have 
higher expression of PD-1 and PD-L1 as compared to PB-derived cells. The data also 
show that PD-L1, but not PD-1, is increased in Teff compared to Treg cells suggesting 




Figure 3.3 Gating strategy for the cell sorting of RA PB and SF CD25-CD127+ Teff and 
CD25+CD127- Treg cells for the generation of a gene expression profiling dataset.  
Flow cytometry plots showing the gating strategy for the cell sorting. Cells were gated 
visually on total lymphocytes followed by CD4+ cells and CD45RO+ cells versus CD45RA+ 
cells. Next, Teff cells (CD25-CD127+) and Treg cells (CD25+CD127-) cells were gated 












Figure 3.4 PD-1 and PD-L1 mRNA expression of memory (CD45RO+) Teff and Treg 
CD4+ T cell subsets from the paired PB and SF of patients with RA.  
(A) The heatmap and the associated graphs represent the results from the gene expression 
array and show the relative expression levels of PDCD1 (PD-1) and CD274 (PD-L1) genes in 
the Teff and Treg cell subsets from the PB and SF of and RA patients (n=5). (B) Expression 
levels of PD-1 and PD-L1 in Treg and Teff cells from the PB (n=5) and SF (n=7) of patients 
with RA. Data in (A) were analysed by Wilcoxon matched-pairs signed-rank test while data in 
(B) were analysed by Mann-Whitney test. *p < 0.05, **p < 0.01 and ***p < 0.001. The 





3.2.3 Gene expression analysis for PD-1 and PD-L1 in HC PB, RA PB and RA 
SF CD14+ monocytes from RA patients  
Next, the expression of PDCD1 (PD-1) and CD274 (PD-L1) was evaluated by 
analysing a previously generated gene expression array performed in HC PB, RA PB 
and RA SF-derived CD14+ monocytes (250).  No significant differences were found 
in PD-1 expression between HC PB monocytes (HC PBM), RA PB monocytes (RA 
PBM) and RA SF monocytes (RA SFM) (Figure 3.5A). PD-1 expression was slightly 
higher in RA PBM compared to HC PBM and further increased in 6 of 9 RA SFM as 
compared to paired RA PBM but the observed differences were not statistically 
significant.  
Next, PD-L1 expression was analysed between HC PBM and RA PBM and no 
difference was found. On the contrary, PD-L1 was significantly upregulated in 9 out 
of 9 RA SFM as compared to paired RA PBM and further increased compared to HC 
PBM (Figure 3.5B). 
These data indicate that CD14+ monocytes deriving from the chronic 
proinflammatory environment found in the inflamed RA joint have high PD-L1 gene 
expression and suggests that RA SFM might have the potential to trigger PD-1 










Figure 3.5 PD-1 and PD-L1 mRNA expression in HC PB, RA PB and RA SF-derived 
CD14+ monocytes.  
(A-B) Expression levels of PD-1 and PD-L1 in CD14+ monocytes obtained from healthy PB 
(n=8) and paired PB and SF from patients with RA (n=7). Data were analysed by Mann 
Whitney test for HC PBM versus RA PBM or SFM and by Wilcoxon matched-pairs signed-
rank test for RA PBM versus RA SFM. *p < 0.05, **p < 0.01 and ***p < 0.001. The 






3.2.4 Flow cytometry analysis of PD-1 and PD-L1 expression in cells subsets 
within PBMC and SFMC from RA and PsA patients 
So far the analysis performed on three different gene expression arrays have 
shown that PDCD1 (PD-1) and CD274 (PD-L1) genes are differentially expressed 
within different cell populations and between RA patients and healthy controls. 
Specifically, PD-1 and PD-L1 are significantly higher in PB memory Teff and Treg 
cells as compared to PB naïve cells but no differences are found when comparing RA 
cells and HC cells in any of the 4 populations tested. Both PD-1 and PD-L1 are 
upregulated in RA SF Teff and Treg as compared to RA PB cells. Finally, PD-L1, but 
not PD-1, is significantly increased in RA SF-derived monocytes as compared to RA 
PB and HC PB monocytes.  
 
The next experiments were performed to investigate the cell surface expression 
of PD-1 and PD-L1 in different cell subsets from both the blood and synovial fluid of 
patients with RA. This investigation was further extended to samples from PsA 
patients. 
In a first set of experiments, paired PB- and SF-derived mononuclear cells 
(PBMC and SFMC) were isolated from patients with RA or PsA and incubated ex vivo 
with the following surface markers: CD3, CD8, PD-1 and PD-L1. Fluorescence Minus 
2 (FM2) staining for both PBMC and SFMC was used as control and the percentages 
of PD-1+ or PD-L1+ cells were evaluated within the CD3+CD8+ and CD3+CD8- T 
cell populations. The gating strategy and the percentage of PD-1+ positive cells in the 
PB and SF for a representative RA is shown in Figure 3.6. This initial gating strategy 
and analysis was performed on n=5 RA and n=5 PsA samples with the main aim to 
confirm literature data for RA and to perform a preliminary investigation for PsA.  
 105 
A second staining panel was designed and applied to all the subsequent 
samples analysed in order to obtain more informative data. In the second gating 
strategy the percentage of PD-1+ or PD-L1+ cells was evaluated within the CD14-
CD3+CD8+ and CD14-CD3+CD4+ T cell populations as well as within the CD14+ 
monocytes population. The gating strategy and the percentage of PD-1+ cells in both 
PB- and SF-derived CD4+ and CD8+ T cells for two representative stainings (1 PsA 
and 1 RA) is shown in Figure 3.7A and 3.7B.  
The frequencies of PD-1+ cells were significantly increased within SF CD4+ T 
cells (identified either by CD3+CD8- cells or CD14-CD3+CD4+ cells) in 10 of 10 RA 
and in 11 of 11 PsA patients as compared to PB (Figure 3.8A and 3.8B).  
In addition, increased frequencies of PD-1+ cells were also found within the 
SF CD8+ T cell compartment in both RA and PsA.  
Next, the frequencies of PB- and SF-derived PD-1+ cells within CD4+ T cells 
and CD8+ T cells were compared between RA and PsA patients (Figure 3.9). For this 
investigation unpaired RA or PsA samples (SF-only, or PB-only) were also included 
in the overall analysis. Data show that no significant differences were found between 














Figure 3.6 Gating strategy for the analysis of PD-1+ cell frequencies in PBMC and 
SFMC.  
Contour plots showing the gating strategy (I) for PD-1 analysis. Cells were gated visually as 
lymphocytes followed by CD3+ versus CD8+ cells. The percentage of PD-1+ cells was 
determined within the CD3+CD8+ and CD3+CD8- subsets. The fluorescence minus one 
control (FMO) was obtained by omitting the PD-1-specific antibody from the antibody 

















































Figure 3.7 Gating strategy for the analysis of PD-1+ cell frequencies in PBMC and 
SFMC.  
Cells were gated as total cells, singlets and CD14+/CD14- cells. CD14- cells were gated as 
CD3+ and CD3- cells and CD4+ or CD8+ T cells were identified within the CD3+ population. 
The percentage of PD-1+ cells was determined within the CD4+ and CD8+ subsets. Contour 
plots of PB and SF cells of one PsA donor (A). For (B) FMO and isotype control of one RA 






































Figure 3.8 PD-1+ T cell frequencies are increased in RA and PsA SF compared to PB.  
Frequencies of PD-1+ T cells were analysed ex vivo by flow cytometry in PBMC and SFMC 
from RA and PsA patients. (A) Cumulative data showing percentage of PD-1+ cells within 
CD3+CD8- or CD3+CD14-CD4+ (RA n=10; PsA n=11) PB and SF cell populations. (B) 
Cumulative data showing percentage of PD-1+ cells within CD3+CD8+ (RA n=7; PsA n=8) 
PB and SF cell populations. Data were analysed by Wilcoxon matched-pairs signed-rank test. 























Figure 3.9 PD-1+ T cell frequencies are similar between RA and PsA.   
Frequencies of PD-1+ T cells were analysed ex vivo by flow cytometry in RA and PsA PBMC 
and SFMC and compared between the two diseases. (A) Cumulative data showing the 
percentage of PD-1+ cells within CD3+CD8- or CD3+CD14-CD4+ PB (RA n=10; PsA n=11) 
and SF (RA n=13; PsA n=11) cell populations. (B) Cumulative data showing percentage of 
PD-1+ cells within CD3+CD8+ PB (RA n=7; PsA n=8) and SF (RA n=10; PsA n=8) cell 
populations. Data were analysed by Wilcoxon matched-pairs signed rank test. *p < 0.05, **p 






Next, the frequencies of PD-L1+ cells amongst T cells in paired PB and SF 
were analysed. Increased percentages of PD-L1+ cells were found in 6 of 6 RA 
patients and in 4 of 5 PsA patients within SF CD4+ T cells (identified either by 
CD3+CD8- cells or CD14-CD3+CD4+ cells) as compared to PB but only RA data 
were statistically significant (Figure 3.10A).  No significant differences were found in 
the percentages of PD-L1+ cells within the SF CD8+ T cell compartment in both RA 
and PsA (Figure 3.10B). The observed statistical differences between RA and PsA 
likely reflect the low number of patients available when this analysis was performed. 
The frequencies of PB and SF-derived PD-L1+ cells within CD4+ and CD8+ T cells 
were compared between patients with RA or PsA and no significant differences were 
found (Figure 3.11). 
PD-1 expression was further analysed by flow cytometry in RA and PsA PB- 
and SF-derived Teff and Treg cells. These experiments were performed to confirm 
data from the gene expression array (section 3.2.2, Figure 3.4). Teff and Treg cells 
were identified as CD4+CD25-CD127+ and CD4+CD25+CD127-, respectively. 
Figure 3.12A shows the gating strategy and the percentages of Teff and Treg cells 
found in the PB and SF of a representative RA sample. In line with published data 
(338-344), Treg cells were increased in the synovial fluid as compared to peripheral 
blood. Figure 3.12B shows a consistent increase of Treg cells percentage in both RA 
and PsA SF samples (paired data) and an overall Treg cell percentage of ~14% for 
inflammatory arthritis (IA) SF as compared to ~6% for IA PB (unpaired data) (Figure 
3.12B). Increased percentages of PD-1+ cells were found in 3 of 3 RA and in 3 of 3 
PsA patients within SF Teff and Treg cells compared to paired PB (Figure 3.13A).  A 
second analysis performed including unpaired samples, showed significantly 
increased percentages of PD-1+ cells within both SF-derived Teff (~48% PD-1+ cells) 
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and Treg (~40% PD-1+ cells) cells as compared to PB-derived Teff (~5% PD-1+ 
cells) and Treg (~7% PD-1+ cells) cells (Figure 3.13B). These data are in line with the 
gene expression analysis described in section 3.2.2 and demonstrate that the increase 
in PD-1 gene expression observed in RA-SF is coupled with increase of the PD-1 
protein at the cell surface level. Furthermore, these data indicate that a similar increase 
at the cell surface level is also detected for PsA. 
Finally, the frequencies of PD-1+ and PD-L1+ cells amongst CD14+ 
monocytes in PB and paired SF were analysed. No significant differences in the 
percentages of PD-1+ cells were found within IA SF CD14+ cells as compared to PB. 
Overall, ~68% of CD14+PD-1+ cells were detected in both IA PB and SF (Figure 
3.14A). This is in line with the results from the gene expression array described in 
figure 3.5A showing no significant differences in PD-1 expression between RA PB- 
and SF-derived CD14+ monocytes.  On the contrary, a significant decrease in the 
percentages of PD-L1+ cells was detected within IA SF-derived CD14+ cells as 
compared to SF (~48% of CD14+PD-L1+ cells in the PB compared to ~20% in the 
SF) (Figure3.14B). This is in contradiction with the data obtained from a different set 
of RA patients and described in Figure 3.5B which showed a significant increase in 





































Figure 3.10 PD-L1+ T cell frequencies are not consistently increased in RA and PsA SF 
compared to PB.  
Frequencies of PD-L1+ T cells were analysed ex vivo by flow cytometry in PBMC and SFMC 
from RA and PsA patients. (A) Percentage of PD-L1+ cells within CD3+CD8- or 
CD3+CD14-CD4+ (RA n=6; PsA n=5) PB and SF cell populations. (B) Percentage of PD-
L1+ cells within CD3+CD8+ (RA n=6; PsA n=7) PB and SF cell populations. Data were 











































Figure 3.11 PD-L1+ T cell frequencies are similar between RA and PsA.   
Frequencies of PD-L1+ T cells were analysed ex vivo by flow cytometry in RA and PsA 
PBMC and SFMC and compared between the two diseases. (A) Percentage of PD-L1+ cells 
within CD3+CD8- or CD3+CD14-CD4+ PB and SF (RA n=6; PsA n=5) cell populations. (B) 
Cumulative data showing percentage of PD-1+ cells within CD3+CD8+ PB (RA n=6; PsA 
n=5) and SF (RA n=6; PsA n=7) cell populations. Data were analysed by Wilcoxon matched-









Figure 3.12 Treg cells frequencies in RA and PsA SF are increased compared to PB.  
Frequencies of CD4+CD25+CD127- cells were analysed ex vivo by flow cytometry in PBMC 
and SFMC from RA and PsA patients. (A) Contour plots of a representative RA sample (PB 
and SF) showing the gating strategy for the identification of CD4+ Treg cells. Cells were 
gated as total cells followed by single cells and CD14+ vs. CD4+ cells. CD4+ cells were 
plotted as CD127 vs. CD25 cells. (B). Percentage of Treg cells in RA and PsA PB and SF 
(Paired analysis: RA n=2; PsA n=3; Unpaired analysis: RA PB n=2, RA SF n=5; PsA PB and 
SF n=3) Data were analysed by Wilcoxon matched-pairs signed-rank test and Mann-Whitney 



























Figure 3.13 PD-1+ T cell frequencies are increased in RA and PsA SF-derived Teff and 
Treg cells compared to PB cells.  
Frequencies of PD-1+ T cells were analysed ex vivo by flow cytometry in PBMC and SFMC 
from RA and PsA patients. (A) Percentage of PD-1+ cells within Teff and Treg (RA n=3; PsA 
n=3) PB and SF cell populations (paired analysis). (B) Percentage of PD-1+ cells within Teff 
and Treg (RA PB n=3, RA SF n=5; PsA PB n=3, PsA SF n=3) PB and SF cell populations. 
Data were analysed by Wilcoxon matched-pairs signed-rank test (A) and by Mann-Whitney 










Figure 3.14 PD-1+ and PD-L1+ cell frequencies within CD14+ monocytes are not 
increased in RA and PsA SF-derived cells compared to PB.  
Frequencies of PD-L1+ cells were analysed ex vivo by flow cytometry in PBMC and SFMC 
from RA and PsA patients. (A) Percentage of PD-1+ cells within RA and PsA PB and SF 
CD14+ monocytes (RA n=2; PsA n=4). (B) Percentage of PD-L1+ cells within RA and PsA 
PB and SF CD14+ monocytes (RA n=5; PsA n=5). Data were analysed by Wilcoxon 











3.3  Discussion  
The data presented in this chapter provide new findings regarding the levels of 
expression of PD-1 and PD-L1 within different cell subsets in both RA and PsA. Gene 
expression analysis performed on PB-derived Teff and Treg cells found no differences 
in PD-1 and PD-L1 expression between RA patients and healthy controls. A 
significant enrichment of PD-1 and PD-L1 expression was detected only within the 
memory cell compartment of both HC and RA, as compared to naïve T cells. On the 
contrary, gene expression analysis performed on RA PB- and RA SF-derived cells 
showed that the expression of both PD-1 and the PD-L1 was increased in SF Teff and 
Treg cells as compared to PB cells.  In line with these data, higher frequencies of PD-
1+ cells were found within Teff and Treg cells in both RA and PsA SF as compared to 
PB. PD-1+ cell frequencies within bulk CD3+CD4+ and CD3+CD8+ T cells were 
also increased in both RA and PsA SF as compared to PB but no difference was found 
between the two diseases. No significant differences, except for RA CD4+ T cells, 
were found in the frequencies of PD-L1+ T cells between PB and SF. PD-1 
expression, both at gene and protein level, was comparable between RA PB and RA 
SF CD14+ cells while a significant enrichment in PD-L1 gene expression was 
detected in RA SF monocytes as compared to HC and RA PB-derived monocytes 
although this was not confirmed by flow cytometry in a different set of patients.  
 
In the literature, several studies performed in mouse models of autoimmune 
disease indicate that PD-1 and its ligand PD-L1 are necessary to control activation and 
cytokine production of self-reactive T cells. In the NOD mouse model of diabetes, 
loss or blockade of either PD-1 or PD-L1 leads to exacerbated disease and increased 
production of proinflammatory cytokines by T cells (210, 345). In C57BL/6 mice with 
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active experimental autoimmune encephalomyelitis (EAE), PD-1 and its ligands PD-
L1 and PD-L2, are highly expressed on cellular infiltrates within the meninges (110) 
and blockade of PD-1 and PD-L1 leads to accelerated disease severity, increased 
presence of reactive T cells and enhanced antibody production (110, 213). Further 
evidence for the critical role of PD-1 in immune regulation can also be found in 
disruption studies demonstrating that in C57BL/6 and BALB/c mice, the lack of PD-1 
leads to development of lupus-like autoimmune proliferative arthritis (57) and severe 
autoimmune dilated cardiomyopathy (58).  
As a result of these findings, several studies have investigated whether 
inducing or overexpressing PD-L1 to trigger PD-1-mediate signalling may be 
beneficial in treating different types of autoimmune diseases. Hirata et al. showed that 
mouse dendritic cells (DCs) genetically engineered to overexpress PD-L1 and myelin 
oligodendrocyte glycoprotein (MOG) significantly reduced T cell responses to MOG, 
cell infiltration into the spinal cord, and the overall severity of MOG peptide-induced 
EAE (346). Similarly, Ding et al. found that in autoimmune BXSB mice, which have 
inflammatory features similar to human systemic lupus erythematosus (SLE), the use 
of a recombinant adenovirus expressing the full-length mouse PD-L1 was able to 
delay the onset of proteinuria, reduce IgG autoantibody production and negatively 
modulate cell proliferation resulting in amelioration of lupus nephritis (347). Finally, 
Schreniner et al. demonstrated that IFN-β, an immune-modulatory treatment for 
multiple sclerosis (MS), was able to upregulate PD-L1 on APC both in vitro and in 
MS patients in vivo inhibiting autologous CD4+ T-cell activation. Importantly, 
neutralisation of PD-L1 on monocytes or monocyte-derived DCs was shown to 
increase the production of inflammatory cytokines IFN-γ and IL-2 and to induce T-
cell proliferation (348). These findings suggest that the PD-1:PD-L1 pathway is 
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important to control T cell activation and has the potential to become a new 
therapeutic target in different autoimmune diseases. 
 
In human RA limited data exist regarding the expression levels of PD-1 and 
PD-L1 in cell phenotypes other than bulk CD4+ T cells while in PsA, data are 
practically non-existent. Hatachi et al. have shown that PD-1+CD4+ T cells are 
increased in the synovial fluid of RA patients treated with disease-modifying anti-
rheumatic drugs (DMARDs) or prednisolone as compared to HC and OA patients 
(323). In line with these findings, Wan et al. also found higher percentages of PD-
1+CD4+ T cells in the SF of RA patients not receiving treatment as compared to OA 
and healthy controls (324).  
A study performed on RA patients treated with either DMARD or anti-TNF 
medication confirmed that CD4+PD-1+ T cells are increased in the SF as compared to 
OA controls (216). The study further demonstrated that PD-1 is expressed in RA 
synovial tissue but not in HC and OA tissue and that PD-1 ligands PD-L1 and PD-L2 
are expressed in both RA and OA but not in HC tissue (216). Finally, work from Rao 
et al. recently identified a new PD-1+CD4+ subset of T cells in the joints and blood of 
seropositive RA patients. This subset, named peripheral helper T cells (THP), is 
phenotypically characterised as PD-1hiCXCR5-CD4+ and expresses a variety of 
chemokine receptors such as CCR2, CX3CR1, and CCR5 (349) (see chapter 4 for a 
description of THP functional characterisation).  
Evidence supporting a possible contribution of PD-1 in modulating T cell 
responses in PsA can be found in studies on human and mouse psoriasis. Interestingly, 
about 15% of psoriasis patients also have undiagnosed PsA. The manifestation of 
psoriasis usually precedes that of arthritis by an average of 10 years and PsA is 
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believed to develop in about 25-30% of patients affected by psoriasis (292, 293). Kim 
et al. found that PD-1 is overexpressed on IL-17+ T cell in the inflamed skin tissue of 
psoriasis patients and in mice with imiquimod (IMQ)-induced psoriasis. Furthermore, 
in IMQ-treated mice, the use of a PD-L1fc fusion protein to trigger PD-1 activation 
reduced psoriatic inflammation when given alone and enhanced the therapeutic effect 
of anti-p40 antibodies when given in combination (350). Similarly, Imai et al. 
compared skin responses of PD-1–deficient (PD-1 KO) mice and wild-type controls in 
an (IMQ)-induced murine model of psoriasis and demonstrated that PD-1 KO mice 
showed severe epidermal hyperplasia, greater neutrophils infiltration, and higher 
expression of the cytokine Th17 (351).  
Thus far, only one study has investigated PD-1 expression in PsA. Peled et al. 
have shown that PD-1+CD3+ T cells are increased in the peripheral blood of PsA 
patients as compared to healthy volunteers and that the levels of PD-1 expression 
inversely correlate with the number of tender and swollen joints, but not with the 
psoriasis area and severity index (PASI) or with the C-reactive protein (CRP) levels 
(352). 
The data presented in this chapter confirm previous findings from the literature 
and further extend our knowledge on the expression levels of PD-1 and PD-L1 in both 
RA and PsA. The analysis of PD-1 and PD-L1 gene expression in CD4+CD45RA+ or 
CD4+CD45RO+ Teff and Treg cells from the PB revealed no statistically significant 
differences between RA patients and healthy controls. Significant differences were 
only found in the expression of PD-1 and PD-L1 between naïve and memory cells 
suggesting that these molecules might be involved in T cell self-regulation during 
secondary immune responses triggered by re-exposure to recurrent antigens. Data 
analysis from a second gene expression array, performed on RA CD4+CD45RO+ 
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cells, demonstrated that the expression of PD-1 and PD-L1 was increased in SF Teff 
and Treg cells as compared to PB cells although the results were not statistically 
significant. PD-1 data are in line with work from Hatachi et al., which described that 
the majority of PD-1+CD4+ cells found in the RA SF were also CD45RO+ (323). 
Importantly, flow cytometry experiments performed on RA and PsA samples 
confirmed that the percentages of PD-1+ cells were increased within RA SF CD4+ 
Teff and Treg cells as compared to PB cells and further showed that this was also the 
case for PsA. Further experiments presented in this chapter demonstrated that PD-1+ 
cells are also significantly increased within SF-derived CD3+CD4+ and CD3+CD8+ 
T cells as compared to PB. This increase can be observed both in RA and PsA patients 
suggesting a similar role for PD-1 in these two different arthrides.  
These results are important for two reasons. Firstly, they confirm and extend 
previous studies, which focused only on bulk CD4+ T cells from RA patients (216, 
323, 324). Secondly, they characterise PD-1 expression in PsA showing that the 
receptor appears to be equally expressed between the two diseases within specific cell 
populations both in the blood and synovial fluid.  
Interestingly, the analysis performed on the second gene expression array also 
suggests that PD-L1 might be upregulated in Teff and Treg cells from the synovial 
fluid of RA patients. This has not been described before and its biological significance 
is unclear. During this thesis, scarcity in sample availability precluded a 
comprehensive study on the surface levels of PD-L1 in RA and PsA-derived Treg and 
Teff cells. Furthermore, considerable variation in PD-L1 expression was found 
amongst RA and PsA samples in SF-derived CD4+ and CD8+ T cells as compared to 
PB. Hence, further experiments are required before conclusive statements can be 
made regarding PD-L1 expression in RA and PsA.  
 122 
Nevertheless, it is important to point out that PD-L1+ T cells might have very 
distinct and important roles within the inflamed joint. PD-L1+ T cells could use the 
ligand to trigger PD-1 activation on other cells in proximity modulating their 
proliferation and cytokine production. PD-L1+ T cells might also have a role in 
regulating Treg cells function skewing other T cells towards a Treg-like phenotype. 
This hypothesis is supported by work from Francisco et al., which showed that PD-L1 
regulates development of Treg and sustains FoxP3 expression enhancing Treg 
suppressive capacities (98) (see chapter 5 and chapter 6 for further details on the role 
of PD-L1 and Treg cells).  
Finally, the presence of PD-L1 on SF-derived cells could have a role in 
modulating chronic T cell responses.  This is interesting because although no 
polymorphisms in the CD274 gene (PD-L1) have been linked to human autoimmune 
diseases yet, Dong et al. described increased autoantibodies against PD-L1 in the 
serum of RA patients as compared to healthy volunteers and demonstrated that 
immobilized antibodies towards PD-L1 were capable of stimulating CD4+ T cell 
proliferation in vitro suggesting a possible bidirectional signalling role of PD-L1 in T 
cell costimulation (353). 
 
Currently, it is unclear why T cell activation persists despite high frequencies 
of PD-1+ T cells detected within RA and PsA joints. One possible explanation is that 
the expression of PD-1 costimulatory ligands is insufficient in synovial T cells and 
macrophages. Three studies investigated PD-L1 cell surface expression on RA SF-
derived CD14+ monocytes as compared to PB-derived monocytes. The results from 
these groups are, however, contradictory with the first two groups reporting increased 
percentages in RA SF-derived PD-L1+CD14+ cells compared to RA PB (324, 354) 
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while the third group reporting a lower percentage of PD-L1+CD14+ cells in the SF 
as compared to PB (216). Analysis from our third array indicates that PD-L1 gene 
expression is increased in RA SF monocytes as compared to HC and RA PB 
monocytes. However, flow cytometry analysis performed on a new set of RA and PsA 
samples could not confirm these results at the cell surface level and in line with work 
from Raptopoulou et al. (216), lower percentages of PD-L1+CD14+ monocytes were 
detected in the SF as compared to PB.  
Some of these differences may be attributed to the variation in patient groups 
with respect to disease activity and therapy. It is also plausible that when monocytes 
are taken out of their proinflammatory environment PD-L1 might be internalised 
limiting the antibody detection power. Interestingly, it was shown by Chang et al. that 
in tumour cells expressing PD-L1, the ligand moved from the surface to the interior of 
the cell after treatment with anti-PD-L1 blocking antibody for 30 minutes at 37°C, 
indicating internalisation (355). Further experiments with increased numbers of 
donors and different reagents might reveal whether PD-L1 is truly increased in SF- 
derived monocytes. 
 
The next chapter explores the ability of PD-1 ligation to modulate cell 
proliferation and cytokine production in CD4+ T cells from healthy volunteers and 
from patients with RA and PsA. Further attention is given to the role of RA and PsA-
derived proinflammatory cytokines and to TNF and IL-6 blocking antibodies. 
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4 Inflammation negatively modulates PD-1-mediated suppression of 
proliferation of human CD4+ T cells 
4.1  Introduction 
The PD-1 receptor is a trans-membrane protein and member of the B7 family 
which plays a critical role in T cell regulation (356). PD-1 is expressed on T cells, 
where its expression increases within the first 24 hrs of T cell activation and decreases 
with antigen clearance (69, 91, 357). Upon ligation of PD-1 by its ligands (PD-L1/B7-
H1 and PD-L2/B7-DC), T cell responses are downregulated (66, 95, 345). Signalling 
through PD-1 leads to inhibition of the phosphatidylinositol 3-kinase (PI3K) resulting 
in reduced Akt phosphorylation and reduced expression of transcription factors Gata3, 
T-bet and Eomes (36, 86). The overall effect of PD-1 ligation is a reduced 
phosphorylation of TCR signalling molecules leading to decreased T cell proliferation 
and cytokine production (60, 61, 345). In mice, it has been documented that disruption 
of the PD-1 gene (pdcd1) leads to lupus-like syndrome, proliferative arthritis, 
diabetes, autoimmune cardiomyopathy and increased susceptibility to collagen-
induced arthritis (CIA) (57, 58, 209, 218, 358). In humans, polymorphisms in the 
PDCD1 gene have been associated with susceptibility to rheumatoid arthritis (RA), 
ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), multiple sclerosis 
(MS) and type 1 diabetes mellitus (236, 359-365). 
 Several investigators, including our own team (chapter 3), have shown that 
frequencies of PD-1+CD4+ T cells are increased in RA synovial fluid (SF) compared 
to RA peripheral blood (PB) (216, 323, 324). However, despite high levels of this 
inhibitory receptor at the site of inflammation, the immune system seems unable to 
regulate persistent T cell activation and cytokine production. Such evidence poses the 
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question as to whether the PD-1 pathway is impaired in the inflamed joint. Thus far, 
only limited data exist regarding PD-1 function in human inflammatory arthritis. An 
indication of a defective PD-1 pathway in RA comes from a study reporting that PD-1 
ligation inhibited cell proliferation and IFN-γ production by CD4+ T cells from 
peripheral blood of RA patients but that synovial fluid CD4+ T cells required higher 
concentrations of the ligand to achieve similar levels of inhibition. The same study 
also reported that peripheral blood CD4+ T cells from healthy controls (HC), RA and 
OA donors display comparable proliferation upon PD-1 ligation (216). While this 
research was unfolding, it was unclear whether PD-1-mediated suppression of 
proliferation was affected by proinflammatory cytokines typically associated with 
inflammatory arthritis. Moreover, the few studies investigating PD-1-ligation in 
inflammatory arthritis mainly focused on RA (216, 366), whereas little was known in 
the context of psoriatic arthritis (PsA).  
This was of particular interest because although PsA and RA are two distinct 
diseases with serological, genetic, and radiological differences they share a number of 
common pathological features including systemic chronic inflammation (367). The 
experiments in this chapter were designed to further investigate the concept of 
impaired PD-1-mediated regulation in RA, extend it to a different inflammatory joint 
disease (PsA) and explore whether inflammation influences the ability of the PD-1 
pathway to function effectively.  
 
Therefore, the aims of this chapter were the following:  
1. Setting up and optimise a reliable assay to test whether PD-1 ligation is able 
to modulate cell proliferation and cytokine production by HC CD4+ T cells.  
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2. Investigate whether PD-1 is functional in CD4+ T cells derived from RA and 
PsA peripheral blood and synovial fluid.  
3. Test how different proinflammatory mediators and biologics influence PD-1-














4.2.1 PD-1 ligation of HC CD4+ T cells 
The first aim of this chapter was to set up an assay to examine how PD-1 
ligation modulates cell proliferation and cytokine production in the presence of its 
ligand PD-L1. CD4+ T cells were negatively isolated from the PB of HC donors 
(purities described in Figure 4.1) and cultured according to previously described 
protocols (60, 127, 216, 368) using increasing concentrations of either PD-L1fc ligand 
or IgG1fc control protein. On day 4, cell cultures were pulsed with 0.25 µCi of [3H]-
thymidine and cell proliferation was assessed by thymidine uptake after 18 hours, on 
day 5.  
 
The effect of PD-L1fc on the proliferation of TCR stimulated HC CD4+ T 
cells is shown in Figure 4.2A and B and is expressed as count per minute (cpm) and 
suppression of proliferation. Data show that PD-1 ligation in presence of PD-L1 
ligand led to a significant and dose-dependent reduction of cell proliferation, whilst no 
effect was observed in the presence of the appropriate IgG1fc control (Figure 4.2). 
These initial experiments were performed with low concentrations of PD-L1fc (0, 0.1 
and 1 µg/ml) in line with a previous investigation (216). In these experiments the 
suppression of proliferation was overall ~20% and ~35% in presence of 0.1 and 1 
µg/ml of PD-L1fc as compared to the medium only condition (0 µg/ml). Further 
experiments including a wider range of concentrations of PD-L1fc ligand and IgG1fc 
control (0, 0.1, 1, 2 and 5 µg/ml) were performed and data confirmed that in HC 
CD4+ T cells, PD-1 ligation led to a dose-dependent reduction in cell proliferation 
with highest suppression of ~48% at 5 µg/ml of ligand as compared to the medium 
only condition (0 µg/ml) (Figure 4.3A and 4.3B).  
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Next, the ability of PD-1 ligation to modulate IFN-γ production was 
investigated. IFN-γ is an established readout cytokine known to be negatively 
modulated following PD-1 ligation (60, 61, 345). Supernatants from HC CD4+ T cell 
cultured in presence of PD-L1fc were collected at day 5 and tested for the presence of 
IFN-γ by enzyme-linked immunosorbent assay (ELISA). 
Notably, IFN-γ production was also inhibited in a dose-dependent fashion both 
at low (Figures 4.4A) and high (Figure 4.4B) concentrations of PD-L1fc ligand. 
Importantly, no decrease in IFN-γ production was detected when HC CD4+ T cells 
were cultured in presence of the IgG1fc control confirming the specificity of the effect 
mediated by the PD-L1fc ligand (Figure 4.4A).  
 
The experiments described above indicate that when HC CD4+ T cells are 
cultured in vitro following TCR-only stimulation, the PD-1 receptor is fully functional 






                     







































Figure 4.1 Extracellular purity staining of negatively isolated CD4+ T cells.        
Representative example of purity stainings of CD4+ T cells isolated from HC PBMC and RA 
and PsA PBMC and SFMC. In this example cells were stained with PerCP-Cy5.5-labelled 
























Figure 4.2 PD-1 ligation reduces proliferation of CD4+ T cells from healthy donors.        
CD4+ T cells were isolated from HC PBMC and cultured for 5 days in plates pre-coated with 
anti-CD3 mAb (OKT3; 1.5µg/ml) and PD-L1fc/IgG1fc (0, 0.1, 1 µg/ml). Proliferation was 
assessed on day 5 by [3H]-thymidine incorporation. (A) HC CD4+ T cell proliferation (cpm) 
and (B) percentage suppression of proliferation following PD-1 ligation by PD-L1fc (n=12) or 
IgG1fc (n=10). Data in A are shown as the mean ± SEM of n=10-12. Data (A-B) were 
analysed by Friedman Test with Dunn’s Multiple Comparison test. *p < 0.05, **p < 0.01 and 





























Figure 4.3 PD-1 ligation reduces proliferation of CD4+ T cells from healthy donors.         
CD4+ T cells were isolated from HC PBMC and cultured for 5 days in plates pre-coated with 
anti-CD3 mAb (OKT3; 1.5µg/ml) and PD-L1fc/IgG1fc (0, 0.1, 1, 2 and 5 µg/ml). 
Proliferation was assessed on day 5 by [3H]-thymidine incorporation. (A) HC CD4+ T cell 
proliferation (cpm) and (B) percentage suppression of proliferation following PD-1 ligation by 
PD-L1fc (n=7) or IgG1fc (n=5-7). Data in A are shown as the mean ± SEM of n=5-7. Data 
(A-B) were analysed by Friedman Test with Dunn’s Multiple Comparison test. *p < 0.05, 








































Figure 4.4 PD-1 ligation reduces IFN-γ production by CD4+ T cells from healthy donors.  
CD4+ T cells from HC PBMC were cultured in plates pre-coated with anti-CD3 mAb (OKT3) 
and PD-L1fc/IgG1fc. Supernatants were collected at day 5 and tested by ELISA for IFN-γ 
production. (A) IFN-γ production in HC CD4+ T cell cultures in presence of PD-L1fc (n=11) 
and IgG1fc (n=5) (0, 0.1 and 1 µg/ml). (B) IFN-γ production in HC CD4+ T cell cultures in 
presence of PD-L1fc (0, 0.1, 1, 2 and 5 µg/ml; n=4). Data in A are shown as the mean ± SEM. 
Data (A-B) were analysed by Friedman Test with Dunn’s Multiple Comparison test. *p < 




4.2.2 PD-1 ligation of HC, RA and PsA CD4+ T cells. 
The experiments described in the previous section have shown that in vitro, 
PD-1 is functionally capable of modulating both proliferation and cytokine production 
of healthy human CD4+ T cells. They also provide a reliable experimental system to 
investigate whether the inflammatory milieu typically found in RA and PsA has a 
direct effect on PD-1-mediated regulation. It was shown (chapter 3) that significantly 
increased percentages of PD-1+ cells are found within RA and PsA SF CD4+ T cells 
(identified either by CD3+CD14-CD4+ cells or CD3+CD8- cells) compared to PB. 
These data suggest that CD4+ T cells at the site of inflammation seem to be suited 
with a highly expressed control mechanism to self-regulate proliferation and cytokine 
production.  
 
To investigate whether PD-1 ligation is functional in patient-derived cells, 
CD4+ T cells were initially isolated from the peripheral blood of RA patients and 
cultured in presence of increasing concentrations of PD-L1fc (low range) as 
previously described. As a control, healthy CD4+ T cells were cultured in parallel and 
cell proliferation was compared between the two sets of donors. In the absence of PD-
L1fc, HC and RA CD4+ T cells from peripheral blood had a similar proliferative 
capacity and no significant difference was found (Figure 4.5A).  
HC and RA CD4+ T cells were then cultured in the presence of increasing 
concentrations of PD-L1fc. In contrast to healthy CD4+ T cells, RA cells appeared to 
be resistant to PD-1-mediated suppression of T cell proliferation (Figure 4.5B, 4.5C). 
Suppression of proliferation of  HC PB CD4+ T cells was ~25% and ~35% in 
presence of 0.1 and 1 µg/ml of PD-L1fc, respectively, compared to medium only 
(Figure 4.5C). Conversely, suppression of proliferation was largely unchanged for RA 
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PB CD4+ T cells (~1% and ~5% in presence of 0.1 and 1 µg/ml of PD-L1fc compared 
to medium only). These data show that peripheral blood RA CD4+ T cells are 
resistant to PD-1-mediated regulation as compared to healthy cells in the selected 
experimental settings. 
The above experiments were performed comparing CD4+ T cells from the 
peripheral blood of healthy donors and RA patients. Next, the proliferation and 
cytokine production of CD4+ T cells from the site of inflammation was tested in the 
same experimental conditions. To address this, new cohorts of RA and PsA patients 
with joint effusions were selected and CD4+ T cells isolated from PBMC and paired 
SFMC were cultured in parallel in absence or presence of PD-L1fc or IgG1fc as 
previously described. For these sets of experiments, cells were cultured using a 
broader concentration range of PD-L1fc ligand (0, 0.1, 1, 2 and 5µg/ml).  
RA and PsA CD4+ T cell proliferation, in absence of PD-L1fc, was not 
significantly different between PB and SF (Figure 4.6A).  In the presence of 
increasing doses of PD-1 ligand, RA and PsA PB CD4+ T cells were resistant to PD-
1-mediated suppression of proliferation as were the paired synovial fluid CD4+ T cells 
(Figure 4.6C, 4.6D). Importantly, the IgG1fc control had no effect on CD4+ T cell 
proliferation (Figure 4.6B).  
Interestingly, the fact that T cells from the site of inflammation are highly PD-
1 positive, even without in vitro TCR stimulation, did not seem to play a role in our 
experimental settings. Indeed, no decrease in PD-1-mediated suppression of T cell 
proliferation was found, even when the ligand was used at the highest concentration of 
5µg/ml. To further confirm these findings, supernatants from RA and PsA cell 
cultures were tested for the presence of IFN-γ. In absence of PD-L1fc, significantly 
higher levels of IFN-γ (~5.4 folds higher) were detected in SF-derived CD4+ T cell 
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cultures compared to PB (Figure 4.7A). This is in line with the literature and likely 
reflects the activated status of the cells from the site of inflammation. Importantly and 
in agreement with proliferation data, IFN-γ levels in the supernatants were not 
significantly affected by increasing concentration of PD-L1fc (Figure 4.7B).  
 
Although these results did not prove that PD-1 signalling is intrinsically 
compromised, they demonstrate that RA and PsA CD4+ T cells display resistance to 
PD-1-mediated regulation under the described experimental conditions. This suggests 
that the particular proinflammatory environment found in patients with RA or PsA 




















Figure 4.5 PD-1 ligation reduces proliferation of PB CD4+ T cells from healthy donors 
but not of PB CD4+ T cells from RA patients.  
CD4+ T cells were isolated from HC PBMC and RA PBMC (n=9) and cultured for 5 days in 
plates pre-coated with anti-CD3 mAb (OKT3; 1.5µg/ml) and PD-L1fc/IgG1fc (0, 0.1 and 1 
µg/ml). (A) HC and RA CD4+ T cell basal proliferation in absence of PD-L1fc (cpm). (B) HC 
and RA CD4+ T cell proliferation (cpm) and (C) percentage suppression of proliferation 
following PD-1 ligation by PD-L1fc. Data in (B-C) were analysed by Friedman Test with 







Figure 4.6 PD-1 ligation is unable to reduce proliferation of PB and SF CD4+ T cells 
from RA and PsA patients.  
CD4+ T cells were isolated from RA PBMC and SFMC and PsA PBMC and SFMC (n=3 RA 
PB/SF; n=4 PsA PB/SF) and cultured for 5 days in plates pre-coated with anti-CD3 mAb 
(OKT3; 1.5µg/ml) and PD-L1fc (0, 0.1, 1, 2 and 5 µg/ml) or IgG1fc (0 and 5 µg/ml). (A) RA 
and PsA CD4+ T cell proliferation (cpm) in absence of PD-L1fc and (B) in presence of 0 and 
5 µg/ml of IgG1fc control. (C) Cell proliferation (cpm) and (D) suppression of proliferation in 
presence of PD-L1fc. Data were analysed by Wilcoxon test (A), Mann Whitney test (B) and 
Friedman Test with Dunn’s Multiple Comparison test (C and D). *p < 0.05, **p < 0.01 and 









Figure 4.7 PD-1 ligation is unable to reduce IFN-γ production by PB and SF CD4+ T 
cells from RA and PsA patients.  
CD4+ T cells from RA and PsA PBMC and SFMC (n=2 RA PB/SF; n=3-4 PsA PB/SF) were 
cultured in plates pre-coated with anti-CD3 mAb (OKT3; 1.5µg/ml) and PD-L1fc/IgG1fc. 
Supernatants were collected at day 5 and tested by ELISA for IFN-γ production. (A) Levels of 
IFN-γ in paired IA PB and IA SF CD4+ T cell cultures in absence of PD-L1fc. (B) Levels of 
IFN-γ in IA PB and IA SF CD4+ T cell cultures in presence of increasing concentration of 
PD-L1fc. Data were analysed by Wilcoxon test (A) and by Friedman Test with Dunn’s 
Multiple Comparison test (B). *p < 0.05, **p < 0.01 and ***p < 0.001. Dotted line indicate 











4.2.3 Levels of proinflammatory cytokines in RA and PsA serum and synovial 
fluid and in PBMC and SFMC cell supernatants 
  The data so far demonstrated that CD4+ T cells from PB and SF of patients 
with RA or PsA are resistant to PD-1 ligation as compared to healthy controls. RA and 
PsA CD4+ T cells, especially those found in the synovial fluid, derive from a highly 
proinflammatory environment and they are likely to be exposed to continuous 
cytokine stimulation.  
Next, the presence of proinflammatory cytokines in RA and PsA serum and 
synovial fluid as well as their ability to interfere with PD-1-mediated T cell 
suppression was investigated. Previously generated Luminex data available in the 
laboratory were analysed to determine the levels of the proinflammatory cytokines IL-
7, IL-15, TNFα, IL-6 and IL-1β in RA-derived paired sera and SF as compared to 
healthy serum. In the RA sera, only slight and not significant increases of IL-7 and IL-
15 were found when compared to HC (Figure 4.8). Conversely, significantly increased 
amounts of IL-7 (~200 pg/ml) and IL-15 (~750 pg/ml) were detected in RA SF when 
compared to RA serum. In this particular set of patients, TNFα	 and IL-1β were 
detected at higher levels only in 5/12 RA sera and SF compared to HC sera and these 
differences did not reach statistical significance. Conversely, IL-6 was increased in the 
RA SF (~1000 pg/ml) as compared to paired RA serum and HC serum (<50 pg/ml) 
(Figure 4.8).  
To further investigate the inflammatory nature of the RA and PsA arthritic 
joint, two additional sets of RA and PsA patients were selected. In these new 
experiments, cytokine levels were determined in the serum and paired SF as compared 
to healthy serum and serum and SF from disease control patients with osteoarthritis 
(OA).  Figure 4.9 shows that in the PsA sera, TNFα and IL-6 were significantly 
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increased when compared to HC serum while in the analysed RA sera only IL-6, but 
not TNFα, was increased. IL-1β was undetected in the selected samples. Conversely, 
strong and significant increases in all three cytokines were detected in both RA and 
PsA synovial fluid when compared to HC or OA controls (Figure 4.10A, 4.10B) 
confirming the inflammatory nature of RA and PsA synovial fluid. Data show that in 
the selected RA and PsA sets there was a common proinflammatory signature for 
TNFα, IL-6 and IL-1β as evidenced by similar cytokine levels between the two 
diseases (Figure 4.10C). The levels of other cytokines including IFN-γ, IL-4, IL-10, 
IL-22, IL-23, IL-25, IL-31 and IL-33 were also investigated but no statistically 
significant variations or clear expression patterns were detected when compared to 
controls and no further investigation was performed (data not shown). 
As a further confirmation of these data and to investigate whether cells from 
the site of inflammation could also produce these cytokines in vitro, paired RA- and 
PsA-derived whole PBMC and SFMC cell cultures were set up. Cells were cultured 
for 48 hrs in presence of soluble anti-CD3 mAb (OKT3; 100 ng/ml) and day 2 
supernatants were analysed by luminex. TNFα, IL-6 and IL-1β were detected in the 
supernatants of both PBMC and SFMC cultures and cytokine levels were significantly 
higher in the SFMC cultures compared to PBMC (Figure 4.11). The data presented in 
this section indicate that TNFα, IL-6 and IL-1β are indeed present in RA and PsA 
serum and SF and they can be further detected in vitro in the supernatants of activated 
PBMC and SFMC cultures.  
Next, the ability of TNFα, IL-6 and IL-1β cytokines to modulate PD-1-








































Figure 4.8 Cytokine levels for IL-7, IL-15, TNFα, IL-6 and IL-1β in the serum and SF of 
RA patients and in the serum of healthy controls (Set I).  
Levels of IL-7, IL-15, TNFα, IL-6 and IL-1β in the serum and paired SF of patients with RA 
(n=12) or in HC serum (n=7) are shown. Data were measured by Luminex and analysed by 
Wilcoxon matched-pairs signed rank test. *p < 0.05, **p < 0.01, ***p < 0.001. Graphs show 







Figure 4.9 Levels of proinflammatory cytokines TNFα, IL-6 and IL-1β in the serum of 
RA and PsA patients (Set II).  
Levels of the proinflammatory cytokines TNFα, IL-6 and IL-1β in the serum of patients with 
RA (n=12), PsA (n=12), OA (n=3-4) or in HC serum (n=7) are shown. Data were measured 
by Luminex and analysed by Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001. Graphs 

















Figure 4.10 Analysis of proinflammatory cytokines TNFα, IL-6 and IL-1β in the serum 
and SF of RA and PsA patients (Set II).  
(A-B) Levels of proinflammatory cytokines TNFα, IL-6 and IL-1β in paired RA and PsA 
serum/synovial fluid (SF) (n=12), in OA (disease control) serum/SF (n = 3-4) and in HC 
serum (n=7). (C) Comparison of proinflammatory cytokines TNFα, IL-6 and IL-1β levels 
between RA and PsA. Data in (A) and (B) were analysed by Wilcoxon matched-pairs signed 
rank test for RA/PsA Serum vs. RA/PsA SF and Mann-Whitney test for RA/PsA SF Vs HC 
serum or OA SF. Data in (C) were analysed by Mann-Whitney test. *p < 0.05, **p < 0.01 and 






Figure 4.11 Cells from the site of inflammation produce higher levels of TNFα, IL-6 and 
IL-1β compared to PB-derived cells.  
Inflammatory arthritis (RA and PsA) paired PBMC and SFMC were cultured with anti-CD3 
mAb (100 ng/ml) for 48 hrs and supernatants were analysed by Luminex (n=8; of which n=6 
RA, n=2 PsA). Data were analysed by Wilcoxon matched-pairs signed rank test. *p < 0.05, 













4.2.4 The effect of proinflammatory cytokines on PD-1-mediated T cell 
regulation 
To elucidate whether inflammation had a functional impact on PD-1-mediated 
suppression of CD4+ T cell proliferation, IL-15 and IL-2 were initially tested for their 
ability to negatively modulate PD-1 ligation in vitro as previously reported by two 
different studies (60, 369). Anti-CD3 activated HC CD4+ T cells were cultured in the 
presence of increasing concentration of PD-L1fc (0, 0.1 and 1µg/ml) and IL-15 or IL-
2 (5 ng/ml) were added from the start of the culture.  
Figures 4.12A and 4.12B show that in 3 representative HC donors and in a 
total of n=7 independent experiments, IL-15 consistently abrogated the suppressive 
effect of PD-1 ligation resulting in increased cell proliferation.  In a similar way to IL-
15, IL-2 was also able to modulate cell proliferation in presence of the PD-L1fc ligand 
(Figure 4.12C).  
Next, the ability of TNFα, IL-6 or IL-1β to abrogate PD-1-mediated ligation 
was evaluated. In the first set of experiments, when HC cells were cultured in the 
presence of each cytokine added singularly but without PD-L1 ligand, no significant 
change in cell proliferation was observed (Figure 4.13A). HC CD4+ T cells were also 
cultured with increasing concentrations of PD-L1fc (0, 0.1 and 1 µg/ml) in the 
absence (medium only) or presence of TNFα, IL-6 or IL-1β (10 ng/ml). As expected, 
in PD-L1fc + medium-only conditions CD4+ T cell proliferation decreased in a dose-
dependent fashion while no change in proliferation was detected in presence of the 
IgG1fc control (Figure 4.13 B).  
Notably, addition of TNFα, IL-6 or IL-1β consistently counteracted PD-1-
mediated regulation as shown by the lack of a significant decrease in cell proliferation 
between the different conditions (Figure 4.13C). These results support the hypothesis 
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that a pool of inflammatory cytokines found in RA and PsA patients can negatively 
modulate the suppressive effects of PD-1 ligation on CD4+ T cells. 
To assess whether this cytokine-mediated effect could be reversed leading to 
restored PD-1-mediated regulation, new experiments using neutralising antibodies 
were performed. To block the biological effect of the cytokines, anti-TNFα 
(adalimumab), anti-IL-6R (tocilizumab) or anti-IL-1β antibodies were added at the 
start of the culture together with the respective target cytokine.  
To verify that the cytokines and blocking antibodies used in these new sets 
of experiments were fully functional, supernatants from TNFα and IL-6-stimulated 
cells cultured in absence or presence of adalimumab and tocilizumab were screened 
by luminex (for TNFα and IL-6) and by ELISA (for IL-10) and compared to medium 
only conditions (Figure 4.14).  Data in Figure 4.14A show that, as expected, TNFα	
was significantly increased in the supernatants of	TNFα-stimulated cultures while no 
TNFα was detected in TNFα + adalimumab stimulated cultures. Conversely, IL-10 
was decreased following TNFα	 stimulation but increased in presence of TNFα + 
adalimumab. This is in line with previous work from our lab (370, 371).  
In IL-6-stimulated cultures, IL-6 and IL-10 were both significantly increased 
compared to medium only while presence of anti-IL6R antibody tocilizumab 
significantly reduced both cytokines. IL-10 increase following IL-6 stimulation has 
been previously reported (372). These results validated the biological activity of our 
cytokines and blocking antibodies. 
The new set of experiments confirmed that addition of each individual 
cytokine significantly abrogated the suppressive effects of PD-1 ligation at both 0.1 
and 1 µg/ml of PD-L1 and further demonstrated that adalimumab, tocilizumab and 
anti-IL-1β mAb were able to completely reverse the cytokine-mediated effects. 
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Representative data from 1 donor (Figure 4.15A) showing cell proliferation and 
cumulative data (Figure 4.15B, 4.15C) displaying suppression of proliferation at 
two different concentrations of PD-L1fc are shown. 
Additional experiments were carried out with higher concentrations (2 and 5 
µg/ml) of PD-L1fc and IgG1fc control in absence or presence of TNFα or IL-6 and 
with adalimumab or tocilizumab. In these new sets of experiments TNFα and IL-6 
were able to modulate PD-1-mediated suppression of proliferation even in the 
presence of higher concentrations of PD-L1fc ligand. Data in figure 4.16A show the 
specificity of PD-L1fc and IgG1fc activity while Figure 4.16B shows a representative 
experiment and cumulative data from three independent donors.  
 
Together, these data add novel insight to the regulation of the PD-1/PD-L1 
pathway showing that T cell and monocyte-derived inflammatory cytokines TNFα, 
IL-6 and IL-1β, which are typically associated with inflammatory arthritis, have a 
profound effect on PD-1-mediated suppression of proliferation. Preliminary data 
suggest that this might also be the case for IL-2 and IL-15. Furthermore, data show 
that biologic drugs routinely used in the treatment of RA and PsA patients have the 












Figure 4.12 IL-15 and IL-2 counteract the PD-L1-mediated suppression of HC CD4+ T 
cell proliferation.  
HC CD4+ T cells were cultured for 5 days in anti-CD3 mAb (OKT3; 1.5 µg/ml) pre-coated 
plates with increasing concentration of PD-L1Fc (0, 0.1 and 1 µg/ml) and in the absence or 
presence of either IL-2 or IL-15 (5 ng/ml). (A) Proliferation in n=3 HC donors and (B) 
cumulative data (n=7) showing HC PB CD4+ T cell proliferation and suppression of 
proliferation of CD4+ T cells cultured in absence (Medium only) or presence of 5 ng/ml of 
IL-15. (C) Proliferation and suppression of proliferation of HC PB CD4+ T cells (n=2) 
cultured in absence (Medium only) or presence of 5 ng/ml of IL-2. Data in (B) are shown as 
the mean ± SEM of n=7 and were analysed by Friedman Test with Dunn’s Multiple 










                                     
Figure 4.13 TNFα, IL-6 and IL-1β counteract the PD-L1-mediated suppression of HC 
CD4+ T proliferation.  
HC CD4+ T cells were cultured for 5 days in anti-CD3 mAb (OKT3; 1.5 µg/ml) pre-coated 
plates with increasing concentration of PD-L1Fc (0, 0.1 and 1 µg/ml) and in the absence 
(Medium only) (n=10) or presence of TNFα (n=10), IL-6 (n=10) or IL-1β (n=6) (10 ng/ml) 
(A) Proliferation in absence of PD-L1fc and in the presence of specific cytokines. (B) 
Proliferation in the presence of PD-L1fc or IgG1fc control in absence of specific cytokines. 
(C) Proliferation in the presence of PD-L1fc and specific cytokines (10ng/ml). Data are shown 
as the mean ± SEM and were analysed by Friedman Test with Dunn’s Multiple Comparison 












































Figure 4.14 Exogenous TNFα and IL-6 are detected in the supernatants and show to 
have biological activity.  
HC CD4+ T cells were cultured for 5 days in anti-CD3 mAb (OKT3; 1.5 µg/ml) pre-coated 
plates ± TNFα or IL-6 (10 ng/ml) and in the presence of TNFα or IL-6 plus specific blocking 
antibodies  (adalimumab; ADA, tocilizumab; TOC, all at 1 µg/ml) (n=5). At day 5 superatants 
were collected and analysed by Luminex (TNFα or IL-6) and ELISA (IL-10). Data were 
analysed by Friedman Test with Dunn’s Multiple Comparison test. *p < 0.05, **p < 0.01 and 














Figure 4.15 TNFα, IL-6 and IL-1β counteract the PD-L1-mediated suppression of 
proliferation of HC CD4+ T cells and their effect is abrogated by blocking antibodies.  
Cell proliferation (cpm) of HC PB CD4+ T cells from one representative experiment (A) and 
suppression of proliferation (B, C) in CD4+ T cells from HC PB in absence (medium, M) or 
presence of 10 ng/ml of TNFα (n=9), IL-6 (n=5) or IL-1β (n=6) ± anti-TNFα (adalimumab; 
ADA), anti-IL-6R (tocilizumab; TOC) and anti-IL-1β  (all at 1µg/ml). Black bars: medium 
only; White bars: + specific cytokine; Gray bars: + specific cytokine and neutralising 
antibody. Data were analysed by Wilcoxon matched-pairs signed rank test. *p < 0.05 and 







Figure 4.16 TNFα and IL-6 counteract the PD-L1-mediated suppression of HC CD4+ T 
cell proliferation in presence of 2 and 5 µg/ml of PD-L1fc.  
(A) Cell proliferation (cpm) of HC CD4+ T cells in presence of PD-L1fc or IgG1fc control 
(n=3). (B, C) Representative experiment and cumulative data showing proliferation (n=1) and 
suppression of proliferation (n=3) in HC CD4+ T cells cultured in absence (medium, M) or 
presence of 10 ng/ml of TNFα or IL-6 ± anti-TNFα (adalimumab; ADA) or anti-IL-6R 
(tocilizumab; TOC) (both at 1µg/ml). Data in B and C are shown as the mean ± SEM. 
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4.2.5 The effect of synovial fluid on PD-1-mediated T cell regulation 
Data presented thus far demonstrated that certain proinflammatory cytokines, 
which are increased in the serum and SF of RA and PsA patients, modulate PD-1-
mediated suppression of proliferation of HC CD4+ T cells. It has been reported that 
addition of autologous synovial fluid to RA PB CD4+ T cell cultures is able to 
negatively modulate PD-1 ligation (216). However, it is not clear whether this is also 
the case for PsA synovial fluid and whether PD-1 ligation can be modulated by 
synovial fluid in HC CD4+ T cells.  
To investigate this further, and extend these data to PsA, two synovial fluid 
samples, 1 RA and 1 PsA, were selected from the RA and PsA sets of patients 
previously tested for the presence of different proinflammatory cytokines (Figure 
4.10). Cytokine levels in the selected RA SF sample were detected as follows: TNFα 
(5 pg/ml), IL-6 (19 ng/ml) and IL-1β (n.d.) (Figure 4.17A). Cytokine levels in the 
selected PsA SF sample were detected as follows: TNFα (31.6 pg/ml), IL-6 (24.4 
ng/ml) and IL-1β (16.9 pg/ml) (Figure 4.18A). This confirmed the proinflammatory 
nature of the selected samples. 
HC CD4+ T cells from healthy donors were cultured in anti-CD3 mAb 
(OKT3) coated plates in presence or absence of PD-L1fc and with or without 0.5% 
sterile acellular SF. In some conditions a combination of 0.5% SF + adalimumab       
(1 µg/ml) was added from the start of the culture. 
Addition of 0.5% RA or PsA synovial fluid to HC CD4+ T cells had two 
effects. First, it reduced the overall proliferation of HC CD4+ T cells. Second, it 
consistently reduced PD-1-mediated suppression of proliferation as compared to 
medium only (Figure 4.17B and 4.18B). TNFα neutralising antibody (adalimumab; 1 
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µg/ml) added together with RA or PsA synovial fluid from the start of the culture was 
able to partially rescue the observed SF-mediated effect.  
These data, although still preliminary, suggest that inflammatory mediators 
found in RA and PsA synovial fluid might have the potential to negatively modulate 
an otherwise functional PD-1 ligation in HC CD4+ T cells and are in line with the 
proinflammatory cytokine experiments performed in section 4.2.4 as well as with 





















































Figure 4.17 RA-derived SF modulates PD-L1-mediated suppression of HC CD4+ T cell 
proliferation.   
HC CD4+ T cells were cultured for 5 days in anti-CD3 mAb (OKT3; 1.5 µg/ml) pre-coated 
plates with increasing concentration of PD-L1Fc (0, 0.1 and 1 µg/ml). (A) Levels of TNFα, 
IL-6 and IL-1β were determined by Luminex in the selected RA SF and in 4 OA SF samples.  
(B) Proliferation (cpm) in absence or presence of 0.5% of RA SF and PD-L1-mediated 
suppression of proliferation in HC PB CD4+ T cells (n=3) in absence (Medium) or presence 
of 0.5% of the same RA SF ± anti-TNFα (adalimumab; ADA). Data were analysed by 
Friedman Test with Dunn’s Multiple Comparison test. *p < 0.05, **p < 0.01 and ***p < 








































Figure 4.18 PsA-derived SF modulates PD-L1-mediated suppression of HC CD4+ T cell 
proliferation.   
HC CD4+ T cells were cultured for 5 days in anti-CD3 mAb (OKT3; 1.5 µg/ml) pre-coated 
plates with increasing concentration of PD-L1Fc (0, 0.1 and 1 µg/ml). (A) Levels of TNFα, 
IL-6 and IL-1β were determined by Luminex in the selected PsA SF and in 4 OA SF samples.  
(B) Proliferation (cpm) in absence or presence of 0.5% of PsA SF and PD-L1-mediated 
suppression of proliferation in HC PB CD4+ T cells (n=4) in absence (Medium) or presence 
of 0.5% of the same PsA SF ± anti-TNFα (adalimumab; ADA). Data were analysed by 
Friedman Test with Dunn’s Multiple Comparison test. *p < 0.05, **p < 0.01 and ***p < 






4.3  Discussion  
The data presented in this chapter provide new findings regarding the ability of 
the PD-1 receptor to regulate cell proliferation in human CD4+ T cells. Firstly, CD4+ 
T cells were stimulated via the TCR in presence or absence of a PD-L1fc chimera to 
mimic PD-1 ligation. This assay demonstrated that CD4+ T cells from the PB of 
patients with RA or PsA are resistant to PD-1-mediated suppression of proliferation as 
compared to healthy CD4+ T cells. Next, it was established that SF-derived CD4+ T 
cells from either RA or PsA patients are also resistant to PD-1-mediated regulation 
despite being highly PD-1 positive. Finally, it was shown that the levels of 
proinflammatory cytokines TNFα, IL-6 and IL-1β are increased in the synovial fluid 
of both RA and PsA patients compared to healthy and osteoarthritis (OA) controls and 
that these cytokines are negative modulators of PD-1 function in vitro. This in line 
with what is observed with cytokines IL-2 and IL-15. Importantly, biologics 
adalimumab (anti-TNFα) and tocilizumab (anti-IL-6R) as wells as anti-IL-1β blocking 
antibody, were found to significantly counteract these cytokine-mediated effects. 
Preliminary data also suggest that RA or PsA synovial fluid added to HC CD4+ T cell 
cultures negatively modulate PD-1-mediated suppression of proliferation.  
 
Several studies have reported the ability of PD-1 to regulate cell proliferation 
and cytokine production in healthy T cells.  First described by Ishida et al. (56) and 
Agata et al. (93) in mice and further characterised by Freeman et al. (60) in both mice 
and human, the PD-1 receptor has emerged in more recent years as a key regulator for 
T cell activation (26, 61, 102, 369). Freeman et al. (60) have shown that TCR 
activation of splenic murine T cells and human CD4+ T cells, in presence of PD-
L1, results in inhibition of cell proliferation and cytokine production in vitro and that 
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the outcome of the interaction between PD-1 and PD-L1 in human CD4+ T cells 
depends on the strength of TCR and CD28 signals. The same group has shown that 
this is also the case in presence of PD-1 second ligand PD-L2 (61).   
The importance of PD-1 engagement with its ligand PD-L1 has been 
extensively characterised in murine models of autoimmune disease. Wang et al. 
investigated the role of PD-L1 in autoimmune diabetes by transgenically 
overexpressing PD-L1 in pancreatic β-cells in non-obese diabetic (NOD) mice and 
described decreased insulitis severity and delayed disease onset compared to controls 
(373).  PD-1 activation via PD-L1 has also been shown to inhibit T cell-mediated 
immune responses and prolong allograft survival in multiple experimental 
transplantation models (374, 375). In murine experimental models of RA, it was 
shown that enhancement of PD-1 crosslink via intraperitoneal injection of soluble 
murine PD-L1fc fusion protein resulted in less severe arthritis and reduced T cell 
proliferation supporting a role for PD-1 in the regulation of inflammation (216). 
Similarly, another study showed that administration of PD-L1fc to collagen-induced 
arthritis (CIA) mice reduces clinical arthritis score and serum levels of 
proinflammatory cytokines IL-17 and IL-23 (215). 
The association between polymorphisms in the PDCD1 human gene and 
susceptibility to RA, AS and SLE (section 4.1) strongly suggests a role for PD-1 in the 
progression of different human inflammatory diseases. 
Using a validated PD-1 ligation assay (60, 127, 368), this study confirmed that 
in vitro, PD-1 engagement with its ligand PD-L1 leads to a significant and dose-
dependent reduction of proliferation and IFN-γ production in healthy control PB-
derived CD4+ T cell. This is in agreement with previous work performed on human 
PB CD4+ T cells (60).  Data presented in this chapter also provide novel evidence that 
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CD4+ T cells from the peripheral blood of RA patients are more resistant to PD-1-
mediated suppression of proliferation as compared to HC CD4+ T cells. Interestingly, 
Raptopoulou et al. reported that PD-1 is capable of suppressing proliferation in PB-
derived CD4+ T cells from RA patients, OA patients and healthy donors and that only 
SF-derived RA CD4+ T cells are resistant to PD-1 ligation in presence of low doses of 
PD-L1 ligand (216). The observed discrepancies might be a consequence of the 
different cohorts of patients used for such experiments and the different sensitivity of 
the methods used to detect T cell proliferation between this thesis ([3H]-thymidine 
assay) and the specific experiment in the cited manuscript which used a 
carboxyfluorescein succnimidyl ester (CFSE) assay for that specific analysis.  
Further indication to support the hypothesis of an impaired PD-1 pathway 
during chronic inflammation can be found in juvenile idiopathic arthritis (JIA). A 
study from Wehrens et al. showed that CD4+ T cells from the synovial fluid of JIA 
patients have increased phosphorylation of the kinase PKB (Akt) and are resistant to 
Treg-mediated suppression. The study also found that TNFα and IL-6, which are 
present at the site of inflammation, induce Akt activation in CD4+ T cells resulting in 
resistance to TGFβ and Treg-mediated suppression (376). This is of interest because it 
has been demonstrated that PD-1 engagement with its ligands leads to inhibition of 
PI3K activation and reduced Akt phosphorylation (36, 68). Hence, in JIA, PD-1-
mediated regulation of SF CD4+T cells might be compromised leading to 
hyperactivation of Akt.  
Importantly, in new sets of experiments performed in this thesis, CD4+ T cells 
from the blood and paired synovial fluid of RA and PsA patients were found to be 
equally resistant to PD-1 ligation in terms of suppression of T cell proliferation and 
IFN-γ production when compared to healthy cells. Results from this thesis further 
 160 
extended the work from Raptopoulou et al., which focused only on RA (216), and 
provided novel insight in CD4+ T cell regulation in PsA demonstrating that CD4+ T 
cells from two different inflammatory arthrides display similar resistance to PD-1-
mediated regulation. These findings are interesting as they indicate that the 
inflammatory milieu associated with chronic inflammation might have a role in 
modulating PD-1-mediated regulation in T cells.  
 
Different cytokines have been shown to modulate PD-1 function. Bennett et al. 
showed that in vitro IL-2, IL-7 and IL-15, but not IL-4 or IL-21, can interfere with 
PD-1 ligation in HC CD4+ T cells resulting in higher cell proliferation (368). The 
authors demonstrated that IL-2 induces STAT5 phosphorylation in TCR activated T 
cells and speculated that because neither IL-4 nor IL-21 can induce pSTAT5, nor can 
rescue PD-1-mediated inhibition, only those cytokines that activate STAT5 can 
negatively modulate the PD-1 pathway. Notably, IL-2, IL-7 and IL-15, can all be 
detected in the circulation and at the site of inflammation of RA and PsA patients 
(270, 377-379) supporting the observation that different cytokines may interfere with 
PD-1 mediated suppression of proliferation in vivo.  
Data analysis performed in this chapter confirmed that increased levels of IL-7 
and IL-15 are found in RA SF when compared to RA and HC serum while functional 
experiments confirmed that IL-15 and IL-2 are able to interfere with PD-1 crosslink in 
vitro as reported by other authors (368, 369). Data from this chapter also show that 
RA and PsA have a very similar proinflammatory cytokine signature for TNFα, IL-6 
and IL-1β and that these cytokines, and possibly acellular SF, are able to reduce PD-1-
mediated suppression of proliferation in HC CD4+ T cells. Furthermore, neutralising 
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antibodies against TNFα,	 IL-6R and IL-1β can reverse the observed cytokine-
mediated effect (380).   
Although these results are novel and interesting they do have limitations. Co-
stimulation via CD28 (60, 368) and IL-2 production following CD28 engagement 
(369, 381) have been shown to negatively modulate PD-1 interaction with PD-L1fc or 
anti-PD-1 antibody leading to increased cell proliferation. Hence, further experiments 
performed in the presence of soluble anti-CD28 might reveal whether the cytokine-
mediated effect observed in TCR-only stimulated cells is still present in presence of 
co-stimulation. Similarly, further experiments using PD-L2 (61), the second ligand for 
PD-1, might be useful to further confirm that RA- and PsA-derived T cell, as well as 
cytokine-stimulated HC T cells, are resistant to PD-1 ligation in vitro (see chapter 6, 
section 6.2.1). Indeed, it cannot be ruled out that the observed effects described in this 
chapter might be strictly dependent on the selected experimental settings.  
The reduced PD-1-mediated regulation observed and described in RA and PsA 
CD4+ T cells and in healthy cells cultured with proinflammatory mediators raises the 
question about potential implications in human inflammatory disease. The increased 
frequencies of PD-1+CD4+ T cells in RA and PsA synovial fluid suggests that, at the 
site of inflammation, PD-1 might have a role in regulating T cell effectors and not 
simply act as a marker for cell exhaustion (382, 383). A confirmation of this theory 
was recently brought by Rao et al. (349), which described that following therapy, PD-
1hiCXCR5-CD4+ T cells (TPH) were reduced in the blood of RA patients and that such 
reduction significantly correlated with a lower disease activity. Synovial and blood-
derived PD-1hiCXCR5- cells were found to express inflammatory chemokine 
receptors CCR2, CX3CR1, and CCR5, which are known to mediate migration to the 
sites of peripheral inflammation (384, 385). Finally, PD-1hiCXCR5- cells had the 
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ability to produce cytokines IL-21 and CXCL13 upon in vitro stimulation and to 
induce differentiation of memory B cells into plasma cells indicating that these cells 
are not simply exhausted but instead hold a possible B cell helper function (349). 
 
It is therefore important to further investigate why, during chronic 
inflammation and despite the presence of high frequencies of PD-1+ T cells in the RA 
and PsA inflamed joint, the PD-1 pathway seems unable to regulate immune 
responses. The next chapter explores a possible mechanism by which 
proinflammatory cytokines modulate PD-1:PD-L1 engagement.  
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5 Soluble PD-1 (sPD-1) is induced by inflammation and abrogates  
PD-1:PD-L1 interaction in vitro 
5.1 Introduction 
A large number of soluble proteins corresponding to the extracellular domain 
of transmembrane receptors and adhesion molecules have been identified and 
characterised in biological fluids (386). These soluble molecules are able to maintain 
binding ability and can function as antagonist, agonists, carrier molecules and 
chaperones modulating immune-regulatory responses and contributing, in some cases, 
to disease pathology (386, 387). There are two known mechanisms by which soluble 
receptors are generated. The first mechanism involves proteolytic cleavage of the 
membrane-bound receptor from the cell surface, which is released in the extracellular 
milieu (388). Examples of soluble receptors generated via proteolytic cleavage, also 
known as “shedding”, include IL-1R, IL-2R, TNF-R, platelet-derived growth factor 
(PDGF) and the adhesion molecule L-selectin (CD62L) receptors (387). The second 
mechanism consists in alternative mRNA splicing which give rise to a polypeptide 
lacking the transmbrane region (389, 390). This truncated form of the receptor is 
generally secreted from the cell (387, 391, 392). A few examples of soluble receptors 
generated through differential mRNA splicing include IL-4R, IL-6R, IL-7R, 
epidermal growth factor (EGF) receptor and leukemia inhibitory factor (LIF) receptor 
(387, 391). Recently, Nielsen et al. have identified a splice variant of the inhibitory 
receptor PD-1 which lacks the trans-membrane domain and whose putative 
translational product is a soluble form of PD-1 (sPD-1) (63). The membrane-bound 
full length PD-1 isoform (flPD-1) is encoded by 5 exons: exon 1 (leader peptide), 
exon 2 (extracellular IgV-like domain), exon 3 (transmembrane domain) and exons 4 
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and 5 (intracellular domain) (393). Four alternatively spliced PD-1 mRNA transcripts 
in addition to flPD-1 have been identified. These splice variants are PD-1Δex2, PD-
1Δex3, PD-1Δex2,3, PD-1Δex2,3,4. All five PD-1 transcripts are constitutively 
expressed by non-stimulated PBMC and further increased following TCR activation 
(63). Interestingly, parallel increases in the expression of PD-1Δex3 and flPD-1 were 
described upon activation. This suggests an important interplay between the two 
variants and a possible functional antagonism on membrane-bound PD-1 mediated by 
sPD-1 (63). As discussed in chapter 4, RA and PsA-derived CD4+ T cells are resistant 
to PD-1-mediated suppression of proliferation. Similarly, HC CD4+ T cells cultured 
in presence of inflammatory mediators such as TNFα, IL-6 or IL-1β and RA or PsA 
synovial fluid are also resistant to PD-1-mediated regulation. It was therefore of 
interest to investigate the mechanism underlying the impaired PD-1-mediated 
suppression of proliferation with a specific focus on the role of sPD-1. 
 
The aims of this chapter were: 
1. To investigate whether proinflammatory cytokines TNFα, IL-6 and IL-1β can 
induce production of sPD-1 by HC CD4+ T cells. 
2. To verify that sPD-1 can be detected ex vivo in the serum and SF of 
inflammatory arthritis patients. 
3. To test whether sPD-1 is able to modulate PD-1:PD-L1 interaction in 
presence of CD4+ T cells only, in CD4+ and CD14+ co-cultures and in a 
Treg-mediated suppression assay.   
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5.2  Results 
5.2.1 Soluble PD-1 is induced in vitro by TNFα and IL-6 in HC CD4+ T cell 
cultures  
The first aim of this chapter was to identify a mechanism to explain, at least in 
part, why PD-1-mediated suppression of proliferation of HC CD4+ T cells is 
abrogated in presence of proinflammatory mediators.   
For this purpose, TCR-activated HC CD4+ T cells were cultured in the 
presence of increasing concentrations of PD-L1 (0, 0.1 and 1 µg/ml) and cell 
supernatants were collected at day 5 and analysed by ELISA for the presence of 
soluble PD-1 (sPD-1). In some experiments proinflammatory cytokines TNFα, IL-6 or 
IL-1β (10 ng/ml) used either alone or with specific neutralising antibodies, were added 
at the start of the culture. In absence of stimulation with exogenous proinflammatory 
cytokines (medium only conditions), sPD-1 was detected barely above the minimum 
detection limit and sPD-1 levels were unaffected by the concentration of PD-L1fc (0, 
0.1 and 1 µg/ml) (Figure 5.1). Conversely, sPD-1 was increased upon TNFα or IL-6 
stimulation (Figure 5.1A), but not in presence of IL-1β stimulation (Figure 5.1B). This 
effect was observed across all the PD-L1fc concentrations tested and was abrogated in 
the presence of specific neutralising antibodies adalimumab (anti-TNFα) and 
tocilizumab (anti-IL-6R) (Figure 5.1A).  A representative plot showing the TNFα-, IL-
6- and IL-1β-mediated effect in HC CD4+ T cells cultured with 1 µg/ml of PD-L1fc is 
shown (Figure 5.1C).  
To investigate whether TNFα and IL-6-mediated increase in sPD-1 was 
associated with increased expression of the PD-1Δex3 splice variant, quantitative 
polymerase chain reaction (qPCR) analysis was performed on HC CD4+ T cells from 
the TNFα and IL-6 stimulated cultures (Fig. 5.2).  Gel electrophoresis was used to 
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analyse the specificity of the PD-1Δex3 forward and reverse primers (primers 
sequences can be found in chapter 2). The qPCR product was run on an a 2% agarose 
gel and the specificity of the PD-1Δex3 forward and reverse primers was confirmed 
with the identification of a single band of 89 base pairs (bp) size which was the 
expected length for the PD-1Δex3 transcript. Primers specificity was further 
confirmed by the presence of single peaks in the specific melting curves of a 
representative run (Figure 5.2A). In line with the ELISA data, TNFα or IL-6 
stimulation consistently increased the PD-1Δex3 transcript as compared to medium 
only (~50% increase). Importantly, adalimumab or tocilizumab were able to abrogate 
the cytokine-mediated increase of PD-1Δex3 transcript as previously shown for sPD-1 
(Figure 5.2B).  
To further test whether cells derived from a proinflammatory milieu are able to 
produce sPD-1, HC PBMC and paired PBMC and SFMC from patients with RA or 
PsA were cultured following anti-CD3 mAb stimulation (OKT3; 100ng/ml) for 48 
hours and cell supernatants were collected and analysed by ELISA for the presence of 
sPD-1. Soluble PD-1 was barely detectable in supernatants from HC and RA and PsA 
PBMC cultures but it was consistently increased in SFMC cultures (Figure 5.3). This 
indicates that sPD-1 production might be directly consequent to cell exposure to 
proinflammatory cytokines typically found in the inflamed joint. The results presented 
in this section indicate that in vitro TNFα and IL-6, but not IL-1β, are able to induce 
sPD-1 in HC CD4+ T cell cultures and that this effect is coupled with increased 
expression of the PD-1Δex3 splice variant transcript.  
The results also indicate that sPD-1 and PD-1Δex3 levels are modulated by 






Figure 5.1 Soluble PD-1 (sPD-1) is induced in vitro by TNFα and IL-6 in HC CD4+ T cell 
cultures and decreases in presence of adalimumab and tocilizumab.  
 (A-C) CD4+ T cells were isolated from HC PBMC and cultured for 5 days in plates pre-
coated with anti-CD3 mAb (OKT3; 1.5 µg/ml) and PD-L1fc (0,0.1 1 µg/ml). Supernatants 
were collected at day 5 and analysed by ELISA. (A-B) HC CD4+ T cells cultured in presence 
of increasing concentrations of PD-L1fc and stimulated with TNFα (10 ng/ml) or TNFα + 
adalimumab (ADA; 1 µg/ml) (n=7), IL-6 (10 ng/ml) or IL-6+Tocilizumab (TOC; 1 µg/ml) 
(n=5-7) and IL-1β (10 ng/ml) or IL-1β+anti-IL-1β (anti-IL-1β; 1 µg/ml) (n=5). (C) 
Cumulative experiment showing HC CD4+ T cells stimulated in the presence of 1 µg/ml of 












Figure 5.2 PD-1Δex3 is induced in vitro by TNFα and IL-6 in HC CD4+ T cells.  
(A) Gel electrophoresis showing PD-1Δex3 primer specificity as demonstrated by a transcript 
of 89bp and by one-peak qPCR melting curves for medium only, +TNFα, +TNFα + ADA, 
+IL-6 and +IL-6 + TOC culture conditions. (B) Expression of PD-1Δex3 transcript in HC 
CD4+ T cells cultured for 5 days in the absence (medium, M) or presence of 10 ng/ml of 
TNFα (n=4) or IL-6 (n=3) ± anti-TNFα (adalimumab; ADA) or anti-IL-6R (tocilizumab; 
TOC) (all at 1 µg/ml). PD-1Δex3 expression was examined by qPCR and normalised to β-













Figure 5.3 Soluble PD-1 (sPD-1) is higher in SFMC culture supernatants compared to 
PBMC culture supernatants.  
Bulk PBMC from HC donors and bulk PBMC and SFMC from RA and PsA donors were 
cultured for 48 hrs in the presence of anti-CD3 mAb (OKT3; 100 ng/ml) (HC: n=3: RA: n=5, 
PsA: n=1). Day 2 supernatants were analysed by ELISA for sPD-1 levels. Data were analysed 














5.2.2 Soluble PD-1 is detected in the serum and SF of both RA and PsA patients 
but not in HC serum and osteoarthritis (OA) serum and SF  
The data so far demonstrated that both the PD-1Δex3 transcript and sPD-1 are 
induced in HC CD4+ T cells upon TNFα and IL-6 stimulation and that sPD-1 is 
detected in SFMC culture supernatants. Next, the presence of sPD-1 in the serum and 
SF of patients with inflammatory arthritis was investigated.  
Two sets of cryopreserved RA and PsA serum and matched SF samples were 
analysed by ELISA for the presence of soluble PD-1. In the first sets of patient 
samples, sPD-1 was detected in 10/14 RA sera and in 11/14 RA SF. Similarly, sPD-1 
was detectable in 8/10 PsA serum and SF samples (Figure 5.4). Soluble PD-1 levels 
for RA serum and SF were detected at ~26.8 and ~13.4 ng/ml respectively, while in 
PsA sPD-1 was detected at ~20.4 ng/ml for the serum, and ~11.9 ng/ml for the SF. 
Although sPD-1 was significantly lower in the PsA synovial fluid compared to the 
PsA serum, no significant differences were found when sPD-1 levels were compared 
between the two diseases. Serum levels of sPD-1 positively and significantly 
correlated with SF levels of sPD-1 in both RA and PsA (Figure 5.4C). These first sets 
(sets 1 & 2) were analysed with the main aim to detect sPD-1 and no investigation was 
performed on a control disease. 
To address this and to further confirm the presence of sPD-1 in the serum and 
synovial fluid of inflammatory arthritis patients, two additional sets of RA and PsA 
patient samples (set 3 & 4) were selected.  In the new experiments healthy serum and 
serum and SF from patients with osteoarthritis (OA) were selected and included in the 
analysis as controls. The two RA and PsA sets included patients not receiving TNF-
inhibitor (TNFi) therapy, patients undergoing TNFi therapy and patients receiving 
methotrexate (MTX) therapy. In this new analysis, sPD-1 was significantly lower in 
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RA SF compared to RA PB and no significant difference was found between PsA 
serum and SF (Figure 5.5A). Soluble PD-1 was detectable in 0/2 HC serum, 0/3 OA 
serum and 0/4 OA SF samples, whilst it was detected at high levels in 13/17 RA and 
13/18 PsA serum and SF samples. Soluble PD-1 levels for RA and PsA were detected 
as follows: ~15.3 ng/ml for RA Serum, ~10.5 ng/ml for RA SF, ~18.4 ng/ml for PsA 
serum and ~15.4 ng/ml for PsA SF (Figure 5.5B).  As an extra internal control, the 
serum and paired SF from one representative OA sample were left untreated or spiked 
with 15 ng/ml of sPD-1fc. Results showed that in the spiked conditions sPD-1 was 
detected at 12.8 ng/ml and 20.8 ng/ml for the serum and SF, respectively (Figure 
5.5C). In line with the analysis performed on the previous sets of patients, serum 
levels of sPD-1 positively and significantly correlated with SF levels of sPD-1 in both 
RA and PsA (Figure 5.5D). 
 
Next, the levels of sPD-1 were investigated in the serum and SF of RA and 
PsA patients not treated with TNFi therapy versus patients treated with TNFi therapy. 
This was of interest because it was previously shown (see section 5.2.1) that the TNFi 
biologic adalimumab was able to abrogate the effect of TNFα on PD-1-mediated 
suppression of proliferation and to negatively modulate both PD-1Δex3 transcript and 
sPD-1 production in HC CD4+ T cell cultures. In this cross-sectional investigation, 
TNFi therapy-treated patients had lower levels of sPD-1 in both the serum and SF as 
compared to non-treated patients.  Soluble PD-1 was detected at 15 ng/ml (serum) and 
at 11,2 ng/ml (SF) in patients not undergoing TNFi therapy. Conversely, sPD-1 levels 
in patients receiving TNFi therapy were detected at 2,1 ng/ml and 1,7 ng/ml for serum 
and SF, respectively (Figure 5.6A). Notably, the observed differences were more 
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pronounced and statistically significant in the RA group as compared to the PsA group 
(Figure 5.6B and 5.6C).  
To further test whether TNFi therapy modulates sPD-1 levels, a preliminary 
longitudinal analysis was performed on 4 RA patients whose serum was collected 
before TNFi therapy (time 0) and at 6 and 12 months after initiation of TNFi therapy. 
Preliminary data showed that in 2/4 patients (patient #1 and patient #4), the serum 
levels of sPD-1 decreased over time upon treatment as compared to time 0. In patient 
#2, although time 0 was not available, sPD-1 was lower at 12 months as compared to 
6 months while in patient #3 sPD-1 levels increased overtime following treatment 
(Figure 5.7). ELISA analysis was performed on the 4 RA serum samples to investigate 
whether the observed changes in sPD-1 levels were coupled with the modulation of 
proinflammatory cytokine TNFα and antiinflammatory cytokine IL-10, but neither 
TNFα nor IL-10 were detected in the tested sera (data not shown).  
The levels of sPD-1 were also investigated in the serum and SF of RA and PsA 
patients not treated with MTX therapy versus patients treated with MTX therapy. 
Overall, patients undergoing MTX therapy had lower sPD-1 in the serum and SF 
compared to patients not treated with MTX therapy, although the observed differences 
were not significant (Figure 5.8A). Unexpectedly, data also revealed that in direct 
contrast with RA, the analysed PsA patients undergoing MTX therapy had higher 
sPD-1 levels in both the serum and SF as compared to patients not treated with MTX 
therapy (Figure 5.8B). 
The presence of possible associations between cytokine levels, disease activity 
score and sPD-1 levels are of clinical interest. Although literature data is conflicting, it 
has been previously documented that sPD-1 levels correlate with certain cytokines in 
either the serum or SF of RA patients. The levels of the cytokines TNFα, IL-6 and IL-
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1β in the serum and SF of RA and PsA patients (sets 3 and 4) as well as in OA and 
healthy controls were previously measured and data are shown in chapter 4.  
Serum levels of sPD-1 positively correlated with serum levels of TNFα in the 
RA group (r2 = 0.41; p=0.02) (Figure 5.9A) but not in the PsA group (Figure 5.9B) 
and no further correlations between IL-6 and IL-1β levels and sPD-1 levels were 
found. Soluble PD-1 levels were also evaluated against the disease activity score of 28 
joints (DAS28), the tender joint count (TJC) or the swollen joint count (SJC) but no 






















Figure 5.4 Soluble PD-1 (sPD-1) is detected in the serum and SF of RA and PsA 
patients. 
(A-B) Soluble PD-1 levels in the serum and SF of RA and PsA samples (sets 1 and 2) were 
analysed by ELISA. The dashed line indicates the minimum detection limit and a log10 scale 
converted from a linear (pg/ml) scale is shown for each graph. (A) sPD-1 levels in paired 
serum and SF from RA (n=14) and PsA (n=10) patients. (B) sPD-1 levels comparison 
between serum and SF from RA and PsA patients (median ± IQR). (C) Correlation between 
serum and SF sPD-1 levels in RA (n=14) and PsA (n=10). Data in (A) were analysed by 
Wilcoxon matched-pairs signed-rank test. Data in (B) were analysed by Kruskal-Wallis test 
with Dunn’s Multiple Comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001. Data in (C) 









Figure 5.5 Soluble PD-1 (sPD-1) is detected at higher levels in the serum and SF of RA 
and PsA patients compared to healthy and OA controls.  
(A-C) Soluble PD-1 levels in HC serum and in the serum and SF of OA, RA and PsA samples 
(sets 3 and 4) were tested by ELISA. The dashed line indicates the minimum detection limit 
and a log10 scale converted from a linear (pg/ml) scale is shown for each graph. (A) sPD-1 
levels in paired serum and SF from RA (n=17) and PsA (n=18) patients. (B) sPD-1 
comparison between HC, OA, RA and PsA serum and SF (HC, n=2; OA, n=3-4; RA, n=17; 
PsA, n=19) (median ± IQR). (C) sPD-1 levels in OA serum and SF without (white bars) and 
with (black bars) soluble PD-1fc (15 ng/ml) spike. (D) Correlation between serum and SF 
sPD-1 levels in RA (n=17) and PsA (n=19). Data in (A) were analysed by Wilcoxon matched-
pairs signed-rank test while data in (B) were analysed by Kruskal-Wallis test with Dunn’s 
Multiple Comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001. Data in (D) were analysed by 












































Figure 5.6 Soluble PD-1 (sPD-1) levels in the serum and SF of RA and PsA patients 
undergoing TNFi therapy are lower as compared to patients not receiving TNFi therapy.  
(A-C) Soluble PD-1 levels in the serum and SF of OA, RA and PsA patients (sets 3 and 4) 
were tested by ELISA. The dashed line indicates the minimum detection limit and a log10 
scale converted from a linear (pg/ml) scale is shown for each graph. (A) Cross-sectional 
analysis of sPD-1 levels in RA and PsA paired serum/SF and OA serum/SF (OA, n=3-4; RA 
n=5, RA(TNFi) n=5, PsA n=6, PsA(TNFi) n=6) (median ± IQR). (B-C) Cross-sectional 
analysis of sPD-1 levels in RA (B) and PsA (C) serum and SF. Data (A-C) were analysed by 


































Figure 5.7 Soluble PD-1 (sPD-1) levels in the serum of RA patients undergoing TNFi 
therapy display variability overtime.  
Longitudinal analysis of the levels of sPD-1 in the serum of RA patients undergoing TNFi 
therapy. sPD-1 was tested by ELISA at time 0 (no TNFi therapy; except for patient #2) and at 
6 and 12 months after start of the therapy. The dashed line indicates the minimum detection 





































Figure 5.8 Soluble PD-1 (sPD-1) levels in the serum and SF of RA and PsA patients 
undergoing MTX therapy are lower and higher, respectively, as compared to patients 
not receiving MTX therapy.  
 (A-B) The levels of sPD-1 in the serum and SF of RA and PsA patients (sets 3 and 4) were 
analysed by ELISA. The dashed line indicates the minimum detection limit and a log10 scale 
converted from a linear (pg/ml) scale is shown for each graph. Cross-sectional analysis of 
sPD-1 levels in RA (A) and in PsA (B) paired serum and SF and OA serum and SF (OA n=3-
4, RA n=5, RA(MTX) n=7; PsA n=6, PsA(MTX) n=6). Data (A-B) were analysed by Mann-










Figure 5.9 Correlations between soluble PD-1 (sPD-1) and proinflammatory cytokines 
levels in the serum and SF of RA and PsA patients.  
(A-D) sPD-1 levels in RA serum n=12 (A), RA SF n=12 (B), PsA serum n=13 (C) and PsA 
SF n=13 (D) were assessed for correlation with the proinflammatory cytokines TNFα, IL-6 
and IL-1β by Spearman's test. Symbols represent individual patients. Individual data were 

































Figure 5.10 Correlations between soluble PD-1 (sPD-1) levels in the serum and SF of RA 
and PsA patients and the disease activity score in 28 joints (DAS28).  
(A-B) sPD-1 levels in the RA serum n=12 and RA SF n=12 (A) and in PsA serum n=13 and 
PsA SF n=13 (B) were assessed for correlation with the disease activity score in 28 joints 
(DAS28) by Spearman's test. Symbols represent individual patients. Individual data were 










Figure 5.11 Correlations between soluble PD-1 (sPD-1) levels in the serum and SF of RA 
and PsA patients and the tender join count (TJC) or swollen joint count (SFJ).  
(A-C) sPD-1 levels in the RA serum n=11 and SF n=11 (A) and in the PsA serum n=12 and 
SF n=12 (B) were assessed for correlation with the tender joint count (TJC) or the swollen 
joint count (SJC) parameters by Spearman's test. Symbols represent individual patients. 












5.2.3 Soluble PD-1 modulates PD-1-mediated suppression of HC CD4+ T cells 
and induces proliferation in CD4+ T cell:CD14+ monocyte co-cultures  
Data so far have shown that sPD-1 is induced by proinflammatory cytokines 
typically detected in RA and PsA, it is found mainly in the supernatants of RA and 
PsA SFMC cultures and it can be detected in the serum and SF of patients with RA or 
PsA. The next experiments were performed to investigate whether sPD-1 was able to 
negatively modulate PD-1-mediated suppression of proliferation in vitro.  
To investigate this, a human PD-1fc chimera was used to mimic the effect of 
naturally occurring sPD-1. First, sPD-1fc was tested for its effect on T cell 
proliferation of anti-CD3 stimulated HC CD4+ T cells cultured in absence of PD-
L1fc. Soluble PD-1fc was added at the beginning of the culture at two increasing 
concentrations (0.5 and 1 µg/ml) and cells were cultured for 5 days. In these 
experiments, sPD-1fc did not significantly increase nor decrease T cell proliferation as 
compared to medium only condition suggesting no direct effect on HC CD4+ T cells 
cultured without the presence of accessory cells (Figure 5.12A).  
Next, HC CD4+ T cells were cultured in plates pre-coated with increasing 
amounts of PD-L1fc ligand and in the absence or presence of sPD-1fc chimera (0.5 or 
1 µg/ml). In PD-L1fc pre-coated plates, addition of sPD-1fc was able to abrogate the 
effect of the ligand in a dose-dependent fashion resulting in a less efficient 
suppression of T cell proliferation compared to medium only (Figure 5.12B, 5.12C).  
In absence of sPD-1fc, the average level of suppression of proliferation in the 
0.1 and 1 µg/ml PD-L1fc conditions was ~20% and ~32%, respectively, as compared 
to medium only (0 µg/ml).  In presence of 0.5 µg/ml of sPD-1fc, suppression of 
proliferation decreased to an average of ~6% and ~18%, respectively. No suppression 
of proliferation (~0%) was found when 1 µg/ml of sPD-1fc was added to the cell 
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cultures (Figure 5.12B, 5.12C). These data indicate that in a HC CD4+ T cell-only 
culture system, sPD-1 is able to negatively modulate an otherwise functional PD-
1/PD-L1 interaction.  
To further investigate the role of sPD-1 during PD-1:PD-L1 interaction, a co-
culture system using HC CD4+ T cells and autologous CD14+ cells as a source of 
natural PD-L1 was set up. Firstly, the ability of HC CD14+ cells to express PD-L1 
was analysed by flow cytometry. HC CD14+ cells were isolated from HC PBMC and 
cultured overnight with either IFN-γ, a known inducer of PD-L1 (59, 324), or 
proinflammatory cytokines IL-6, TNFα and a combination of IL-6 + TNFα. These 
proinflammatory cytokines have also been described as inducers of PD-L1 expression 
(394-396). After 12 hours in culture, the majority of IFN-γ-treated cells were PD-L1+ 
as compared to cells left unstimulated (Medium: ~18% of CD14+PD-L1+ cells; IFN-
γ: ~98% of CD14+PD-L1+ cells). This was also the case when cells were stimulated 
with IL-6, TNFα or with a combination of IL-6 + TNFα (Figure 5.13A, 5.13B). TNFα 
was a stronger inducer of PD-L1 as compared to IL-6 (Medium: ~5%; IL-6: ~30%; 
TNFα: ~70% of CD14+PD-L1+ cells) and the two cytokines showed a synergistic 
effect when used together (IL-6 + TNFα: ~90% of CD14+PD-L1+ cells). These data 
indicate that, in vitro, HC CD14+ cells are able to upregulate PD-L1 following 
cytokine stimulation. 
Next, freshly isolated HC CD4+ T cells and autologous monocytes were 
cultured at a 1:1 ratio, with soluble anti-CD3 mAb (100 ng/ml) in the absence or 
presence of increasing doses of sPD-1fc or IgG1fc control (0.25, 0.5 and 1 µg/ml).  
Addition of sPD-1fc led to a dose-dependent increase in T cell proliferation 
compared to control-treated cells. The observed increase in proliferation was 
statistically significant in presence of 1 µg/ml of sPD-1fc (Figure 5.14A, 5.14B). 
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Importantly, no variation in proliferation was observed in presence of the specific 
IgG1fc control. These results were confirmed in additional experiments in which HC 
CD4+ T cells were cultured with autologous CD14+ monocytes at a 1:0.5 ratio 
(Figure 5.14C) and in preliminary experiments with HC CD8+ T cells cultured with 
autologous CD14+ monocytes at 1:1 ratio (Figure 5.14D). In these experiments HC 
CD8+ T cell proliferation increased to an average of ~37% in presence of 1 µg/ml 
sPD-1fc as compared to medium only (Figure 5.14D). 
 
These data indicate that soluble PD-1fc used to mimic natural soluble PD-1 
modulates PD-1 ligation in both an artificial system (PD-L1fc pre-coated plates) as 














Figure 5.12 Soluble PD-1 (sPD-1) modulates PD-1-mediated suppression of HC CD4+ T 
cells.  
(A) HC CD4+ T cells (n=9) were cultured with immobilised anti-CD3 mAb (OKT3) in the 
presence of increasing concentrations of sPD-1fc (0, 0.5 and 1 µg/ml). Proliferation was 
assessed at day 5 by [3H]-thymidine incorporation and displayed as count per minute (cpm). 
(B) Proliferation and (C) suppression of proliferation of HC CD4+ T cells cultured in anti-
CD3 mAb (OKT3) and PD-L1fc pre-coated plates with or without sPD-1fc (0.5 and 1µg/ml) 
(n=9-10). Data were analysed by Friedman Test with Dunn’s Multiple Comparison test. *p < 







































Figure 5.13 PD-L1 expression in HC CD14+ monocytes increases with IFN-γ, IL-6 and 
TNFα cytokine stimulation.  
CD14+ monocytes where positively isolated from HC PBMC and cultured overnight at 37 ºC 
in medium only or in medium supplemented with IFN-γ, IL-6, TNFα or a mix of IL-6 and 
TNFα (All cytokines used at 10 ng/ml). PD-L1 expression was assessed after 12 hrs by flow 
cytometry. (A) Representative experiments. Shaded histograms represent the isotype control, 
open histograms indicate the expression profile for PD-L1 with/without the specific cytokine 
stimulation. (B) Cumulative data showing the percentage of monocytes expressing PD-L1 





















































Figure 5.14 sPD-1 induces proliferation in HC CD4+ and CD8+ T cell/CD14+ monocyte 
co-cultures.  
Proliferation (A) and suppression of proliferation (B-C) of HC CD4+ T cells cultured for 5 
days with autologous CD14+ monocytes at a 1:1 ratio (n=7) and 1:0.5 ratio (n=3, except 
sIgG1; 1 µg/ml, n=2) in the presence of soluble anti-CD3 mAb (100 ng/ml) and soluble PD-
1fc/IgG1fc control (0, 0.25, 0.5 and 1 µg/ml). (D) Proliferation and suppression of 
proliferation of HC CD8+ T cells cultured with autologous CD14+ monocytes at 1:1 ratio 
(n=2) in the presence of soluble anti-CD3 mAb (100 ng/ml) and soluble PD-1fc/IgG1fc 
control (1 µg/ml). Data were analysed by Wilcoxon signed rank test (A-B). *p < 0.05 and 
***p < 0.001. 
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5.2.4 Soluble PD-1 does not modulate the regulatory function of HC 
CD4+CD25+ Treg cells in vitro 
Data so far have shown that a sPD-1fc chimera, used to mimic sPD-1, can 
negatively modulate PD-1 ligation in CD4+ T cell-only cultures and in CD4+:CD14+ 
co-cultures but it is unclear whether or not sPD-1 has also a role in modulating Treg-
mediated regulation. This is of interest because PD-L1-mediated signalling in PD-1+ 
induced regulatory T cells (iTregs) has been shown to increase the protein expression 
of forkhead box 3 (FoxP3) leading to enhanced suppressive functions (98, 394). 
Hence, sPD-1 could potentially act by disrupting PD-1/PD-L1 interaction influencing 
Treg-mediated suppression.  
To investigate this further, an in vitro Treg cell suppression assay was set up. 
An initial optimization of the assay was performed to evaluate the ability of HC Treg 
cells to regulate T effector (Teff) cells proliferation. HC PB-derived Treg 
(CD4+CD25+CD127low) cells were positively isolated and cultured with autologous 
cell trace violet (CTV)-stained PBMC (Teff cells) in the presence of anti-CD3 mAb 
(OKT3; 100 ng/ml) or with anti-CD3/CD28 activation beads (1 bead/5 cells). Teff 
cells were cultured with Treg cells at 3 different Teff:Treg cell ratios (1:0, 1:0.25 and 
1:0.5) and proliferation of CD4+ and CD8+ cells within the Teff population was 
assessed in parallel experiments on day 3 by gating on CTV+ populations. A 
representative plot showing Treg cells purity in two representative HC donors and the 
gating strategy of the Treg suppression assay is shown in Figure 5.15A and Figure 
5.15B.  
In these initial experiments, the presence of Treg cells led to a cell ratio–
dependent reduction in the proliferation of autologous CD4+ and CD8+ cells (Figure 
5.16A and 5.16B). Cell proliferation in absence of Treg cells was higher in beads-
 189 
stimulated cultures (Figure 5.16B) compared to anti-CD3-stimulated cultures (Figure 
5.16A). Similarly, the suppressive capacity of Treg cells was higher in beads-
stimulated cultures compared to anti-CD3-stimulated cultures showing percentages of 
suppression of ~70% and ~80% compared to ~40% and ~60% (ratios 1:0.25 and 1:0.5, 
respectively). As readout for Treg cells ability to control cell activation, PD-1+ cell 
percentages and PD-1 medium intensity fluorescence (MFI) were also evaluated in a 
group of Teff cells cultured with or without Treg cells in presence of anti-CD3 
(OKT3) stimulation or anti-CD3/CD28 beads. 
PD-1 expression was consistently increased in both CD4+ and CD8+ T cells 
upon cell activation and in absence of Treg cells (Figure 5.17A and Figure 5.18A). On 
the contrary, addition of Treg cells to the cultures consistently reduced the percentage 
of PD-1+CD4+ and PD-1+CD8+ cells as well as PD-1 MFI in a dose-dependent 
fashion (Figure 5.17B and 5.17C and Figure 5.18B and 5.18C). Teff cell, instead of 
Treg cells, were then added to the cultures (1.5:0 ratio) to control for cell density, and 
no difference in PD-1+ percentages or PD-1 MFI were found as compared to 1:0 
condition (Figure 5.17 and 5.18).  
These results demonstrated that the suppression assay was functional and that 
HC PB-derived Treg cells suppressed proliferation of autologous Teff cells despite the 
different methods used for activation. The data further demonstrated that Treg cells 
can modulate Teff cell activation as shown by decreased percentages of PD-1+ Teff 
cells and decreased PD-1 MFI.  
 
Next, further experiments were set up to investigate whether the presence of 
sPD-1fc added from the start of the culture could modulate Treg-mediated regulation 
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of proliferation and cytokine production. Firstly, the proliferation of Teff cells 
cultured in absence of Treg cells and with sPD-1fc at 1 and 2 µg/ml was evaluated.  
Unexpectedly, in these experimental conditions, sPD-1fc had no effect on 
proliferation as shown by similar percentages detected across all conditions for both 
CD4+ and CD8+ cells (Figure 5.19A, 5.19B).  Teff cells were then cultured in 
presence of Treg cells at 3 different cell ratios in absence or presence of sPD-1fc or 
sIgG1 control. Data show that in all conditions Treg cells led to a ratio-dependent 
reduction in the proliferation of CD4+ and CD8+ cells and that addition of sPD-1fc 
during the co-culture, had no positive or negative effect on their ability to suppress 
Teff cells proliferation (Figure 5.19C, 5.19D).  
Next, co-culture supernatants were tested for the presence of cytokines IFN-γ 
and TNFα. In line with the proliferation data, activation with anti-CD3/CD28 beads 
was able to induce higher production of both cytokines as compared to activation with 
anti-CD3 only. Furthermore, Treg cells strongly suppressed the secretion of IFN-γ and 
TNFα in a cell ratio-dependent fashion but the levels of suppression observed were 
not significantly different between medium only and +sPD-1fc or +IgG1 control 
conditions (Figure 5.20A, 5.20B).  
These data indicate that in the selected experimental conditions, soluble PD-1 
is unable to negatively or positively modulate Treg-mediated suppression of 










Figure 5.15 Gating strategy for the analysis of the Treg cell suppression assay.  
(A) Purity staining of PB-derived Treg cells from two representative HC donors showing that 
,phenotypically, isolated cells are CD4+CD25+ and CD4+CD127low. (B) Gating strategy for 
the Treg suppression assay. (B) FACS plots from a representative donor stimulated with anti-
CD3/CD28 beads and analysed at day 3. Cells from Treg:Teff co-cultures were gated and 
analysed as follows: First total cells, followed by singlets, live/CD14- cells and finally CD4+ 
versus CD8+ cells. The dilution of the CTV dye was assessed for CD4+ and CD8+ cells in 







Figure 5.16 HC CD4+CD25+ Treg cells are able to suppress autologous CD4+ and CD8+ 
cell proliferation.  
HC PBMC (Teff cells) were labelled with cell trace violet (CTV) and cultured in the presence 
of anti-CD3 monoclonal antibody (100 ng/ml) (A) or anti-CD3/CD28 beads (1 bead every 5 
cells) (B) ± autologous PB CD4+CD25+ Treg cells (added at the indicated Teff:Treg cell 
ratios). On day 3, cell proliferation was assessed by gating on CD4+ and CD8+ cells within 
PBMC Teff cells. (A-B) Cumulative data showing the percentage of proliferating cells and the 
percentage of suppression in the absence or presence of Treg cells (n=10). The percentage of 
Teff proliferation is shown for each Teff:Treg cell ratio. Bars show the mean ±  SEM. Data 
were analysed by Kruskal-Wallis test with Dunn’s multiple comparison test. *p < 0.05, **p < 













Figure 5.17 HC CD4+CD25+ Treg cells suppress PD-1 expression in OKT3-stimulated 
autologous Teff cells.  
HC PBMC (Teff cells) were labelled with cell trace violet (CTV) and cultured in the presence 
of anti-CD3 monoclonal antibody (100 ng/ml) ± autologous PB CD4+CD25+ Treg cells 
(added at the indicated Teff:Treg cell ratios). On day 3, PD-1 expression was assessed by 
gating on CD4+ and CD8+ cells within PBMC Teff cells. (A) PD-1+ cells within CD4+ and 
CD8+ cells cultured in absence (medium) or presence (+OKT3) of TCR stimulation and in 
absence of Treg cells (n=5). (B-C) PD-1+ cell percentage (%) and PD-1 medium intensity 
fluorescence (MFI) of CD4+ and CD8+ cells cultured without/with autologous CD4+CD25+ 













Figure 5.18 HC CD4+CD25+ Treg cells suppress PD-1 expression in anti-CD3/CD28 
bead-stimulated autologous Teff cells.  
HC PBMC (Teff cells) were labelled with cell trace violet (CTV) and cultured in the presence 
of anti-CD3/CD28 activation beads (1 bead every 5 cells) ± autologous PB CD4+CD25+ Treg 
cells (added at the indicated Teff:Treg cell ratios). On day 3, PD-1 expression was assessed by 
gating on CD4+ and CD8+ cells within PBMC Teff cells. (A) PD-1+ cells within CD4+ and 
CD8+ cells cultured in absence (medium) or presence (+OKT3) of TCR stimulation and in 
absence of Treg cells (n=5). (B-C) PD-1+ cell percentage (%) and PD-1 medium intensity 
fluorescence (MFI) of CD4+ and CD8+ cells cultured with/without autologous CD4+CD25+ 












                    
Figure 5.19 HC CD4+CD25+ Treg cell-mediated suppression of proliferation is not 
modulated by sPD-1. 
HC PBMC (Teff cells) were labelled with cell trace violet (CTV) and cultured in the presence 
of anti-CD3 monoclonal antibody (100 ng/ml) or anti-CD3/CD28 beads (1 bead every 5 cells), 
± autologous CD4+CD25+ Treg cells (added at the indicated Teff:Treg cell ratios) and ± sPD-
1fc (1 and 2 µg/ml) or sIgG1fc (Ctrl: 2 µg/ml). On day 3, cell proliferation was assessed by 
gating on CD4+ and CD8+ cells within PBMC Teff cells. (A-B) Effect of sPD-1 or sIgG1 
control on Teff proliferating cells stimulated with (A) anti-CD3 monoclonal antibody or (B) 
anti-CD3/CD28 beads in absence of Treg cells. (C-D) Cumulative data showing the 
percentage of proliferating CD4+ and CD8+ cells (within PBMC) in presence of Treg cells 








Figure 5.20 HC CD4+CD25+ Treg cell-mediated suppression of IFN-γ and TNFα 
production is not modulated by sPD-1. 
HC PBMC (Teff cells) were labelled with cell trace violet (CTV) and cultured in the presence 
of (A) anti-CD3 monoclonal antibody (100 ng/ml) or (B) anti-CD3/CD28 beads (1 bead every 
5 cells), ± autologous PB CD4+CD25+ Treg cells (added at the indicated Teff:Treg cell 
ratios) and ± PD-1fc (1 and 2 µg/ml) or IgG1fc (2 µg/ml). On day 3, cell culture supernatants 
were collected and analysed by ELISA for the presence of IFN-γ and TNFα. The broken 









5.3 Discussion  
 The data presented in this chapter provide new findings regarding the 
production of sPD-1 and its biological activity. Firstly, it was demonstrated that TNFα 
or IL-6 added to HC CD4+ T cells induce soluble PD-1 production and that the 
biologics adalimumab (anti-TNFα) and tocilizumab (anti-IL6R) abrogate this increase. 
Next, it was demonstrated that TNFα or IL-6 induce expression of the PD-1Δex3 
splice variant in HC CD4+ T cells and that this effect is also abrogated by biologics. It 
was shown that sPD-1 is produced in higher levels by SFMC as compared to PBMC 
and that sPD-1 is detected at high levels in the serum and SF of patients with RA and 
PsA, but not in healthy or OA controls. A cross-sectional analysis further showed that 
RA and PsA patients treated with TNFα inhibitor (TNFi) therapy had significantly 
lower sPD-1 in both the serum and SF as compared to patients not treated with TNFi 
therapy. RA patients treated with MTX therapy were shown to have lower sPD-1 as 
compared to RA patients not treated with MTX, although the observed difference was 
not statistically significant. On the contrary, sPD-1 levels were higher in MTX-treated 
PsA patients as compared to non-treated PsA patients. Mechanistically, it was 
demonstrated that a recombinant sPD-1fc chimera, used to mimic naturally occurring 
sPD-1, was able to abrogate PD-1-mediated suppression of proliferation in HC CD4+ 
T cell-only cultures. Soluble PD-1fc was also found to induce proliferation in HC 
CD4+:CD14+ co-cultures but had no effect on Treg-mediated suppression of 
proliferation or cytokine production. 
 
In the literature several pieces of evidence indicate that soluble inhibitory 
receptors play important roles during immune responses contributing, in some cases, 
to disease pathology. One example is the leukocyte-associated Ig-like receptor 
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(LAIR)-1. LAIR-1 is a collagen receptor that inhibits the immune cell function upon 
collagen binding. The soluble counterpart of LAIR-1, named LAIR-2, has been shown 
to prevent cross-linking between LAIR-1 and collagens. LAIR-2 can be induced in 
vitro by stimulation of PBMC with PMA and ionomycin and it is increased in the 
synovial fluid of patients with rheumatoid arthritis as compared with osteoarthritis 
patients (397). The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is another 
well-characterized inhibitory receptor that exists both in a membrane-bound form and 
in a soluble form (sCTLA-4) (398-401). Soluble CTLA-4 has been described in 
human serum and its presence has been associated with several autoimmune diseases 
including systemic lupus erythematosus and autoimmune thyroid disease (47, 402-
405).  
Recently, thanks to the extensive studies performed by the scientific 
community on the PD-1 pathway in cancer immunotherapy, sPD-1 has emerged as an 
important immunologic modulator both in cancer as well as in autoimmunity. The 
biological activity of sPD-1 has been studied mainly in antiviral and antitumor 
immunity while its role in inflammatory arthritis is not well established. In antiviral 
and antitumor immunity, several authors have shown that sPD-1 is able to interfere 
with PD-1-mediated inactivation of cytotoxic T cells leading to enhanced T cell ability 
to fight against cancerous and infected cells (406-409).  
He et al. used a eukaryotic plasmid (pPD-1A) that expresses the extracellular 
domain of murine PD-1 (sPD-1) and demonstrated that sPD-1 can bind PD-1 ligands 
PD-L1 and PD-L2 in vitro and enhance anti-tumour immunity in vivo (406).  
Similarly, Shin et al. have shown that sPD-1 can synergise with herpes simplex virus 
thymidine kinase (HSVtk) leading to tumour regression (407). In this study it was 
shown that in HSVtk expressing tumour cells, exposure to the prodrug ganciclovir 
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(GCV), leads to inhibition of DNA polymerase, single-strand DNA breaks and tumour 
cell death by direct cytotoxicity. Soluble PD1 cDNA was integrated into a replication-
deficient adenovirus (Ad5mTR.sPD-1) harboring HSVtk and this was used to show 
that both in vitro and in vivo, sPD1 synergised with HSVtk boosting antitumor 
immunity by amplifying CD8+ T cell responses via blockade of PD-L1 in the tumour 
microenvironment (407). Finally, Sorensen et al. compared the concentration of sPD-
1 in the serum of advanced epidermal growth factor receptor (EGFR)-mutated non-
small cell lung cancer patients prior to treatment with EGFR inhibitor drug erlotinib 
and at the time of progression. Interestingly, sPD-1 was detected in the serum of 
patients and further increased upon therapy showing an association between sPD-1 
levels and prolonged patient survival (410). Further evidence supporting the 
importance of sPD-1 in T cell regulation can be found in simian antiviral immunity. It 
has been shown that blockade of PD-1 ligands in vitro using a soluble recombinant 
PD-1fc fusion protein can improve CD4+ and CD8+ antigen-specific T cell responses 
(408). Administration of sPD-1fc, in vivo, enhances simian immunodeficiency 
virus (SIV)-specific CD4+ and CD8+ T cell proliferation both in the blood and the gut 
(408). In line with these findings, Onlamoon et al. showed that sPD-1 led to increased 
SIV-specific proliferation of CD4+ and CD8+ T cells in rhesus macaques (409).  
 
In human inflammatory arthritis, the increase in PD-1 expression suggests that 
this receptor has the potential to reduce inflammation by controlling excessive T cell 
activation. However, fragmented data exist regarding i) the driving factors of sPD-1 
production and ii) whether or not sPD-1 has the ability to interfere with the PD-1:PD-
L1 interaction, thereby blocking the negative signal from membrane-bound PD-1.  
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In regard to sPD-1 production, Nielsen et al. have shown that PD-1Δex3 
transcript is increased in HC PBMC following TCR activation and CD28 co-
stimulation as compared to non-activated cells (63). Furthermore, Wan et al. 
demonstrated that ex vivo bulk T cells purified from RA PBMC and SFMC have 
higher expression of the PD-1Δex3 splice variant compared to healthy and OA 
controls (324). In line with these findings, Liu et al. recently demonstrated that bulk 
PBMC analysed ex vivo from patients with RA have increased PD-1Δex3 transcript as 
compared to OA and HC PBMC (366). These data suggest that soluble PD-1, the 
putative translational product of PD-1Δex3, could be produced by both PBMC and 
SFMC. Furthermore, data also suggest that the increase in the PD-1Δex3 transcript, 
which is found in RA PB and SF-derived T cells, might be caused by sustained 
proinflammatory cytokine exposure from the environment in which these cells are 
found.  
The data presented in this chapter support this theory as they demonstrate that 
in vitro, sPD-1 is detected in RA and PsA PBMC culture supernatants, although at 
very low levels, and it is further increased in SFMC cultures. The data also 
demonstrate that TNFα or IL-6, which were found to be increased in the arthritic joint, 
are capable of inducing both PD-1Δex3 splice variant and sPD-1 protein in HC CD4+ 
T cells and that this cytokine-mediated effect is abrogated by the biologics 
adalimumab (anti-TNFα) and tocilizumab (anti-IL6R).   
Thus far, the PD-1Δex3 splice variant appears to be the only reported and 
validated mechanism driving the production of sPD-1 and no other mechanisms have 
been described. Nonetheless, it is possible that a certain amount of PD-1 might be 
released from the cell membrane via other as yet undescribed mechanisms including 
shedding of the membrane-bound receptor. An interesting recent report, demonstrated 
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that expression of the PD-1 ligands (PD-L1 and PD-L2) in infant foreskin fibroblasts 
can be regulated through proteolytic cleavage by metalloproteinases (MMPs) 
including MMP-9 and MMP-13 (411).  
MMPs such as MMP-9 and MMP-13 have been previously described in the 
arthritic joint (412, 413) and future studies may reveal whether these MMP molecules 
might have also a role in the generation of sPD-1.  
Importantly, the experiments performed in this chapter on four sets of patient 
samples (2 RA and 2 PsA) found that sPD-1 can be detected in the serum and synovial 
fluid of both arthrides but not in healthy and OA controls. These results are important 
as they confirm that sPD-1 is present during chronic inflammation. These data also 
support and extend the findings of three recent studies (324, 354, 366), which focused 
only on RA patients. The studies from Wan et al. and Liu et al. found that sPD-1 
serum levels positively correlated with the presence of rheumatoid factor (RF) and 
with the levels of TNFα in either the serum or SF of RA patients (324, 366).  The 
results from the two groups are, however, contradictory with one group reporting a 
positive correlation between sPD-1 and TNFα in the serum (366) while the other 
reporting a positive correlation between sPD-1 and TNFα only in the synovial fluid 
but not in the serum (324).  Data from this thesis confirm that sPD-1 and TNFα 
positively correlate in the RA serum while no significant correlation between other 
cytokines and either sPD-1 levels, Disease Activity Scores (DAS28), Tender Joint 
Count (TJC) and Swollen Joint Count (SJC) are found. Such differences might be 
attributed to many factors including the different cohorts selected for the studies as 
well as the different treatments and numbers of the recruited patients.  
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In this chapter, the role of methotrexate (MTX) and TNFα inhibitor (TNFi) 
therapies in modulating sPD-1 levels was also investigated. This is of interest because 
high sPD-1 levels in both serum and SF as well as variations in response to therapy 
could potentially be used to evaluate disease activity. Greisen et al. (354) showed that 
in a longitudinal set of plasma samples from the CIMESTRA study with early RA 
patients evaluated at 0 and 9 months after MTX therapy, plasma levels of sPD-1 
decreased after 9 months and were comparable to the levels detected in healthy 
volunteers. Soluble PD-1 was found to strongly correlate with IL-21, IgMRF and anti-
CCP antibodies (354) indicating a possible role in disease progression. Interestingly 
the same group also showed that in a cross-sectional analysis of plasma and synovial 
fluid (SF) from patients with chronic RA, sPD-1 was higher in the SF than in the 
plasma suggesting also an important role for this molecule when the disease is well 
established and present for years.  
In line with longitudinal analysis from previous reports (354, 366), the cross-
sectional analysis performed in this thesis on RA and PsA serum and SF revealed that 
RA patients treated with methotrexate (MTX) therapy had overall lower sPD-1 levels 
in both serum and SF compared to RA patients not treated with MTX therapy, 
although the observed differences were not statistically significant. Interestingly, this 
was not the case for PsA where MTX-treated patients had significantly higher levels 
of sPD-1 in both serum and SF as compared to patients not treated with MTX therapy. 
These data suggest that in RA and PsA patients, MTX therapy might modulate sPD-1 
levels in yet undescribed mechanisms. The cross-sectional analysis performed in this 
thesis further revealed that RA and PsA patients treated with TNFi therapy had lower 
levels of sPD-1 both in the serum and SF as compared to patients not treated with 
TNFi therapy. Although the observed differences were greater in RA than in PsA, 
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these results are in line with in vitro data (chapter 5, section 5.2.1) showing that anti-
TNFα	 biologic	 adalimumab is able to reduce PD-1Δex3 transcript and sPD-1 
production in HC CD4+ T cell cultures. Furthermore, they also partially align with our 
preliminary longitudinal analysis showing that sPD-1 serum levels decreased overtime 
upon TNFi therapy in 2 of 4 samples tested.  
The role of therapeutics in modulating sPD-1 in RA and PsA serum and SF is 
of clinical interest. However, it is important to point out that the observed differences 
between RA and PsA described in this chapter might be a consequence of the cross-
sectional nature of the analysis performed as well as the limited number of patient 
samples, which were available at the time when this work was performed. Hence, 
further longitudinal studies on RA and PsA patients treated with MTX, adalimumab or 
tocilizumab are required before conclusive statements can be made regarding the 
effect of therapy in vivo. 
 
As mentioned above, the modulatory role of sPD-1 has been predominantly 
investigated in murine antitumor and simian antiviral immunity while the role of sPD-
1 during PD-1:PD-L1 interactions in human T cells is not well established. Wan et al. 
showed that PD-1 fusion protein (PD-1fc) added to isolated RA synovial fluid CD4+ 
T cells cultured with irradiated autologous SFMC is able to induce cell proliferation in 
a dose-dependent fashion (324). Similarly, Liu et al. cultured RA CD4+ T cells with a 
stable human PD-L1 transfected cell line (L929-PD-L1) and described an increase in 
cell proliferation upon treatment with PD-1fc (366). Although these results suggest 
that sPD-1 might induce proliferation in RA CD4+ T cells co-cultured with other cell 
types they did not directly prove that sPD-1 is able to abrogate PD-1 ligation with its 
ligand PD-L1.  
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Hence, further experiments performed in this thesis attempted to assess 
whether sPD-1 displayed functional antagonism in HC CD4+ T cell and could inhibit 
membrane-bound PD-1 ligation by its ligand PD-L1. Data presented in this chapter 
demonstrated that sPD-1 is biologically active in vitro and can counteract PD-1-
mediated suppression of proliferation of healthy CD4+ T cell in a dose-dependent 
fashion (section 5.2.3, Figure 5.12). Furthermore, data also showed that sPD-1 
enhances HC CD4+ T cell proliferation when co-cultured with autologous CD14+ 
monocytes, which naturally express PD-L1 and further upregulate it in presence of 
IFN-γ, IL-6 or TNFα (section 5.2.3, Figure 5.14). These results are important as they 
provide evidence for the biological role of sPD-1 and further suggest that during 
chronic inflammation sPD-1 might interfere with the PD-1 pathway thereby disrupting 
T cell regulation. This is supported by two recent human studies. In the first study, 
Aarslev et al. showed that in autoimmune hepatitis (AIH) sPD-1 is significantly 
elevated in AIH patients with active disease and in incomplete responders to standard 
therapy compared with responders and healthy controls (414). In the second study, 
Yanaba et al. described that patients with diffuse cutaneous systemic sclerosis (SSc) 
have higher levels of sPD-1 than those with limited SSc or healthy individuals and 
that sPD-1 levels in the serum of patients positively correlate with the severity of skin 
disease (415).  
 
Finally, the effect of sPD-1 was investigated in T regulatory (Treg) cell-
mediated suppression. Treg cells and the PD-1 pathway are both critical in controlling 
immune responses. Elimination of either one can lead to strong T cell responses and 
development of autoimmunity (98, 394). CD4+CD25+ Treg cells are important in 
controlling the severity of arthritis and mouse studies have shown that exacerbated 
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disease can be detected following Treg cells depletion (416, 417) while CD4+CD25+ 
adoptive transfer leads to reduction in disease duration (418). Treg cells are increased 
in the inflamed joints of patients with RA and PsA (334, 338-343, 419, 420) but 
despite their presence, inflammation persists, and it is unclear whether these cells are 
impaired in different arthrides.  
Functionally, some groups have reported that Treg cells from the peripheral 
blood of RA patients are unable to suppress T effector (Teff) cell proliferation (272, 
421, 422) while the majority of studies, however, have shown that peripheral blood 
CD4+CD25+ Treg cells have an intact regulatory function and they are capable of 
regulating the proliferation of Teff cells ex vivo (325, 339, 342, 344, 423-425). 
Similarly, CD4+CD25+ Treg cells from the inflamed joints of patients with arthritis 
have also been shown to be functionally intact and capable of suppressing 
proliferation and cytokine production ex vivo (338-344, 419, 426, 427). 
Notably, the PD-1:PD-L1 interaction has been shown to be important for the 
maintenance of a correct Treg function. Francisco et al. demonstrated that stimulation 
with PD-L1fc-coated beads can increase the de-novo generation of CD4+FoxP3+ 
Tregs from naïve CD4+ T cells. PD-L1fc was also shown to enhance both FoxP3 
expression and the suppressive function of established induced Tregs (iTregs). 
Mechanistically, it was demonstrated that PD-L1fc induced iTreg cells from naïve T 
cells by downregulation of the Akt-mTOR signalling and upregulation of PTEN (98, 
394). This is in line with studies demonstrating the effects of rapamycin and mTOR 
inhibition on the development of Treg cells (428-430).  
These findings suggest that any disruption of this pathway could potentially 
have negative effects on Treg cells functions. For example, an antagonist effect 
mediated by sPD-1, which in this thesis was shown to be highly upregulated in RA 
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and PsA, could partially block PD-1:PD-L1 interaction modulating the maintenance of 
regulatory T cell function within the joints of RA and PsA patients.  
To further investigate this possibility, a Treg:Teff suppression assay was set up 
and the effect of sPD-1 on Treg-mediated suppression was evaluated. Initial 
experiments confirmed that in vitro, CD4+CD25+ Treg cells from healthy volunteers 
were able to negatively modulate autologous CD4+ and CD8+ T cell proliferation and 
to modulate the percentage of PD-1+ cells in the co-cultures. Unexpectedly, addition 
of sPD-1fc to Teff cells in absence of Treg cells did not enhanced proliferation. 
Furthermore, addition of sPD-1 to Treg:Teff co-cultures did not modulate Treg cells-
mediated suppression of proliferation nor cytokine production.  These results are 
partially in contrast with previous data showing that sPD-1 is able to induce cell 
proliferation in HC CD4+ T cells cultured with autologous CD14+ monocytes. In the 
selected suppression assay, bulk PBMC were used as effectors in line with a previous 
investigation (431) and with the intent to recreate a more physiological environment 
without eliminating different accessory cells normally found during immune 
responses in vivo. The absence of sPD-1-mediated effects might be dependent on the 
experimental design used in this specific set of experiments. Addition of sPD-1 to 
bulk PBMC might lead to activation of yet undiscovered biological mechanisms, 
which might be in place to prevent cell proliferation. This could be investigated 
further by re-designing the experiments and culturing Treg cells in presence of 
isolated CD4+ or CD8+ T cells as effectors and with autologous CD14+ monocytes as 
APC to mimic the CD4+:CD14+ set up of our previous experiments. The different 
sensitivity of the methods used to detect cell proliferation (CTV in the Treg-
suppression assay versus [3H]-thymidine uptake in CD4+:CD14+ co-cultures) might 
also be partially responsible for the observed results. CTV dye dilution was chosen for 
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this specific test because of our interest in using flow cytometry to have a more 
exhaustive and comprehensive analysis of the different cell populations involved in 
the assay. Additional tests using [3H]-thymidine incorporation might reveal whether 
the observed results are due to a sensitivity issue. Finally, the loss of biological 
activity of the soluble PD-1fc chimera and the variability of the donors tested might 
have also played a role. Further experiments with increased numbers of donor as well 
as with new batches of reagents might generate a different outcome and help to clarify 
better if sPD-1 has a role in modulating Treg-mediated suppression.  
 
In conclusion, this chapter provides additional evidence for sPD-1 as a putative 
modulator of PD-1-mediated regulation in human CD4+ T cells and suggest that in 
both RA and PsA, sPD-1 might have a role in disease progression. 
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6 General Discussion 
In this final chapter the key findings presented in this thesis will be 
summarised, followed by a discussion of important outstanding questions related to 
this work and potential directions for future work.  
 
6.1 Summary of results described in this thesis 
The work presented in this thesis was designed with the intent to (i) bring 
together individual pieces of data in the disease context of RA, (ii) extend them into a 
different inflammatory joint disease to validate the general principle of impaired PD-
1-mediated regulation, and (iii) investigate why such a prominent regulatory pathway 
is not working effectively in the context of inflammatory arthritis. To address this, I 
have provided data showing that in RA as well as in PsA patients the PD-1 receptor is 
upregulated on synovial T cells and that CD4+ T cells from PB and SF of either 
patient group are resistant to PD-1 ligation in vitro. Next, I showed that 
proinflammatory cytokines TNFα, IL-6 and IL-1β are increased in both RA and PsA 
and they act as negative modulators of PD-1 function in vitro. In addition, I 
demonstrated that current biologics (adalimumab and tocilizumab) used routinely in 
patient treatment, as well as anti-IL-1β, are able to counteract this cytokine-mediated 
effect. These data add novel insight to the field of rheumatology and demonstrate that 
inflammatory cytokines typically associated with arthritis (TNFα, IL-6 and IL-1β) 
have a role in counteracting the suppressive effect of PD-1 ligation on CD4+ T cells. 
Results discussed here also indicate that T cell and monocyte-derived inflammatory 
cytokines have a profound effect on PD-1-mediated T cell regulation. My data show 
that biologic drugs directly abrogate this cytokine-mediated effect and successfully 
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restore PD-1-mediated regulation of T cell proliferation. Finally, I confirmed that 
TNFα drives soluble PD-1 production in HC CD4+ T cells and I described that IL-6 
has also such an ability, which has not been shown previously. In addition, I showed 
that sPD-1 levels are lower in RA and PsA patients undergoing TNFi therapy and in 
RA patients undergoing MTX therapy as compared to patients not treated with anti-
TNF or MTX. Together, these findings form an informative data set that advances our 
knowledge on the function of the PD-1/PD-L1 signalling pathway in inflammatory 
arthritis.  Furthermore, this is the first study to examine PD-1 function in RA and PsA 
simultaneously, and to provide evidence that the inflammatory milieu of these two 
diseases has a role in negatively modulating PD-1 ligation. 
 
In chapter 3 the analysis of a gene expression array performed on RA PB- and 
RA SF-derived cells demonstrated that the expression of PD-1 is increased in SF Teff 
and Treg cells as compared to PB cells. In line with these data, flow cytometry 
analysis also demonstrated that the frequencies of PD-1+ cells within CD4+ and 
CD8+ T cell subsets and in CD4+CD25+ Treg cells are increased significantly in the 
SF from patients with RA or PsA when compared to PB, thus extending the findings 
from previous studies focusing only on RA-derived CD4+ Teff cells (216, 323, 324, 
432). The observed increase in the frequencies of PD-1+ T cells suggests that in RA 
and PsA, PD-1 might have a role in regulating Teff and Treg cells, especially at the 
site of inflammation. Interestingly, despite increased frequencies of PD-1+ T cells, 
inflammation persists, further suggesting that this pathway is impaired in these 
diseases. Lower percentages of PD-L1+CD14+ cells were found in the SF of RA and 
PsA patients as compared to PB.  
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This is line with a previous report further showing that similar expression 
levels of PD-L1 can be found between RA and OA-derived synovial tissue and 
suggesting that synovial PD-L1 concentrations, in certain groups of patients, might 
not be adequate to effectively downregulate autoreactive T cells (216)  
PD-1 function in inflammatory arthritis is still widely unexplored. One study 
reported that PD-1 ligation inhibited cell proliferation and IFN-γ production by CD4+ 
T cells from peripheral blood of RA patients. The same study further demonstrated 
that synovial fluid CD4+ T cells required higher concentrations of PD-L1fc to achieve 
similar levels of inhibition (216). The authors speculated that the inflammatory milieu 
found in the RA joint might be accountable for reduced PD-1-mediated suppression. 
However, no specific mediator of the effect was identified (216).  
 
It has been shown previously that the common gamma chain cytokines IL-2, 
IL-7 and IL-15 as well as CD28 co-stimulation, can interfere with PD-1 crosslinking 
(60, 368). Hence, in chapter 4, I sought to investigate i) the ability of PD-1 ligation to 
regulate proliferation and cytokine production in RA- and PsA-derived CD4+ T cells 
and ii) the role of inflammation as a possible negative modulator of PD-1-mediated 
regulation. My data demonstrated that CD4+ T cells from both blood and synovial 
fluid of RA and PsA patients are more resistant to PD-1 ligation in terms of 
suppression of T cell proliferation and IFN-γ production when compared to healthy 
cells. Data also demonstrated that proinflammatory cytokines TNFα, IL-6 and IL-1β 
abrogate PD-1-mediated suppression of proliferation in healthy CD4+ T cells and that 
cytokines inhibitors counteract these effects in vitro. In line with these data, I was able 
to show that cell-free SF from RA or PsA patients added to healthy CD4+ T cell 
cultures was also able to reduce PD-1-mediated suppression of proliferation. These 
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findings are important as they provide new evidence that the presence of certain 
proinflammatory cytokines typically found in RA and PsA can be critical in 
determining the outcome of PD-1 engagement during the immune response.  
 
The aim of the experiments described in chapter 5 was to identify and test a 
mechanism, which would explain, at least in part, how inflammation modulates PD-1-
mediated regulation. For this purpose, cell supernatants from HC CD4+ T cell cultures 
stimulated with proinflammatory cytokines were analysed and it was found that TNFα 
and IL-6, but not IL-1β, induced the secretion of sPD-1. Importantly, ex vivo analysis 
confirmed that sPD-1 levels were significantly increased in the serum and SF of 
patients with RA or PsA compared to healthy or OA controls pointing to a biological 
role of sPD-1 both systemically and locally in the inflamed joint of different 
inflammatory arthrides. The latter data support and extend two recent studies showing 
that sPD-1 is detected in the serum and SF of patients with RA (324, 354).  
 
Recent studies have also shown that expression of the PD-1Δex3 splice variant 
is observed in T cells from patients with RA, but only minimally in T cells from 
patients with OA or from HC (324, 366). In healthy human CD4+ T cells it appears 
that cytokines TNFα, IL-17 and IFN-γ drive the expression of PD-1Δex3 mRNA 
(366). My data confirmed that in HC CD4+ T cells, TNFα drives PD-1Δex3 splice 
variant, and further demonstrated that PD-1Δex3 splice variant and sPD-1 protein are 
regulated by IL-6 and can be negatively modulated by therapeutic antibodies 
adalimumab and tocilizumab.  
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Preliminary analysis from a cross-sectional investigation of RA and PsA serum 
and SF also showed that patients treated with TNFi therapy have lower sPD-1 levels 
compared to patients not treated with TNFi therapy and that this is also the case for 
RA patients treated with MTX therapy as compared to patients not treated with MTX. 
TNFi therapy data are novel and in line with my experiments showing that anti-TNFα 
(adalimumab) is able to reduce both PD-1Δex3 splice variant mRNA and sPD-1 
protein in vitro. MTX data are also novel and in line with a longitudinal analysis 
performed by Liu et al., which measured serum levels of sPD-1 in RA patients before 
and after treatment with MTX and reported a decrease following MTX medication 
(366).  
 
Data from chapter 5 indicate that certain cytokines can induce PD-1Δex3 and 
sPD-1 production. However, metalloproteinases (MMPs) such as MMP-9 and MMP-
13, which have been previously described in inflammatory arthritis (412, 413), might 
also be responsible for the generation of sPD-1 through proteolytic cleavage. This is 
supported by a recent investigation showing that expression of PD-L1 and PD-L2 is 
regulated by MMPs in infant foreskin fibroblasts (411). Notably, the experiments 
performed in chapter 5 have also shown that a recombinant PD-1 chimera (sPD-1fc), 
used to mimic naturally occurring sPD-1, is functionally able to counteract PD-L1fc-
mediated suppression of healthy CD4+ T cell proliferation. Soluble PD-1fc was also 
found to enhance CD4+ T cell proliferation when HC CD4+ T cells are co-cultured 
with autologous CD14+ monocytes that can naturally express PD-L1. These findings 
indicate that sPD-1 might act as a decoy during APC-mediated regulation of T cells 
via PD-1/PD-L1 signalling.  
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Based on previous literature discussed in chapter 5, which suggests that 
disruption of PD-1:PD-L1 interactions negatively modulates Treg cell function, this 
thesis investigated whether sPD-1 negatively modulated Treg function in vitro using a 
Treg suppression assay. Soluble PD-1 had no effect on Treg-mediated regulation of 
proliferation nor on cytokine production and further experiments are required before 
conclusive statements can be made regarding the effect of sPD-1 in a Teff:Treg co-
culture system. However, recent evidence from studies performed in inflammatory 
diseases such as chronic autoimmune hepatitis (AIH) (414) and cutaneous systemic 
sclerosis (SSc) (415) strongly support the notion that sPD-1 might actively interfere 
with the PD-1 pathway, thereby disrupting T cell regulation (see chapter 5 discussion). 
Importantly, and in line with data presented in this thesis, cytokines TNFα and IL-6, 
two inducers of PD-1Δex3 splice variant (380), can be detected in AIH (433) and in 
SSc (434, 435) supporting the hypothesis that sPD-1 is a product of the inflammatory 
milieu and providing further evidence of a bioactive function of this soluble molecule.   
 
The bioactive function of sPD-1 is also evident in cancer. It is now widely 
demonstrated that PD-L1 positive tumour cells engage with PD-1 positive tumour-
infiltrating T cells to downregulate their cytotoxic functions (207).  Soluble PD-1 is 
detected in the tumour microenvironment where it engages with PD-L1-expressing 
tumour cells disrupting their evasion mechanism and promoting T cell cytotoxicity. In 
a murine model of hepatocarcinoma it was shown that combined treatment of IL-21 
and sPD-1 enhanced T cell cytotoxicity, increased the number of cytotoxic T cells and 
NK cells and upregulated the cytokines IFN-γ and IL-2 resulting in a more efficacious 
antitumor immune response (436). Bartee et al. generated a recombinant myxoma 
virus (vPD-1), which inhibits the PD-1/PD-L1 pathway by secreting a soluble form of 
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PD-1 from infected cells, and demonstrated that tumour-localized secretion of sPD-1 
strongly modulates anti-tumour CD8+ T cell responses (437). These studies are in line 
with reports by He et al. (406) and Shin et al. (407) in mice, and work by Amancha et 
al. (408) and Onlamoon et al. (409) in simians (see chapter 5 discussion). 
The mechanisms leading to sPD-1 in the tumour microenvironment are 
currently unclear. Inflammatory mediators such as TNFα, IL-6, IFN-γ, IL-17, TGF-β, 
and IL-10 (438, 439) and metalloproteinases MMP-9 and MMP-13 (440) are found in 
the tumour microenvironment and different cytokines have been shown to participate 
in both the initiation and progression of cancer through different mechanisms 
including upregulation of PD-L1 on tumour cells (207, 438, 439). However, it remains 
to be determined whether cytokines such TNFα and IL-6 are also able to exert anti-
tumorigenic effects through direct induction of sPD-1 and whether MMP-9 and MMP-
13 can cleave membrane-bound PD-1 and its ligands in the tumour microenvironment.  
Interestingly, PD-L1 is also present in some cancer patients in a soluble form 
(sPD-L1) and it has been associated with immune suppression and poor prognosis in 
patients with advanced lung cancer (441), renal cell carcinoma (442), large B cell 
lymphoma (443), nasal natural killer/T-cell lymphoma (444), multiple myeloma and 
melanoma (445).  
This suggests that sPD-1 and sPD-L1 are regulatory factors to the PD-1/PD-L1 
signalling pathway, each having opposite effects. In inflammatory arthritis limited 
data is available on sPD-L1. sPD-L1 appears to be upregulated in the serum and 
synovial fluid of RA patients and serum levels correlate with rheumatic factor (RF) 
(324).  However, it is not known whether sPD-L1 has a downregulatory function and 
can engage with membrane-bound PD-1 blocking T cell activation and cytokine 
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production or if it binds to sPD-1 leading to formation of sPD-1:sPD-L1 complexes at 
the site of inflammation.  
 
Collectively, data presented in this thesis provide new evidence that the 
inflammatory environment of the RA and PsA joint compromises PD-1/PD-L1-
mediated T cell regulation and that production of sPD-1 might counteract the function 




























Figure 6.1 Schematic overview of selected findings from this thesis.  
(A) RA and PsA PB and SF-derived CD4+ T cells cultured in the presence of anti-CD3 mAb 
and PD-L1 chimera are resistant to PD-1-mediated suppression of proliferation and cytokine 
production. RA-derived cells express PD-1Δex3 (324). Increased levels of TNFα, IL-6 and 
IL-1β are detected in both RA and PsA SF when compared to HC and OA controls. (B) The 
presence of TNFα, IL-6 or IL-1β is able to abrogate the suppressive effects of PD-1 ligation 
on healthy CD4+ T cells suggesting that inflammation negatively modulates PD-1-mediated 
regulation. Soluble PD-1 is detected in the supernatants of TNFα- and IL-6-stimulated 
cultures and HC CD4+ T cells from the same cultures show increased expression of the PD-
1Δex3 splice variant. (C) Soluble PD-1 modulates PD-1-mediated suppression of HC CD4+ T 
cell proliferation and induces proliferation in CD4+T cell:CD14+ monocyte co-cultures. (D) 
sPD-1 is not detected in HC and OA controls, while it can be found at high levels in RA and 
PsA serum and SF. Furthermore, sPD-1 levels are lower in RA and PsA patients undergoing 
TNFi therapy as compared to patients not treated with TNFi or MTX therapy.  
 


































































6.2 Outstanding questions and future investigation 
This part of the discussion analyses new lines of research that could be 
pursued to implement the data already generated in this thesis and to extend our 
knowledge about T cell regulation in inflammatory arthritis. In the next sections I will 
describe possible new experiments on three different topics including: 
• The role of PD-L2 (B7-DC) in RA and PsA  
• The role of PD-1 in modulating Treg cell-mediated suppression  
• The role of soluble CD80 (sCD80) in T cell regulation 
 
6.2.1 Does PD-L2 modulate T cell proliferation of RA- and PsA-derived CD4+ 
T cells and in CD4+:CD14+ co-cultures?  
The work presented in this thesis has shown that CD4+ T cells derived from 
RA and PsA patients are resistant to PD-1-mediated regulation when cultured in 
presence of PD-L1 in vitro. However, as discussed in chapter 1, PD-1 has a second 
ligand named PD-L2 (61, 62), which has a three-fold higher affinity for PD-1 as 
compared to PD-L1 and is able to inhibit T cell proliferation and cytokine production 
(61). PD-L2 is also expressed on activated human CD4+ and CD8+ T cells and PD-L2 
engagement at the surface of T cells appears to reduce cytokine production and cell 
proliferation (446). Several lines of evidence suggest that PD-L2 is important to 
prevent autoimmunity. PD-L2-/- mice have increased activation of CD4+ and CD8+ T 
cells in vivo when compared to wild type (WT) mice and lack of PD-L2 has been 
shown to modulate T cell tolerance (447). Following PD-L2 blockade, exacerbation of 
disease is observed in mouse models of experimental autoimmune encephalomyelitis 
(EAE) (213) and autoimmune kidney disease (448) while PD-L2 polymorphisms are 
associated with susceptibility to systemic lupus erythematosus (SLE) in humans (449).  
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In RA and PsA very little is known about PD-L2. Recently, Greisen et al. 
showed that PD-L2 knockout mice have increased bone mass density compared to 
wild type mice and that PD-L2 can be detected in pre-osteoclasts suggesting a role of 
PD-L2 in bone homeostasis (450). PD-L2 expression is increased in RA synovial 
tissue as compared to healthy tissue but PD-L2 levels are similar between RA and OA 
(216). PD-L2 expression pattern in PsA has never been investigated and whether PD-
L2 is able to control proliferation and cytokine production in RA- and PsA-derived T 
cells have never been tested either. Hence, further experiments designed to test PD-L2 
suppressive activity in T cells are of clinical interest. To answer this, different 
research approaches could be pursued.  
Firstly, CD4+ and CD8+ T cells from the blood of healthy volunteers and from 
the blood and SF of RA and PsA patients could be cultured in vitro in presence of 
increasing doses of PD-L2fc ligand. My hypothesis is that these experiments will 
confirm that RA- and PsA-derived cells are resistant to PD-1 ligation even in presence 
of PD-1 second ligand PD-L2. These experiments would be repeated in presence of 
both PD-L1fc and PD-L2fc ligands to address whether the two inhibitory ligands have 
a joint effect on healthy- and patient-derived cells. Similarly to experiments performed 
in this thesis using PD-L1fc, my hypothesis is that TNFα, IL-6, IL-1β or sPD-1 
addition to the cell culture will abrogate PD-1-mediated suppression of proliferation in 
healthy CD4+ T cells cultured in presence of PD-L2fc by a sPD-1-dependend 
mechanism as seen for PD-L1fc. 
Data from this thesis also demonstrated that addition of exogenous sPD-1 to 
HC CD4+:CD14+ co-cultures modulates T cell proliferation in a dose-dependent 
fashion (380). As CD4+ T cells alone did not proliferate following sPD-1 stimulation, 
this indicates that, in vitro, sPD-1 likely interferes with PD-L1 and possibly PD-L2 
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expressed on monocytes. One question that arose from my CD4+:CD14+ co-culture 
experiments and that has not been addressed is whether sPD-1 is able to interfere with 
PD-L1, PD-L2 or both ligands. This is of interest because it would provide new 
information about sPD-1 modulatory activity.  
To address this point the CRISPR-Cas9 genome editing technique could be 
used to generate PD-L1 knockout (KO), PD-L2 KO and PD-L1/PD-L2 KO monocyte-
derived dendritic cells. Generally it takes several days to perform CRISPR-Cas9 and 
the technique typically requires selection to enrich for Cas9 transfected cells. Since 
monocytes have a short lifespan in culture, it would not be possible to perform gene 
editing fast enough to allow time for functional assays. A possible solution for this 
issue could be to use already differentiated APCs or to target a progenitor cell type 
and then differentiate monocytes in vitro from a genome-edited precursor. 
Following genome editing, PD-L1/2 KO cells would be incubated with 
autologous CD4+ T cells and cultured with anti-CD3 and increasing concentrations of 
sPD-1. My hypothesis is that if sPD-1 binds specifically to PD-L1, no increase in 
proliferation should occur in the PD-L1-KO condition. Conversely if sPD-1 binds 
only to PD-L2, no increase in proliferation should occur in the PD-L2-KO condition. 
This experiment would identify whether sPD-1 binds to both PD-L1 and PD-L2 
ligands or only to one of them. In a different approach CD14+ monocytes could be 
pre-treated with blocking antibodies towards either PD-L1 or PD-L2 to modulate their 
ability to crosslink PD-1. Next, treated monocytes would be incubated with 
autologous CD4+ T cells and cultured with anti-CD3 and increasing concentrations of 
sPD-1. One limitation of this experiment lays in the fact that it is unclear whether 
blocking antibodies for PD-L1 and PD-L2 induce reverse signalling in the monocytes. 
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Hence, this should be accurately tested during the experiments, for example, by 
analyzing cytokine production and cell signalling molecules. 
 
6.2.2 Does PD-1 modulate Treg-mediated suppression in RA and PsA? 
A key outstanding question that I have begun to address in this thesis is 
whether sPD-1 regulates the suppressive function of Treg cells in vitro. Soluble PD-1 
levels are high in the serum and SF of RA and PsA patients (chapter 4) and whether 
sPD-1 has an effect on Treg cell-mediated suppression is currently unknown. The 
immune-inhibitory PD-1 receptor is expressed on activated T cells, including 
FoxP3+ Treg cells. However, it is unclear whether PD-1 expression on Treg cells is 
required for their immune regulatory function, especially in autoimmune settings. 
Francisco et al. demonstrated that in the presence of anti-CD3 and TGF-β, PD-L1-Ig 
induces a profound increase in de novo generated CD4+FoxP3+ Tregs from naïve 
CD4+ T cells while PD-L1-/- APCs are unable to properly convert naïve CD4+ T cells 
to iTreg cells. PD-L1-Ig was also shown to enhance FoxP3 expression and 
suppressive functions of established iTregs suggesting an essential role of PD-L1 for 
iTreg cell induction and function (98). More recently, Zhang et al. (451) described 
that in mice, deficiency of PD-1 affects the Treg compartment by increasing the 
generation of ex-FoxP3 cells (452) (T helper cells derived from FoxP3+ T cells) and 
contributing to the expansion of effector/memory T cells suggesting that PD-1 
regulates the relative abundance of Treg and effector T cells to maintain immune 
tolerance (451). Because depletion of CD25+CD4+ Treg cells or ablation of 
FoxP3+ Treg cells leads to development of autoimmunity (453-455), I began to test 
the hypothesis that sPD-1 can interfere with PD-1:PD-L1 interactions and have a 
negative impact towards the suppressive function of Treg cells.  
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In my experiments whole PBMC were used as effector cells. This choice was 
made with the intent to recreate a more physiological experimental condition and 
keeping in account that different cell populations, such as T cells, B cells and APCs 
express PD-L1 upon activation and might use it to crosslink PD-1 on Treg cells 
modulating their ability to suppress proliferation and cytokine production. However, 
the data obtained from the Treg suppression assay showed that sPD-1 added from the 
beginning of the co-culture did not modulate Treg cells ability to control proliferation 
and cytokine production (chapter 5). Hence, further investigation is needed to test 
whether PD-L1 on T effector cells is important for Treg cells suppressive functions.  
To evaluate the effect of blocking the engagement of PD-1+ Treg cells by PD-
L1/2+ Teff cells two different approaches could be tested. In the proposed 
experiments I would use CD4+CD25+ Treg cells, CD4+CD25- Teff cells and CD14+ 
monocytes or CD3/CD28 coated beads to provide co-stimulation 
In my first approach, CD4+CD25- Teff cells and CD14+ monocytes would be 
incubated overnight in presence of anti-CD3 stimulation and in absence of Treg cells. 
This step will initiate upregulation of PD-L1 and PD-L2 on Teff cells and monocytes. 
After 12 hours, autologous Treg cells would be added for the remaining 36 hrs of 
culture. Blocking antibodies towards PD-L1 and PD-L2 or increasing concentrations 
of soluble PD-1 and the appropriate controls would also be added for the remaining 36 
hrs of culture. My hypothesis is that PD-L1 blocking antibodies and sPD-1 will 
abrogate PD-1:PD-L1 interactions having a negative impact towards the suppressive 
function of Treg cells and resulting in higher Teff cells proliferation as compared to 
the controls. These experiments should also be performed blocking only one ligand at 
the time to evaluate whether differences exist between PD-L1 and PD-L2 modulatory 
activity. 
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The second experimental approach to evaluate the role of PD-L1 and PD-L2 in 
this system would involve knocking down PD-L1, PD-L2 or both by CRISPR-
Cas9 genome editing in CD4+CD25- Teff cells. PD-L1, PD-L2 or PD-L1/2 knockout 
Teff cells or control Teff cells would be cultured from the start in presence of 
CD4+CD25+ Treg cells and stimulated with anti-CD3/CD28 coated beads for 48 hrs. 
My hypothesis for these experiments is that higher proliferation and higher cytokine 
production should be detected using Teff cells lacking PD-1 ligands. In these 
experiments anti-CD3/CD28 beads stimulation could be substituted with addition of 
CD14+ monocytes to the culture provided that PD-1 ligands are also knocked out or 
blocked by specific antibodies in these cells. As previously stated in section 6.2.1, 
CRISPR-Cas9 in primary CD4+ T cells present technical challenges including 
optimisation of lentiviral transduction, subsequent selection and expansion of clones 
in which gene editing has occurred successfully and maintenance of cell viability to 
successfully isolate single cell clones. 
 
 
6.2.3 Does soluble CD80 (sCD80) pair with sPD-1 to promote persistent T cell 
activation? 
A third topic that requires further investigation is whether soluble CD80 
(sCD80) act synergistically with sPD-1 to negatively modulate T cell regulation. The 
biological activity of the costimulatory molecule CD28 has been extensively studied. 
CD28 is constitutively expressed by T cells and interacts with the B7 molecules CD80 
and CD86 expressed mainly by APCs. This interaction results in increased T cell 
proliferation, IL-2 production, and resistance to apoptosis (24) while blockade of it via 
the humanised fusion protein CTLA-4-Ig (abatacept) has shown clear benefits in 
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patients with different inflammatory arthrides including RA, PsA and JIA (313, 318). 
Several pieces of evidence suggest that soluble CD80 (sCD80) may have a role in 
negatively modulating T cell regulation in a similar fashion as sPD-1. Soluble CD80 is 
increased in the serum and SF of RA patients compared to healthy and OA controls 
and it positively correlates with the levels of RF (324, 456). CD80 binds to PD-L1 
with a binding affinity, which is approximately equal to its affinity for CD28. 
Importantly, PD-L1:CD80 interactions have been shown to directly downregulate T 
cell responses in vitro (127). This suggests that in RA and possibly in PsA, sCD80 
may negatively modulate T cell regulation through three distinct mechanisms: i) 
binding PD-L1 and preventing PD-L1+ cells from regulating PD-1+ activated T cells 
(similarly to sPD-1), ii) binding PD-L1 and preventing PD-L1+ cells from regulating 
CD80+ T cells by reverse signalling through T cell–expressed CD80, and iii) 
enhancing T cell activation by costimulating T cells through CD28. The hypothesis 
that sCD80 might be important for the regulation of T cell function is supported by 
recent studies with human and mouse tumour cells where sCD80 (CD80-fc consisting 
of the extracellular CD80 IgV and IgC regions fused to an IgG-fc domain) and 
membrane-bound CD80 prevented PD-L1+ tumour cells from binding to PD-1+ T 
cells and sustaining IFNγ production by activated PD-1+CD4+ and PD-1+CD8+ T 
cells (457, 458). In order to investigate the role of sCD80 in inflammatory arthritis, 
future experiments could be designed as follows: Firstly, the presence of sCD80 
should be assessed by ELISA in healthy serum and serum and SF from patients with 
rheumatoid and psoriatic arthritis. Ideally, the analysis should include tests on newly 
diagnosed patients and follow-ups after initiation of TNFi and MTX therapy to assess 
whether sCD80 levels are modulated by treatment overtime and whether different 
treatments specifically modulate sCD80 levels. Next, sCD80 gene expression analysis 
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should be performed on ex vivo PB- and SF-derived T cells from both RA and PsA 
and coupled with experiments aimed at detecting sCD80 in cell supernatants before 
and after cell activation and culture with proinflammatory cytokine and specific 
blocking antibodies. The rationale behind these experiments is based on data showing 
that, like sPD-1, sCD80 is generated in human cells by alternative splicing (459) while 
it is unclear whether specific cytokines drive the transcription of the spliced variant. 
Finally, in vitro functional experiments using sCD80 alone and together with sPD-1 
could be performed to investigate whether these soluble receptors are able to modulate 
T cell proliferation and cytokine production in presence or absence of PD-L1 and PD-
L2 ligands. In order to provide a truly comprehensive analysis, these experiments 
should be performed on PB and PB- and SF-derived CD4+ and CD8+ T cells from 
healthy volunteers and from RA and PsA patients. These experiments might provide 
novel data on how T cells are regulated at the site of inflammation in different human 
arthrides. 
 
6.3 Concluding remarks  
The PD-1 receptor is a potent immunoregulatory molecule, which plays an important 
role in the regulation of T cell activation and in the maintenance of cell tolerance. The 
onset of autoimmune-like adverse effect in cancer patients treated with anti-PD-1 
therapy implies that the converse strategy of engaging the PD-1 receptor to deliver an 
inhibitory signal might be a promising way to control inflammation in different 
autoimmune conditions. Multiple approaches are under investigation to target immune 
checkpoints for the treatment of autoimmune diseases. These new approaches include 
ligand–fc fusion proteins and artificial ligands. Preclinical studies in the CIA murine 
model of RA support the feasibility of this therapeutic strategy as they show that 
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injection of the artificial ligand PD-L1fc (215, 216), CD200fc (460) and 
PECAM1-derived peptide (461) ameliorate the disease and reduces inflammation. 
Another therapeutic strategy that is currently under investigation is the use of 
antibodies called “bispecific” which co-ligate an inhibitory and activating receptor 
enhancing the inhibitory receptor signal. PD-1-CD3 bispecific antibodies have shown 
efficacy in the treatment of mice with experimental autoimmune encephalomyelitis 
(EAE) (462) and further studies might reveal whether they are also effective in other 
inflammatory conditions including RA and PsA. Simultaneous targeting of different 
inhibitory receptors expressed by the same cell or by different cells might also be a 
feasible approach. The rationale behind this type of treatment lays in the fact that 
combined PD-1 and CTLA-4 blockade in cancer patients has additive effect on the 
incidence and the severity of autoimmune-like adverse effects (199). These different 
strategies using high-affinity antibodies or artificial ligands have the potential to 
provide stronger modulation as compared to naturally expressed ligands. They might 
also provide therapeutic effects in conditions where the natural ligand is not properly 
functioning, minimally expressed or when its activity is negatively modulated by a 
soluble form of their specific receptor as shown in this thesis for soluble PD-1. Thus, 
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Summary
The programmed cell death 1 (PD-1) receptor plays a major role in
regulating T cell activation. Our aim was to determine how inflammation
influences PD-1-mediated T cell suppression. Flow cytometry analysis of
rheumatoid arthritis (RA) and psoriatic arthritis (PsA) synovial fluid (SF)
mononuclear cells showed an increase in the percentage of PD-11 cells
within the CD41 and CD81 T cell compartment compared to paired
peripheral blood (PB). Upon in-vitro T cell receptor (TCR) stimulation of
healthy control (HC) CD41 T cells in the presence of plate-bound PD-L1fc
chimera, significantly decreased proliferation and interferon (IFN)-g
secretion was observed. In contrast, CD41 T cells from RA and PsA PB and
SF appeared resistant to such PD-1-mediated inhibition. Addition of the
proinflammatory cytokines tumour necrosis factor (TNF)a, interleukin
(IL)-6 and IL-1b, which were increased in RA and PsA SF compared to
osteoarthritis (OA) SF, consistently abrogated PD-1-mediated suppression
in HC CD41 T cell cultures. This effect was reversed by inhibitors of these
cytokines. Soluble PD-1 (sPD-1) levels were increased in cell culture
supernatants from TNFa and IL-6-stimulated cultures compared to
untreated controls, and also in RA and PsA, but not in OA, serum and SF.
Functionally, addition of sPD-1fc counteracted PD-1-mediated suppression
of HC CD41 T cells, and increased T cell proliferation in HC CD41 T cell/
monocyte co-cultures. These in-vitro findings indicate that CD41 T cells
from patients with RA and PsA show increased resistance to PD-1-mediated
suppression, which may be explained in part by the presence of soluble PD-
1 in the inflammatory environment.
Keywords: inflammatory arthritis, IL-6, PD-1, PD-L1, TNFa
Introduction
The programmed cell death 1 (PD-1) receptor, a trans-
membrane protein and member of the B7 family, plays a
critical role in T cell regulation [1]. PD-1 is expressed on T
cells, where its expression increases within the first 24 h of
T cell activation and decreases with antigen clearance
[2–4]. Upon ligation of PD-1 by its ligands (PD-L1/B7-H1
and PD-L2/B7-DC), T cell responses are down-regulated
[5,6]. PD-1 ligation leads to inhibition of the phosphatidyl-
inositol 3-kinase (PI3K) pathway, resulting in reduced Akt
(protein kinase B) phosphorylation and reduced expression
of transcription factors GATA-3, T-bet and Eomes [7,8].
The overall effect of PD-1 ligation is decreased T cell activa-
tion and cytokine production [9–12]. The clinical relevance
of PD-1 in immune regulation is evidenced by the recent
success of PD-1 blockade in the treatment of certain end-
stage cancers, leading to reduced tumour burden and
enhanced anti-tumour immunity in a considerable number
of patients [13,14]. Conversely, in inflammatory conditions
it has been documented that disruption of the PD-1 gene
(pdcd1) in mice leads to lupus-like syndrome, proliferative
arthritis, diabetes, autoimmune cardiomyopathy and
increased susceptibility to collagen-induced arthritis (CIA)
[15–20]. In humans, polymorphisms in the PDCD1 gene
have been associated with susceptibility to rheumatoid
arthritis (RA), ankylosing spondylitis (AS), systemic lupus
erythematosus (SLE), multiple sclerosis (MS) and type 1
diabetes mellitus [21–25].
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Several investigators have shown that frequencies of PD-
11 CD41 T cells are increased in RA synovial fluid com-
pared to RA peripheral blood (PB) and healthy control
(HC) PB [20,26,27]. However, despite high levels of this
inhibitory receptor at the site of inflammation, the
immune system seems unable to regulate persistent T cell
activation and cytokine production. This poses the ques-
tion as to whether the PD-1 pathway is impaired during
inflammation. An indication of a defective PD-1 pathway
in RA comes from a study indicating that RA synovial fluid
(SF) CD41 T cells show reduced PD-1-mediated inhibition
compared to RA PB cells [20]. This suggests that under
conditions of chronic inflammation the PD-1 pathway is
modulated. Thus far, little is known regarding the PD-1/
PD-L1 pathway in the context of psoriatic arthritis (PsA).
PsA and RA, while sharing a number of common patholog-
ical features, are two distinct diseases with serological,
genetic and radiological differences [28]. Here we deter-
mined the expression of PD-1 on T cells from PB and SF of
patients with RA or PsA, and investigated how inflamma-
tory mediators associated with RA and PsA affect PD-1-
mediated T cell suppression. Our data indicate that CD41
T cells from patients with RA and PsA are compromised in
their PD-1-mediated inhibition and reveal a potential role
for soluble PD-1 (sPD-1) in the aberrant PD-1-mediated
regulation in these diseases.
Materials and methods
Patients and healthy volunteers
Heparinized PB and matched SF samples were obtained
from patients with RA and PsA recruited from the rheuma-
tology out-patient clinic at Guy’s and St Thomas’ Hospital
NHS Trust (London, UK). Information on clinical and
demographic parameters is provided in Supporting infor-
mation, Table 1. HC subjects were recruited from among
local student and staff volunteers. Written informed con-
sent was received from all participants. Ethics approval was
given by the Bromley Research Ethics Committee (approval
no. 06/Q0705/20) for HC, RA and PsA and by the Guy’s
Research Ethics Committee (approval no. 01/05/01) for
osteoarthritis (OA). All samples were collected in compli-
ance with the Declaration of Helsinki.
PBMC, SFMC and cell subset isolation
PB mononuclear cells (PBMC) and SF mononuclear cells
(SFMC) were isolated by LymphoprepTM (Axis-Schield,
Oslo, Norway) density-gradient centrifugation. Cell subsets
were isolated by magnetic separation (Miltenyi Biotech,
Bergisch Gladbach, Germany and Dynabeads Thermo-
fisher, Paisley, UK) and purity was determined by flow
cytometry. CD41 T cells (purity range 95–99%) were iso-
lated by negative isolation from PBMC or SFMC or from
the CD14-depleted cell fractions following the manufac-
turers’ instructions. CD141 monocytes (purity range 96–
98%) were selected positively using CD14 MicroBeads
(Miltenyi Biotec).
Cell culture
Cell subsets were cultured for 5 days in culture medium
(RPMI-1640; GIBCO, Paisley, UK), supplemented with 1%
penicillin/streptomycin, 1% L-glutamine (GIBCO) and 10%
heat-inactivated fetal calf serum (GIBCO) and maintained at
378C and 5% CO2 atmosphere. Cells were stimulated with
either plate-bound anti-CD3 monoclonal antibody (mAb)
(OKT3; Janssen-Cilag Ltd, High Wycombe, UK) (1!5 mg/
ml) in CD41 T cell only cultures or with soluble anti-CD3
mAb (OKT3; Janssen-Cilag Ltd) (100 ng/ml) in CD41
T cell/CD141monocyte co-cultures.
Flow cytometry analysis of cell frequency and
phenotype
For ex-vivo analysis of frequency and phenotype of each cell
subset, PBMC or SFMC were stained extracellularly for 30
min at 48C using different combinations of the following
antibodies: fluorescein isothiocyanate (FITC)-conjugated
CD279 (PD-1; BioLegend, Cambridge, UK), phycoerythrin
(PE)-conjugated CD274 (PD-L1; BD Pharmingen, Oxford,
UK), PE/cyanin 7 (Cy7)-conjugated CD3 (Biolegend), peridi-
nin chlorophyll (PerCP)/Cy5!5-conjugated CD4 (Biolegend),
PacBlue-conjugated CD8 (Biolegend), allophycocyanin
(APC)-conjugated CD8 (Biolegend) and Vio770-conjugated
CD14 (Miltenyi Biotech). Following surface staining, cells
were fixed in 2% paraformaldehyde (PFA) for 15 min at 48C,
washed twice and acquired on a BD fluorescence activated
cell sorter (FACS)Calibur or a BD FACSCanto II. Data were
analysed using FlowJo software (version 7.6.5; Tree Star, Ash-
land, OR, USA).
T cell proliferation and PD-1 ligation assays
96 well flat-bottomed plates (Costar, Corning Inc., Corn-
ing, NY, USA) were coated with anti-CD3 mAb (OKT3;
Janssen-Cilag Ltd) (1!5 mg/ml) and with either PD-L1fc or
immunoglobulin (Ig)G1fc (R&D Systems, Abingdon, UK)
(ranging from 0 to 5 mg/ml according to the experiment) in
phosphate-buffered saline (PBS) solution (Sigma Aldrich,
Poole, UK) for 4 h at 378C and 5% CO2. Plates were
washed twice with PBS before cells were added for culture.
CD41 T cells were isolated from cryopreserved HC PBMC,
RA and PsA PBMC and RA and PsA SFMC and plated at a
concentration of 1 3 105 cells per well in a final volume of
200 ll of culture medium. In some cultures, human
recombinant tumour necrosis factor (hrTNF)a, human
recombinant interleukin (hrIL)-6 or hrIL-1b (all at 10 ng/
ml; R&D Systems) were added in the absence or presence
of anti-TNFa drug adalimumab (AbbVie, Chicago, IL,
USA), anti-IL-6R drug tocilizumab (Roche, Basel,
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Switzerland) or anti-IL-1b mAb (R&D Systems) (all at 1
mg/ml). In some cultures, HC CD41 T cells were cultured
in PD-L1fc (0, 0!1 and 1 mg/ml)-coated plates in the pres-
ence of soluble PD-1fc (0!5 and 1 mg/ml; R&D Systems). In
other experiments, freshly isolated HC CD41 T cells and
autologous CD141 monocytes (used as a source of PD-L1
ligand) were co-cultured in 96-well flat-bottomed plates
(Costar, Corning Inc.) at 1 : 1 ratios (total cells per well
1 3 105) in culture medium containing 100 ng/ml soluble
anti-CD3 mAb and soluble PD-1fc or IgG1fc (0, 0!25, 0!5
and 1 mg/ml). In all assays, at day 4, cells were pulsed with
[3H]-thymidine (0!25 lCi/well) (GE Healthcare, Little
Chalfont, UK) and T cell proliferation was assessed after
18 h (on day 5) using a Topcount scintillation counter
(Perkin Elmer, Cambridge, UK). Proliferation was deter-
mined and expressed as counts per minute (cpm) and as
suppression of T cell proliferation (%) according to the fol-
lowing formula: [(medium only condition2PD-L1fc con-
dition)/medium only condition] 3 100.
Detection of soluble cytokines and soluble PD-1
CD41 T cell culture supernatants were collected at day 5
and stored at 2808C. IFN-g levels were determined by
enzyme-linked immunosorbent assay (ELISA) using the
ELISA MAXTM standard set (Biolegend). Levels of sPD-1
were determined by human PD-1 DuoSet ELISA (R&D
Systems). Serum samples from HC donors and serum and
paired cell-free SF samples from patients with OA, RA or
PsA were collected and stored at 2808C until analysed by
ELISA (for sPD-1; R&D Systems) or Bio-Plex ProTM (for
TNFa, IL-6 and IL-1b; Bio-Rad Laboratories) on the Lumi-
nex FlexMap 3D platform (Luminex Corporation, Austin,
TX, USA). All assays were performed according to the
manufacturers’ protocols.
RNA extraction and real-time–quantitative
polymerase chain reaction (RT–qPCR)
Total RNA was isolated using the ReliaPrepTM RNA cell
Miniprep System (Promega, Southampton, UK) according
to the manufacturer’s protocol. cDNA synthesis was per-
formed using a high-capacity cDNA reverse transcription
kit (Applied Biosystems, Foster City, CA, USA) and mRNA
expression of PD-1Dex3 was determined using the Sensi-
MixTM SYBR No-ROX Kit (Bioline, London, UK). Data
were collected and analysed on a Rotor-Gene Q thermocy-
cler (Qiagen, Hilden, Germany). The b-actin gene was
used as an endogenous control and relative gene expression
was expressed as 2–DDCT. PCR primer pairs (IDT, Leuven,
Belgium) were as follows: PD-1Dex3, 50-AGGGTGACAGG
GACAATAGG-30 and 50-CCATAGTCCACAGAGAACAC-
30, b-actin, 50-ATTGGCAATGAGCGGTTC-30 and 50-
CGTGGATGCCACAGGACT23’.
Statistical analysis
Significance testing was performed with GraphPad Prism
software (version 7; GraphPad, La Jolla, CA, USA) using
the appropriate statistical tests, as indicated in the figure
legends.
Results
PD-11 T cell frequencies are increased in RA and PsA
synovial fluid compared to peripheral blood
First, we investigated the frequencies of PD-11 cells among
T cells in PB and paired SF from patients with RA and PsA.
Significantly increased percentages of PD-11 cells were
found within SF CD41 T cells (identified either by
CD31CD14–CD41 cells or CD31CD8– cells) compared to
PB (Fig. 1a,b). In addition, increased percentages of PD-11
cells were found within the SF CD81 T cell compartment
in both RA and PsA (Fig. 1c,d).
PD-1 ligation reduces proliferation of CD41 T cells
from healthy donors, but not CD41 T cells from
patients with RA or PsA
To investigate whether the PD-1 expression is func-
tional in RA and PsA, we set up a PD-1 ligation assay
using anti-CD3 and PD-L1fc (or IgG1fc as control)-
coated plates, based on previously described protocols
[9,29,30]. As expected, PD-1 ligation resulted in a sig-
nificant and dose-dependent reduction of healthy con-
trol PB-derived CD41 T cell proliferation, while no
effect was observed in the presence of IgG1fc control
(Fig. 2a,b). IFN-g production was also inhibited in a
PD-L1fc dose-dependent fashion (Supporting informa-
tion, Fig. S1a). We then compared PD-1 ligation of
PB-derived CD41 T cells from healthy donors and
patients with RA in parallel experiments. In contrast to
the suppressive effects on T cell proliferation observed
upon PD-1 ligation of CD41 T cells from healthy
donors, CD41 T cells from patients with RA appeared
to be resistant to PD-1-mediated suppression of T cell
proliferation (Fig. 2c,d). Next, we cultured CD41 T
cells from the blood and synovial fluid from patients
with RA and PsA with increasing doses of plate-bound
PD-L1fc. Even at the highest dose of PD-L1fc (5 mg/ml)
we did not detect a decrease in T cell proliferation
upon PD-1 ligation (Fig. 2e,f). Similarly, when RA and
PsA cell culture supernatants were tested for IFN-g
production, we could not detect a consistent decrease
in the levels of IFN-g (Supporting information, Fig.
S1b). These data indicate that CD41 T cells from the
blood and synovial fluid of patients with RA or PsA
are resistant to PD-1 ligation compared to healthy
control cells.
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TNFa, IL-6 and IL-1b counteract PD-1-mediated
suppression of CD41 T cell proliferation
Because RA and PsA CD41 T cells, especially those from the
synovial fluid, are derived from a proinflammatory environ-
ment, we sought to examine how inflammatory cytokines
may influence PD-1-mediated T cell suppression. First, we
determined the levels of TNFa, IL-6 and IL-1b in RA and
PsA-derived sera and paired SF, compared to healthy serum
and serum and SF from disease control patients with osteoar-
thritis (OA). Increased levels of all three cytokines were
detected in both RA and PsA SF when compared to HC
serum or OA SF (Fig. 3a,b). These data confirm the inflam-
matory nature of SF in both RA and PsA. In the analysed RA
and PsA sera, we only found mild increases of TNFa and IL-
6 compared to healthy or OA control serum.
Next, we assessed whether the presence of TNFa, IL-6 or
IL-1b had a functional impact on PD-1-mediated suppres-
sion of CD41 T cell proliferation. HC CD41 T cells were cul-
tured with increasing concentrations of PD-L1fc (0, 0!1 and 1
mg/ml) in the absence or presence of TNFa, IL-6 or IL-1b (10
ng/ml). To block the effect of the cytokines, the anti-TNFa
drug adalimumab, anti-IL-6R drug tocilizumab or anti-IL-1b
mAb (1 mg/ml) were added at the beginning of the culture
where indicated. Addition of each individual cytokine was
able to abrogate the suppressive effects of PD-1 ligation on
CD41 T cell proliferation at both 0!1 and 1 mg/ml PD-L1
concentrations (Fig. 3c). In each sample tested, adalimumab,
tocilizumab and anti-IL-1b mAb were able to reverse these
cytokine-mediated effects completely. Together, these data
indicate that the RA- and PsA-associated inflammatory cyto-
kines TNFa, IL-6 and IL-1b can counteract the suppressive
effects of PD-1 ligation on CD41 T cells, at least in vitro.
Soluble PD-1 (sPD-1) is induced in vitro by TNFa and
IL-6 in HC CD41 T cell cultures and can be detected in
serum and SF of both RA and PsA patients
Having demonstrated that TNFa, IL-6 and IL-1b can be
detected in RA and PsA patients and that each of these
Fig. 1. Programmed cell death 1 (PD-1)1 T cell frequencies are increased in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) synovial fluid
compared to peripheral blood. Frequencies of PD-11 T cells were analysed ex vivo by flow cytometry in peripheral blood mononuclear cells
(PBMC) and synovial fluid mononuclear cells (SFMC) from RA and PsA patients. (a) Contour plot of CD31CD14–CD41PD-11 cells from
paired PBMC and SFMC of one representative PsA donor. (b) Cumulative data showing percentage of PD-11 cells within CD31CD8– or
CD31CD14–CD41 (RA n5 10; PsA n5 11) PB and SF cell populations. (c) Contour plot of CD31CD81PD-11 cells from paired PBMC and
SFMC of one representative RA donor. (d) Cumulative data showing percentage of PD-11 cells within CD31CD81 (RA n5 7; PsA n5 8) PB
and SF cell populations. Data were analysed by Wilcoxon matched-pairs signed-rank test. *P< 0!05, **P< 0!01 and ***P< 0!001. Isotype control
staining showed a similar result to fluorescence minus 1 (FMO) staining (Supporting information, Fig. S5).
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Fig. 2. Programmed cell death-1 (PD-1) ligation reduces proliferation of CD41 T cells from healthy donors but not CD41 T cells from patients with
rheumatoid arthritis (RA) or psoriatic arthritis (PsA). (a–f) CD41 T cells were isolated from healthy control (HC) peripheral blood mononuclear cells
(PBMC) and RA and PsA PBMC and synovial fluid mononuclear cells (SFMC) and cultured for 5 days in plates precoated with anti-CD3monoclonal
antibody (mAb) (OKT3; 1!5 mg/ml) and PD-L1fc/IgG1fc (0, 0!1, 1, 2 and 5 mg/ml). Proliferation was assessed on day 5 by [3H]-thymidine incorporation.
(a) HC CD41 T cell proliferation (cpm) and (b) suppression of proliferation following PD-1 ligation by PD-L1fc (n5 7) or immunoglobulin (Ig)G1fc
(n5 5–7). (c) Cell proliferation (cpm) and (d) suppression of proliferation of CD41 T cells isolated from HC and RA PBMC (n5 9) in presence of PD-
L1fc. (e) Cell proliferation (cpm) and (f) suppression of proliferation of CD41 T cells isolated from RA and PsA PBMC and paired SFMC in presence of
PD-L1fc (n5 3 RA PB/SF; n5 4 PsA PB/SF). Data were analysed by Friedman test with Dunn’s multiple comparison test. *P< 0!05, **P< 0!01 and
***P< 0!001. Data in (b,d,f) show mean6 standard error of the mean.
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cytokines abrogates PD-L1fc activity in vitro, we sought to
identify a possible underlying mechanism. ELISA analysis
of HC CD41 T cell supernatants from cytokine-stimulated
cultures revealed that both TNFa and IL-6 were able to
induce sPD-1 compared to medium-only conditions (Fig.
4a,b). No significant increase in sPD-1 was observed in IL-
1b-stimulated cultures (Fig. 4c). This increase in sPD-1
was abrogated in the presence of adalimumab or
Fig. 3. Tumour necrosis factor (TNF)a,
interleukin (IL)-6 and IL-1b counteract
the programmed cell death-ligand 1
(PD-L1)-mediated suppression of
healthy control (HC) CD41 T cell
proliferation. (a,b) Levels of
proinflammatory cytokines TNFa, IL-6
and IL-1b in paired rheumatoid
arthritis (RA) and psoriatic arthritis
(PsA) serum/synovial fluid (SF)
(n5 12), in osteoarthritis (OA) (disease
control) serum/SF (n5 3–4) and in HC
serum (n5 7). Wilcoxon’s matched-
pairs signed-rank test for RA/PsA
serum versus RA/PsA SF and Mann–
Whitney test for RA/PsA SF versus HC
serum or OA SF. *P< 0!05, **P< 0!01
and ***P< 0!001. (c) Plates were coated
with PD-L1fc at the indicated
concentrations, and PD-L1-mediated
suppression of proliferation by CD41 T
cells from HC PB was assessed in
absence (medium, M) or presence of 10
ng/ml of TNFa (n5 9), IL-6 (n5 5) or
IL-1b (n5 6) 6 anti-TNFa
(adalimumab; ADA), anti-IL-6R
(tocilizumab; TOC) and anti-IL-1b (all
at 1 mg/ml). Data in (c) were analysed
by Wilcoxon matched-pairs signed-rank
test. *P< 0!05 and **P< 0!01.
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Fig. 4. Soluble programmed cell death-1 (sPD-1) is induced in vitro by tumour necrosis factor (TNF)a, interleukin (IL)-6 in HC CD41 T cell
cultures and can be detected in serum and synovial fluid (SF) of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients. (a–c) sPD-1
levels in supernatants of healthy control (HC) CD41 T cells stimulated with (a) TNFa (10 ng/ml) or TNFa1 adalimumab (ADA; 1 mg/ml)
(n 5 7), (b) IL-6 (10 ng/ml) or IL-61 tocilizumab (TOC; 1 mg/ml) (n 5 5–-7) and (c) IL-1b (10 ng/ml) or IL-1b1 anti-IL-1b (anti-IL-1b; 1
mg/ml) (n 5 5). (d) sPD-1 levels (median with interquartile range) in RA and PsA paired serum/synovial fluid (SF) and osteoarthritis (OA)
serum/SF (OA, n 5 3–4; RA, n 5 17; PsA, n 5 18). (e) sPD-1 levels (median with interquartile range) in control disease OA (n 5 3–4), RA
(n 5 5) and PsA (n 5 6–7) serum and SF of patients treated with TNFi versus non-TNFi therapy. Data in (a,b,c,e) were analysed by Mann–
Whitney test while data in (d) were analysed by Kruskal–Wallis test with Dunn’s multiple comparison test. *P< 0!05, **P< 0!01, ***P< 0!001.
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tocilizumab. Quantitative PCR analysis of HC CD41 T cells
from the same TNFa- and IL-6-stimulated cultures
revealed increases of the PD-1Dex3 splice variant (Support-
ing information, Fig. S2). These results are in line with a
previous study from another group reporting that TNFa
promotes sPD-1 expression [31] but also identify IL-6 as
an inducer of sPD-1 and PD-1Dex3.
In addition, ELISA analysis revealed that sPD-1 was
detectable in none of three OA serum and none of four OA
SF samples, while it was detected at high levels in 13 of 17
RA and 13 of 18 PsA serum and SF samples (Fig. 4d). Addi-
tionally, cross-sectional analysis of serum and SF from
patients with RA or PsA undergoing TNF-inhibitor (TNFi)
therapy revealed lower levels of sPD-1 when compared to
patients not receiving TNFi therapy (Fig. 4e). These data
show that proinflammatory cytokines such as TNFa and
IL-6 can modulate the amount of sPD-1 in vitro and that
TNFi therapy might modulate sPD-1 levels in the serum
and SF of patients with inflammatory arthritis.
sPD-1 modulates PD-1-mediated suppression of HC
CD41 T cells and induces proliferation in CD41 T
cell/CD141 monocyte co-cultures
To investigate whether sPD-1 is able to modulate PD-1/
PD-L1 interactions, we first tested if sPD-1fc itself pro-
motes T cell proliferation of anti-CD3 stimulated HC
CD41 T cells cultured in the absence of PD-L1fc. In these
experimental conditions, sPD-1fc did not induce any
increase in cell proliferation (Supporting information, Fig.
S3), suggesting no direct effect on HC CD41 T cells. We
then cultured HC CD41 T cells in the presence of increas-
ing amounts of PD-L1fc ligand in the absence or presence
of sPD-1fc chimera (0!5 or 1 mg/ml). In PD-L1fc precoated
plates, addition of sPD-1fc was able to abrogate the activity
of the ligand in a dose-dependent fashion, resulting in less
efficient suppression of T cell proliferation when compared
to medium only (Fig. 5a,b). These data indicate that in a
CD41 T cell-only culture system, sPD-1 is able to modulate
negatively an otherwise functional PD-1/PD-L1
interaction.
To investigate further the ability of sPD-1 to modulate
the PD-1/PD-L1 interaction, we set up a co-culture system
using HC CD41 T cells and autologous CD141 cells as a
source of natural PD-L1. The ability of HC CD141 cells to
express PD-L1 was tested by flow cytometry by culturing
the cells overnight with 10 ng/ml of IFN-g, a known
inducer of PD-L1 [27,32] (Supporting information, Fig.
S4). Freshly isolated HC CD41 T cells and autologous
monocytes were cultured at a 1 : 1 ratio with soluble anti-
CD3 mAb (100 ng/ml) in the absence or presence of
increasing doses of sPD-1 or IgG1fc control (0!25, 0!5 and
1 mg/ml). Addition of sPD-1fc led to a significant dose-
dependent increase in T cell proliferation compared to
control-treated cells (Fig. 5c,d). These data indicate that
soluble PD-1 receptor can modulate PD-1 ligation in both
an artificial system (PD-L1fc precoated plates) as well as in
a more physiological context (in the presence of PD-L11
APC).
Discussion
The present study provides evidence for compromised PD-
1 mediated suppression in CD41 T cells from patients with
RA and PsA. Our study identifies the proinflammatory
cytokines TNFa, IL-6 and IL-1b as negative modulators of
PD-1-mediated T cell suppression in vitro and demon-
strates that sPD-1 is capable of interfering with effective
PD-1 ligation. To our knowledge, this is the first study to
examine PD-1 function in RA and PsA simultaneously, and
to provide evidence that the inflammatory milieu of these
two diseases has a role in modulating PD-1 ligation.
We show that the frequencies of PD-11 cells within
CD41 and CD81 T cell subsets are increased significantly
in the synovial fluid from patients with RA or PsA when
compared to peripheral blood, thus extending the findings
from previous studies focusing only on RA [20,26,27,33].
The increase in the frequencies of PD-11 T cells suggests
that in RA and PsA PD-1 might have a role in regulating T
cell effectors, especially at the site of inflammation. How-
ever, despite this increased frequency of PD-11 T cells,
inflammation persists, suggesting that this pathway is
impaired in these diseases.
Thus far, only limited data exist regarding PD-1 function
in inflammatory arthritis. One study using a PD-L1fc chi-
mera demonstrated that PD-1 ligation inhibited cell prolif-
eration and IFN-g production by CD41 T cells from
peripheral blood of RA patients, but that synovial fluid
CD41 T cells required higher concentrations of PD-L1fc to
achieve similar levels of inhibition [20]. The authors specu-
lated that the inflammatory milieu found in the RA joint
might be accountable for reduced PD-1-mediated suppres-
sion, as they showed that addition of cell-free SF to RA PB
CD41 T cells modulated PD-1 ligation negatively [20].
However, no specific mediator of the effect was identified.
It has been shown previously that the common gamma
chain cytokines IL-2, IL-7 and IL-15, as well as CD28 co-
stimulation, can interfere with PD-1 cross-linking via
pSTAT-5 activation [9,29]. In our study, we show that in
both RA and PsA, CD41 T cells from the blood and syno-
vial fluid are more resistant to PD-1 ligation in terms of
suppression of T cell proliferation and IFN-g production
when compared to healthy cells. We show that the proin-
flammatory cytokines TNFa, IL-6 and IL-1b are found at
increased levels in RA and PsA SF, and can reduce PD-1-
mediated suppression of proliferation in CD41 T cells
from healthy donors. Inhibitors of these cytokines can
counteract this effect. These findings provide further evi-
dence that the presence of certain proinflammatory
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cytokines can be critical in determining the outcome of
PD-1 engagement during the immune response.
Mechanistically, our data demonstrate that TNFa and
IL-6, but not IL-1b, induce the secretion of sPD-1 by
CD41 T cells, and that sPD-1 levels are increased signifi-
cantly in the serum and SF of patients with RA or PsA
compared to OA. The latter data support and extend two
recent studies that showed that sPD-1 can be detected in
the serum and SF from patients with RA [27,34]. In these
studies sPD-1 serum levels correlated positively with the
Disease Activity Score (DAS28), the presence of rheuma-
toid factor, and with levels of TNFa in the RA SF but not
the serum [27,34]. Recent studies showed that expression
of the PD-1Dex3 variant is observed in T cells from
patients with RA, but only minimally in T cells from
patients with OA or from HC [27,31]. PD-1Dex3 is a splice
Fig. 5. Soluble programmed cell death 1 (sPD-1) modulates PD-1-mediated suppression of healthy control (HC) CD41 T cells and induces
proliferation in CD41 T cell/CD141 monocyte co-cultures. (a) Proliferation and (b) suppression of proliferation of HC CD41 T cells cultured in
anti-CD3 monoclonal antibody (mAb) (OKT3) and PD-L1fc pre-coated plates with or without soluble PD-1fc (0.5 and 1 mg/ml) (n 5 9–10). (c)
Proliferation and (d) suppression of proliferation of HC CD41 T cells cultured with autologous CD141 monocytes at a 1 : 1 ratio (n 5 7) in
presence of soluble anti-CD3 mAb (100 ng/ml) and soluble PD-1fc/IgG1fc control (0, 0!25, 0!5 and 1 mg/ml). Data were analysed by Friedman’s
test with Dunn’s multiple comparison test (a,b) and Wilcoxon’s signed-rank test (c,d). *P< 0!05 and ***P< 0!001.
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variant of PD-1, which lacks the transmembrane domain
and whose putative translational product is a soluble form
of PD-1 [34,35]. It was shown that TNFa, IL-17 and IFN-g
can increase PD-1Dex3 splice variant mRNA expression in
healthy human CD41 T cells [31]. Our data indicate that
in addition to those cytokines, sPD-1 protein expression
and PD-1Dex3 splice variant mRNA expression can also be
regulated by IL-6. Furthermore, preliminary analysis from
a cross-sectional investigation of PsA and RA serum and SF
suggests that patients treated with TNFi therapy have lower
sPD-1 levels compared to patients not treated with TNFi
therapy. Further longitudinal studies on patients treated
with adalimumab or tocilizumab are required, however,
before conclusive statements can be made regarding the
effect of biologics on sPD-1 levels.
Our data demonstrate that the inflammatory cytokines
TNFa and IL-6 can lead to increased levels of PD-1Dex3
splice variant as well as sPD-1. It is possible that a certain
amount of PD-1 might also be released from the cell mem-
brane via other mechanisms. The presence of high levels of
certain metalloproteinases (MMPs) such as MMP-9 and
MMP-13 has been described previously in inflammatory
arthritis [36,37], and it has been shown recently that
expression of the PD-1 ligands PD-L1 and PD-L2 in infant
foreskin fibroblasts can be regulated through proteolytic
cleavage by MMPs [38]. Future studies may reveal whether
such an MMP-mediated proteolytic cleavage may also con-
tribute to generation of soluble PD-1.
Notably, we show, using a recombinant PD-1 chimera,
that sPD-1 is functionally able to counteract PD-L1fc-
mediated suppression of healthy CD41 T cell proliferation,
and to enhance CD41 T cell proliferation when co-
cultured with CD141 monocytes that can naturally express
PD-L1. Importantly, recent studies in autoimmune hepati-
tis [39] and cutaneous systemic sclerosis [40] support the
notion that sPD-1 might interfere with the PD-1 pathway,
thereby disrupting T cell regulation.
Collectively, our data indicate that CD41 T cells from the
PB and SF of patients with chronic RA or PsA are more
resistant to PD-1-mediated regulation than CD41 T cells
from healthy individuals. We show that the proinflamma-
tory cytokines TNFa, IL-6 and IL-1b, which are present at
increased levels in the inflamed joints of RA and PsA
patients, are capable of negatively modulating PD-1 ligation
in vitro. Finally, we show that TNFa and IL-6 are capable of
inducing sPD-1 in HC CD41 T cells and that sPD-1 modu-
lates T cell proliferation by interfering with PD-1 ligation.
Thus, our findings provide new evidence that the inflam-
matory environment of the RA and PsA joint compromises
PD-1/PD-L1-mediated T cell regulation.
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Supplementary Table 1. Demographic and clinical
parameters of the patients included in the study. Some
samples were used for flow cytometry or functional assays
only, whilst other samples were only used for cytokine
detection in serum and SF. Clinical and demographic
data are provided, where available. Abbreviations used:
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DAS28, disease activity score of 28 joints; DMARDs,
disease-modifying anti-rheumatic drugs.
Supplementary Figure 1. PD-1 ligation reduces IFN-c
production by HC CD41 T cells but not RA or PsA
CD41 T cells. CD41 T cells from HC PBMC, RA and
PsA PBMC and SFMC were cultured in plates pre-coated
with anti-CD3 mAb (OKT3) and PD-Llfc/IgGlfc. Super-
natants were collected at day 5 and tested by ELISA for
IFN-g production. (a) IFN-g production in HC CD41 T
cell cultures in presence of PD-L1fc (0, 0!1 and 1 lg/m1
range; n511 and 0, 0!1, 1, 2 and 5 lg/m1 range; n54).
(b) IFN-g production in RA and PsA CD41 T cell cul-
tures; IA PB (RA n52; PsA n53) and IA SF (RA n52;
PsA n54). Data were analysed by Friedman Test with
Dunn’s Multiple Comparison test. *P< 0!05, **P< 0!01
and ***P< 0!001.
Supplementary Figure 2. Expression of PD-1Dex3 tran-
script in activated HC CD41 T cells in presence of
TNFa and IL-6. HC CD41 T cells were cultured in
absence (medium, M) or presence of 10 ng/ml of TNFa
(n54) or IL-6 (n53) 1/- anti-TNFa (adalimumab;
ADA) or anti-IL-6R (tocilizumab; TOC) (all at 1 mg/ml)
for 5 days. PD-1Dex3 expression was examined by qPCR
and normalised to b-Actin housekeeping gene
(mean6 SEM).
Supplementary Figure 3. Proliferation of HC CD41 T
cells in presence of increasing sPD-lfc concentrations.
HC CD41 T cells (n59) were cultured with immobilised
anti-CD3 mAb (OKT3) in presence of increasing concen-
trations of sPD-lfc (0, 0!5 and 1 mg/ml). Proliferation was
assessed at day 5 by [3H]-thymidine incorporation and
displayed as counts per minute (cpm). Data (mean6
SEM) were analysed by Friedman Test with Dunn’s Multi-
ple Comparison test. *P< 0!05, **P< 0!01 and
***P<0!001.
Supplementary Figure 4. PD-L1 expression in CD141
monocytes following IFN-c stimulation. CD141 mono-
cytes where positively isolated from HC PBMC and cul-
tured overnight at 378C in medium only or in medium
supplemented with IFN-g (10 ng/ml). PD-L1 expression
was assessed after 12 hrs by flow cytometry. (a) Represen-
tative experiment. Shaded histograms represent the iso-
type control, open histograms indicate the expression
profile for PD-L1 with/out IFN-g stimulation. (b) Cumu-
lative data (n53).
Supplementary Figure 5. PD 11 T cell frequencies are
increased in synovial fluid compared to peripheral
blood. Contour plot of CD31CD41PD-11 cells from
paired PBMC and SFMC of one representative RA donor.
FMO controls and isotype controls are shown for the
CD31CD41populations.
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